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Abstract  
 
 
    Recombinant production of therapeutic proteins provides huge benefits to human health and 
promises solutions to some of the most devastating and currently untreatable diseases in 
healthcare. Key to the development of new therapeutic proteins is to optimize and engineer living 
cells, namely cell factories, to produce therapeutic proteins by taking advantage of the cells 
protein production machinery. However, there is an insufficient understanding of the cellular 
processes and their regulatory mechanisms that hinder optimal therapeutic protein production 
such as cell growth, protein productivity and product quality. Our successes are dependent on 
getting a better understanding of the biological processes that comprise the cell factory, and the 
ability to directly engineer the cell factory for beneficial production of both new and existing 
therapeutic products.    
    In this thesis, the development of a number of novel tools is reported that aim to accelerate the 
construction of production cell lines for therapeutic proteins with optimal phenotypic attributes 
for industrial processes. Chinese hamster ovary (CHO) cells are the predominant production host 
for therapeutic proteins, and are the cell factory of interest in this thesis. The core of the thesis is 
revolved around the development and application of genome editing techniques that enable us to 
precisely engineer the genome of CHO cells by either rendering specific-targeted genes un-
functional or inserting new genes in precise genomic locations. This allows us to i) facilitate 
improved studies of gene functions, ii) remove cellular traits that are disadvantageous to protein 
production, iii) control and predict the level and stability of protein expression, and iv) design and 
engineer new cellular functions. 
    Overall, the results of this thesis illustrate the benefits of advancing the toolbox for designing 
and engineering CHO cell lines. Each chapter demonstrates direct applications of strategies to 
improve the therapeutic production capabilities of CHO cell factories, with the goal to speed up 
the development process of new therapeutic proteins and reducing the costs in order to benefit a 
broader range of patients around the globe.    
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Dansk sammenfatning 
 
 
Rekombinant produktion af terapeutiske proteiner giver enorme fordele for menneskers sundhed 
og præsenterer os for løsninger på nogle af de mest alvorlige og i øjeblikket ubehandlede 
sygdomme i sundhedsvæsenet. Nøglen til udviklingen af nye terapeutiske proteiner er at optimere 
og konstruere de levende celler, nemlig cellefabrikkerne, til at producerer terapeutiske proteiner 
ved at udnytte cellernes eget proteinproduktions maskineri. Vores forståelse af de cellulære 
processer og reguleringsmekanismer er imidlertid utilstrækkelig, og forhindrer optimal 
terapeutisk proteinproduktion, såsom øget cellevækst, protein produktivitet og protein kvalitet. 
Fremtidige succeshistorier er afhængige af at vi får en bedre forståelse af de biologiske processer, 
der omfatter cellefabrikken, og evnen til direkte at konstruere cellefabrikken til gavnlig 
produktion af både nye og eksisterende terapeutiske produkter. 
    I denne afhandling rapporteres udviklingen af en række nye værktøjer, der sigter mod at 
fremskynde konstruktionen af produktionscellelinier til fremstilling af terapeutiske proteiner 
med optimale fænotypiske egenskaber for industrielle processer. Kinesiske hamster ovarie 
(CHO) celler er den dominerende produktionsvært for terapeutiske proteiner, og er 
cellefabrikken af interesse i denne afhandling. Kernen i afhandlingen drejer sig om udvikling og 
anvendelse af genomredigeringsteknikker, der gør det muligt for os at præcis redigere genomet 
af CHO-celler ved at gøre udvalgte gener ufunktionelle eller indsætte nye gener på præcise 
genomiske steder. Dette tillader os at i) letter forbedre studier af genfunktioner, ii) fjerne 
cellulære træk, der er en ulempe for proteinproduktion, iii) kontrollere og forudsige niveauet og 
stabiliteten af proteinekspression, og iv) designe og konstruere nye cellulære funktioner. 
    Samlet set illustrerer resultaterne af denne afhandling fordelene ved at videreudvikle 
værktøjskassen til at designe og konstruere CHO-cellelinjer. Kapitlerne i afhandlingen 
demonstrerer direkte applikationer af strategier til at forbedre CHO-cellefabrikkernes 
terapeutiske produktionskapacitet, med det formål at fremskynde udviklingsprocessen af nye 
terapeutiske proteiner og reducere omkostningerne til gavn for en større andel patienter over 
hele verden.!
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Introduction 
 
Therapeutic proteins have enabled effective treatments for some of the most difficult medical 
conditions that threaten human health, as they are able to modulate physiological processes at a 
cellular level. The early therapeutic proteins were derived from animal- and subsequently human-
sources. A groundbreaking achievement in the field of therapeutic proteins was the establishment of 
recombinant production of therapeutic proteins, where living cells are utilized as host systems for the 
protein production. It allows the production of large quantities of human proteins in a controlled 
environment. This has improved the access to these life-changing treatments, and simultaneously 
reduced the risk of pathogen transmission and immune reactions to potential foreign components in 
the products. Treatments are currently offered for a wide range of diseases such as cancer, 
autoimmune disorders, hormone and growth factor deficiencies, and benefits health of  millions of 
people worldwide 1 2.  
 
The demand for new therapeutic products is continuously increasing in order to broaden the range of 
medical conditions that are being treated. To expand the access to these life-changing products, the 
products need to be made safer and more affordable. Increasing the production levels, and creating a 
more robust and reproducible production host system will accelerate the development and 
commercialization of new products and reduce manufacturing costs. The product itself should display 
maximal biochemical and biophysical uniformity in protein folding, monodispersity, and PTMs to 
increase product safety and keep up with the increasing regulatory demands 3.  
 
Since the approval of the first recombinant therapeutic protein expressed in Chinese hamster ovary 
(CHO) cells over 30 years ago 2, CHO cell lines have become the primary production host for 
therapeutic proteins, producing 7 out of the top 10 best selling therapeutic proteins from 2016 4. CHO 
cells are favoured mainly due to their ability to produce proteins with post-translational modifications 
(PTMs) biologically similar to those found in humans. A requirement for optimal safety, quality and 
efficacy. Thus, therapeutic proteins produced in CHO cells are superior to those produced in 
microbial hosts. CHO cells have been successfully used in production of safe and high-quality 
therapeutic proteins for decades, generating a stronger regulatory track record than any other cell line 
used today 2. They can grow in suspension culture making them ideal for large-scale bioprocesses 
and they achieve relatively high productivity levels for certain products 5. 
 
During the development of new therapeutic proteins or biosimilars, a new production host cell line 
also needs to be developed. A typical cell line development pipeline involves the transfection of 
expression cassettes with a recombinant gene (encoding the protein of interest) and a selection 
marker, followed by selection and gene amplification to increase the number of recombinant gene 
copies. Due to random integration of the recombinant gene in the genome and the amplification 
process, the resulting clones display highly heterogeneous phenotypes, known as clonal variation. 
Subsequently, a large number of clones needs to be screened to identify a stable high-producing clone 
candidate, followed by scale-up and process optimization. The cell line development pipeline 
1
typically requires a timeline of six to twelve months 6. Successes currently achieved in CHO host cell 
development are impressive with substantial increase in titers since the introduction of the first 
recombinant therapeutic protein 5. The successes are mostly driven by unpredictable, labour-intensive 
and time-consuming screening and bioprocess optimization 2,5. The development processes are often 
product-specific and not easily reproduced, requiring the entire pipeline to be repeated for each new 
product. Additionally, the production processes still suffer from cellular limitations such as low 
productivity of certain proteins, requirement for advanced growth media, and limited growth capacity 
leading to longer and more expensive manufacturing processes as compared to bacterial- or yeast-
based production host systems. 
 
Advancements in cell line development technologies are crucial to support the effort of accelerating 
the development of safer, more affordable and more complex therapeutic products. With the 
availability of several CHO cell line draft genomes 7,8  and genome engineering technologies 9, the 
field is moving towards more rational engineering approaches. CHO cells have lagged behind 
microbial cell factories in terms of cell line engineering due to the late arrival of both annotated 
genomes and available genome editing tools. A combination of an increased understanding of cellular 
processes and the ability to precision engineer genomes will provide the means to start re-engineering 
CHO cells with new and improved capabilities - more attuned to highly efficient bioprocesses. The 
new precise genome editing tool - Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)/CRISPR-associated protein 9 (Cas9) - recently entered the field of CHO cell engineering 
10. This tool is easier to establish, less time-consuming, more efficient, and much more cost-effective 
than other gene editing methods such as transcription activator-like effector nucleases and zinc-finger 
nucleases. CRISPR/Cas9 technology has the potential to revolutionize current cell line generation 
strategies to enable rational design and engineering of CHO production hosts.  With a rational 
engineering approach, the cell line development will be more predictable in terms of production levels 
and stability, speeding up development and bringing the product to the market in a shorter time frame.  
 
The goal of this PhD project is to expand the available genome editing tools for CHO cell line 
engineering. It aims to contribute to the advancement of synthetic biology within the field of 
recombinant protein therapeutic production; with a vision of being able to one day build CHO cells 
from scratch with optimal functionalities for therapeutic protein production, in a fast, predictable and 
user-friendly manner.  
 
 
  
2
Thesis structure 
 
 
The research presented in this thesis was completed in a collaborative effort between me and my 
colleagues. This thesis is divided into five parts, centered around my main projects: the development 
and rational use of site-specific genome editing tools. In Chapter 1, a review serving as an 
introduction to the field of CRISPR/Cas9 genome editing, and its potential applications and future 
perspectives in the field of CHO cell engineering is presented. Chapter 2 builds on chapter 1, and 
presents a protocol on how to step-by-step use the genome editing tool CRISPR/Cas9 to knockout 
target genes in CHO cells. Chapter 3 present a study where we successfully utilized the 
CRISPR/Cas9 genome editing tool to knockout multiple genes simultaneously in CHO cells. In 
Chapter 4, the first case of targeted gene integration using CRISPR/Cas9 without the use of an 
antibiotic selection marker is presented. Chapter 5, shows how site-specific gene insertion tools can 
be applied to achieve more accurate comparative biological studies, using the field of transcriptomics 
as a test case.  Finally, Chapter 6 contains a few concluding remarks about the results and future 
perspectives for the research presented in this thesis.  
!
3
Chapter 1 
!
CRISPR/Cas9 as a genome editing tool 
 
 
This chapter introduces the history and concept of CRISPR/Cas9, and its use as a genome editing 
tool for engineering purposes of CHO cell lines. CRISPR/Cas9 was introduced to mammalian cell 
engineering in the infancy of this PhD project and plays a major role throughout the studies 
presented in this thesis. We discuss the many different applications, future directions and potential 
of genome editing on the road to building next-generation CHO cell factories. 
4
© 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 979
1  Introduction
Chinese hamster ovary (CHO) cells are the primary
expression system for manufacturing biopharmaceuti-
cals. CHO cells account for 35.5% of the total cumulative
(1982–2014) biopharmaceutical product approvals since
the first market approval of tissue plasminogen activator
produced from recombinant CHO (rCHO) cells in 1987 [1,
2]. Despite extensive use of CHO cells as the workhorse of
the biopharmaceutical industry, CHO cells were consid-
ered as a ‘black box’ due to lack of genomic information.
This hindered efforts to understand the molecular basis of
high level production of recombinant proteins in CHO
cells. Thus, the impressive progress in CHO cell culture
technology was achieved by empirical approaches such
as screening and process optimization. Such approaches
are effective in obtaining high level production of many
recombinant proteins, including recombinant antibodies
and Fc-fusion proteins, with yields up to 10 g/L and over
[3]. However, such yields are often limited to only certain
types of product. In addition, a high degree of variability
Review
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of rCHO cells requires laborious and expensive processes
to select the best clone for the production of each new
therapeutic candidate [2]. 
The systems biology approach toward rational design
of microbial production hosts has been driven by three
main resources: genomic information, genome-scale
pathway information/computational models, and genetic
engineering tools [4]. The same drivers for CHO cells have
recently arisen, thus permitting genome-scale science for
CHO cells. The complete genomic sequence of CHO-K1
cells became publicly available in 2011 [5], and since then
sequencing efforts have resulted in additional genomic
sequence data being available for the Chinese hamster
and various CHO cell lines [6–8]. Now an active effort is
underway in the CHO community to refine the genome
assembly and annotation for the Chinese hamster [9]. The
emergence of CHO genomes enables in-depth interpreta-
tion of various 'omics data sets [10] and construction of
CHO genome-scale models, such as computational mod-
els of the CHO metabolic network [4, 11]. Integration of
'omic resources with modeling approaches may unveil
the underlying mechanism between genotype and phe-
notype in CHO cells. This could contribute to identifica-
tion of either biomarkers for determining high producing
and stable CHO cells or novel and non-intuitive targets for
CHO cell line engineering. 
The emerging targets will necessitate extensive and
efficient validation of the genetic manipulations. Genome
editing tools have been developed including zinc-finger
nucleases (ZFNs), transcription activator-like effector
nucleases (TALENs) and the more recent RNA-guided
engineered nucleases (RGENs) derived from the bacterial
clustered regularly interspaced short palindromic repeat
(CRISPR)/CRISPR-associated (Cas) system, which enables
one to cut and modify specific target DNA sites in a pre-
cise manner [12]. Compared with conventional gene tar-
geting strategies based on homologous recombination,
these programmable nucleases innovatively enhance the
induction of DNA damage repair pathways, triggered by
site-specific DNA double strand breaks (DSBs). The
induction of DNA damage repair pathways results in tar-
geted genome modification including gene knockout,
gene correction/insertion and chromosome rearrange-
ments [12]. Armed with genome editing technologies,
large-scale genetic manipulation and genome analysis of
CHO cells is feasible. These engineering efforts now
enable the development of next-generation recombinant
protein production in CHO hosts, with their accompany-
ing improved productivity and protein quality. Notably, of
the current genome editing nucleases, RGENs, hereafter
referred to as CRISPR/Cas9, have been evolving rapidly
due to their simple composition based on the principles of
Watson-Crick base pairing between small guide RNAs
and the targeted genomic sites rather than the use of
modular DNA recognition proteins. This feature confers
ease of use, rapid and cost-effective design in addition to
high targeting efficiency that has led to widespread
implementation of CRISPR/Cas9 for genetic modification
of various types of organism and cell [13–15]. A compari-
son of the advantages and disadvantages of the ZFNs,
TALENs and RGENs has previously been reviewed [16,
17].
In conjunction with the advent of revolutionary
CRISPR/Cas9-mediated genome engineering, tomes of
research and review papers have been published since
2013, highlighting its short history and diverse applica-
tions [13–15]. The biotechnological potential of this sys-
tem is of particular interest, and so here we highlight the
role of CRISPR/Cas9 in CHO cell engineering. We first
briefly describe the principle of the CRISPR/Cas9 system
and genome editing in cells, followed by its potential with
examples consisting of four applications. We then review
experimental procedures for genome engineering with
the CRISPR/Cas9 system in mammalian cells including
CHO cells. Finally, we conclude by discussing the past,
present and future of CHO cell factory engineering via
CRISPR/Cas9-mediated genome editing.
2  CRISPR/Cas9 in adaptive immunity
CRISPR/Cas systems have evolved in prokaryotes to pro-
vide adaptive immunity against foreign genetic elements
such as viruses and plasmids [18]. The CRISPR loci typi-
cally consist of a clustered set of Cas genes and a CRISPR
array – a series of repeat sequences (direct repeats) inter-
spaced by variable sequences (spacers). The spacers cor-
respond to short sequences within foreign genetic ele-
ments (protospacers), such as phage sequences [19].
Three major CRISPR/Cas systems (I–III) are classified
based on their genetic content and distinct mechanism to
achieve CRISPR-mediated adaptive immunity [20]. The
overall theme of type II CRISPR-mediated adaptive immu-
nity can be divided into three stages after the invasion of
foreign genetic elements. The first stage is spacer acqui-
sition, where protospacers are cleaved by different Cas
proteins and subsequently inserted into the CRISPR array
as spacers [18]. Biogenesis and processing of CRISPR
RNA (crRNA) form the second stage, where CRISPR
arrays are transcribed and subsequently processed into
smaller crRNAs, each composed of a direct repeat and a
spacer [21]. Trans-activating crRNA (tracrRNA) is also
transcribed from the CRISPR locus and contributes to the
processing of crRNA, by hybridizing with the direct
repeats and forming an RNA duplex that is cleaved by
RNase III [22]. In the final step Cas9 and crRNAs (includ-
ing tracrRNA) hybridize to form an active ribonucleopro-
tein complex. This complex scans invading DNA for a tar-
get complementary to the crRNA spacer sequence, and
directs the cleavage of the target DNA by the Cas9 nucle-
ase [23–25]. This targeted cleavage by CRISPR/Cas9 has
been used to enable rational genome editing.
www.biotechnology-journal.com www.biotecvisions.com
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Cas9 system derived from Streptococcus pyogenes, the
PAM is a 5´-NGG sequence [25]. For other Cas9 orthologs
there may be different PAM requirements [23, 24, 27, 28,
31]. The Cas9-RNA complex rapidly searches for guide
RNA complementarity by dissociating from non-PAM
sites [32]. Only upon binding to a PAM sequence does the
Cas9-RNA complex look for guide RNA complementary in
the flanking DNA [32]. Base pairing between the target
sequence and the crRNA leads to the activation of the two
nuclease-domains of Cas9 (HNH and RuvC-like domains)
[33], which also requires PAM recognition [32]. The Cas9
protein can be programmed to target and cleave any
 dsDNA sequence of interest if it primes the PAM
sequence, simply by changing the DNA target binding
sequence in the guide RNA. The Cas9 protein can also be
converted into a nicking enzyme, which is a mutant ver-
sion of Cas9 created by inactivating one of the two nucle-
ase-domains, to facilitate genome editing with minimal
mutagenic activity [28, 34, 35]. While ZFNs and TALENs
have been used for a longer period of time, many
www.biotecvisions.comwww.biotechnology-journal.com
Biotechnology
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3  CRISPR/Cas9-mediated genome editing 
The foundation for utilizing the CRISPR/Cas9 as program-
mable nucleases for genome editing was laid by a few
essential findings: DNA is the primary target of CRISPR/
Cas systems [26], Cas9 is the only protein needed to gen-
erate DSBs in the target sequence [27], and crRNA
hybridizes with trans-activating crRNA (tracrRNA) to
facilitate RNA-guided targeting of the Cas9 protein [22].
In 2013, the CRISPR/Cas9 system was successfully engi-
neered to accomplish genome editing in mammalian
cells, by recombinant expression of crRNA-tracrRNA
together with Cas9 to create DSBs [28, 29]. The RNA
duplex tracrRNA-crRNA, which can be fused to a single
guide RNA (gRNA), guides the Cas9 protein to target
DNA where it introduces site-specific DSBs (Fig. 1A) [23].
Target recognition by Cas9 requires both a 20-nt target
complementary sequence in the crRNA and a protospac-
er adjacent motif (PAM) sequence adjacent to the crRNA
binding region in the target DNA [25, 30]. In the CRISPR/
3’
5’
3’
5’
5’
3’
3’
5’
5’
3’
5’
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5’
DSB PAM
gRNA
Cas9
NHEJ HDR
Indel Premature Precise gene
mutation stop codon modification
Genomic
DNA
Repair
template
A
B
3’
5’
5’
3’
PAMCas9
5’
3’
PAM
tracrRNA
crRNAsequence
guide RNA
Join RNAs
gRNA
Figure 1. Genome editing with
CRISPR/Cas9. (A) The trans-activating
CRISPR RNA (tracrRNA) and the CRISPR
(crRNA) are fused together as a single
guide RNA (gRNA), and guide the Cas9
nuclease to the target DNA that is com-
plementary to the guide sequence. 
(B) The Cas9 nuclease from the micro-
bial CRISPR adaptive immune system is
directed to specific DNA sequences via
base-pairing of the guide sequence on
its guide RNA (gRNA) (green) with the
DNA target. Binding of a protospacer-
adjacent motif (PAM, orange) down-
stream of the target site helps to direct
Cas9-mediated DNA double strand
breaks (DSBs). DNA DSBs are typically
repaired by the error-prone non-homolo-
gous end joining (NHEJ) or error-free
homology directed repair (HDR). In the
NHEJ pathway, indels can be introduced
during ligation of the dissected DNA
ends and eventually lead to frameshift
mutations and functional gene knock-
out. In the HDR pathway, recruitment of
accessory factors that direct genomic
recombination with homology arms on
an exogenous repair template facilitates
the introduction of precise gene modifi-
cation [13].
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researchers are now also exploiting the CRISPR/Cas9 sys-
tem as a genome editing tool, and employing it in a sub-
stantial number of species and cell types (see [15] and
Table 1). 
4  Applications of CRISPR/Cas9-mediated
genome editing 
The basis for performing targeted genome editing is the
creation of DSBs in the genomic site of interest. Nuclease
induced DSBs in mammalian genomes can be resolved by
the endogenous DNA repair mechanism, which has
evolved into two major pathways: nonhomologous end
joining (NHEJ) and homology directed repair (HDR)
(Fig. 1B) [16, 36, 37]. In the absence of repair templates,
NHEJ ligates both dissected DNA ends directly without
DNA-end resection, which can generate mutations at the
DSB site. In contrast, HDR repair precisely restores DSBs
on the basis of repair templates harboring a homologous
DNA sequence that includes endogenous sister chro-
matids or exogenous donor repair templates. HDR
includes homologous recombination (HR) and single-
strand annealing (SSA), which are initiated by DNA-end
resection. HR is the most common form of HDR and has
sub-pathways using repair templates for accurate repair
rather than using intra-homologous regions flanking the
DSB in SSA, which results in the trimming of the inter-
vening region [36, 37]. Given the inherent feature of the
HR pathway, its precise manner of repair in order to pre-
serve the genetic materials – HDR will be referred to as HR
in this context. A recent alternative repair mechanism,
called microhomology-mediated end joining (MMEJ), lies
between NHEJ and HDR, and relies on microhomologous
sequences for error-prone end joining following DNA-end
resection [36, 38, 39]. Even though MMEJ is reported to
be induced at considerably lower levels than HDR [38], it
compensates the absence of NHEJ or HDR that is
observed in cancer cells [40, 41]. 
In the following sections, we provide examples of
CRISPR/Cas9-mediated genome editing applying the dif-
ferent DNA repair pathways for engineering purposes
(Fig. 2).
4.1  CRISPR/Cas9-mediated gene disruption
In mammalian cells, DSBs generated by CRISPR/Cas9 are
preferentially repaired by error-prone NHEJ, which caus-
es insertion/deletion (indel) mutations at target sites
(Fig. 2A). Indel formation can lead to frameshift mutations
in the coding region of genes, which disrupts their prop-
er translation and results in functional knockout of the tar-
get genes. HDR can also be applied to generate gene
knockouts when Cas9 and gRNA are introduced with
donor repair templates containing premature stop codon
or various lengths of bases, which induces frameshift
mutations. Many mutations induced by CRISPR/Cas9
without exogenous donor repair templates are also likely
to be associated with MMEJ [42]. In general, NHEJ has
been applied due to its mechanistic flexibility, lack of
requirement for DNA-end resection and repair templates,
and because it is not confined to S and G2 phases during
the cell cycle [36, 37]. HR-based gene targeting occurs
infrequently in mammalian cells [43], and is typically
observed at more variable frequency with programmable
nuclease-induced DSBs [15]. Thus, NHEJ-driven
approaches have been primarily exploited to achieve
gene knockouts in mammalian cells via CRISPR/Cas9 [28,
30, 44]. Our group demonstrated high efficiency of
CRISPR/Cas9-mediated disruptions of the C1GALT1-spe-
cific chaperone (COSMC) and fucosyltransferase 8 (FUT8)
genes in CHO cells with indel frequencies up to 47.3%
based on NHEJ [45]. Simple design and preparation of
CRISPR/Cas9 enable simultaneous modification of multi-
ple target sequences by introducing multiple gRNAs,
referred to as multiplexing [28, 30, 46–48]. 
While Cas9 normally induces DSBs, single strand
breaks (SSBs) can be created by Cas9 nickases, which
only have one active nuclease domain. SSBs are repaired
by the high-fidelity HDR or base excision repair (BER)
pathway to decrease the frequency of unwanted indels
generated at off-target sites. A double nicking strategy
consisting of Cas9 nickases with a pair of offset gRNAs
can produce SSBs on different DNA strands that result in
production of composite DSBs and efficient indel muta-
tions at on-target sites (Fig. 2B). Because off-target nick-
ing is repaired precisely, the double nicking approach
increases the targeting specificity of Cas9-mediated
knockout significantly [28, 34, 35, 49]. 
Simultaneous introduction of DSBs using paired
CRISPR/Cas9 cleavage in different genomic loci can give
rise to deletions of the intervening chromosomal segment
from kilobase-size [49, 50] to megabase-size (Fig. 2C) [50,
51] or chromosomal rearrangements including interchro-
mosomal translocations and intrachromosomal inversions
depending on target loci (Fig. 2C and 2D) [52]. The feasi-
bility of chromosome-scale genome engineering facili-
tates not only inactivation of entire gene clusters but also
investigation of a structural change of chromosomes and
its effect. In particular, large deletions of genomic regions
allow characterization of genes and genetic elements
such as promoters, enhancers and other regulatory ele-
ments.
4.2  CRISPR/Cas9-mediated site-specific gene
integration
Conventional gene targeting for defined sequence inser-
tion or replacement by HR requires several kilobase (kb) of
homologous sequences and positive/negative selection
markers on targeting vectors [53]. However, the success
rate is markedly low at a frequency of one per 105 to 107
www.biotechnology-journal.com www.biotecvisions.com
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treated cells, which hampers the use of HR [54]. The intro-
duction of DSBs can overcome these limitations while
increasing the frequency of HR and reducing constraints
on the vector design. Donor repair templates in the form
of either plasmid DNA or single-stranded oligodeoxynu-
cleotides (ssODNs) can be used to insert a gene of inter-
est into target sites coupled with CRISPR/Cas9 [55].
Homologous sequences, referred to as homology arms,
flank the insertion sites, and their size can be less than
1 kb each on plasmid-based donor repair templates. Co-
delivery of plasmid donors with CRISPR/Cas9 compo-
nents has achieved site-specific integration of transgenes
encoding reporter proteins and/or antibiotic resistance
markers [30, 56] or introduction of restriction sites into a
target locus in mammalian cells (Fig. 2E) [28, 55]. Using
ssODNs provides an alternative method for short modifi-
cations at target sites with high efficiencies and simple
synthesis. And 40–50  bp of short flanking homologous
sequences on each side of ssODNs can successfully lead
to HDR-based gene replacements [28, 30, 35, 55]. A dou-
ble nicking-induced HDR can also be leveraged to intro-
duce a restriction site at a target locus with comparable
efficiencies obtained with wild-type Cas9 nuclease [35]. 
HDR-independent knock-in strategies have expanded
options for CRISPR/Cas9-mediated gene insertion [35, 57].
Double nicking-mediated generation of defined overhangs
at a target genomic site could insert a double-stranded
oligodeoxynucleotide (dsODN), containing compatible
overhangs, via non-HDR mediated ligation (Fig. 2F) [35].
MMEJ-mediated gene knock-ins can also be applied in
human cells, resulting in cassette integration [57]. 
4.3  CRISPR/Cas9-mediated gene activation 
and repression
Inactivation of both nuclease domains of Cas9 nuclease
results in a nuclease-null Cas9, often termed ‘dead’ Cas9
(dCas9). Despite loss of nuclease activity, dCas9 retains
www.biotecvisions.comwww.biotechnology-journal.com
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IndelNHEJ
A
Large deletion
Inversion
NHEJ
C
TranslocationNHEJ
D
NHEJ
F
+ Donor 
DNA
Small insertion
Transgene insertion 
Correction
HDR
+ Donor 
DNA
+ Donor 
DNA
E
BER/
HDR
B
Indel
Figure 2. Types of genome editing
 application using CRISPR/Cas9.
(A) CRISPR/Cas9-mediated generation
of a single DNA DSB can result in inser-
tion and deletion (indel) mutations if the
break is repaired by the non-homolo-
gous end joining (NHEJ). 
(B) Repair of two simultaneously intro-
duced DNA single strand breaks (SSBs)
by nicking Cas9 can result in indel muta-
tions if repaired by base excision repair
(BER) or homology directed repair
(HDR). (C) Repair of two simultaneously
introduced DNA DSBs can result in large
deletion or inversion of the entire inter-
vening stretch of DNA if repaired by
NHEJ. (D) Repair of DNA DSBs on two
different chromosomes can result in
translocation. (E) Repair of a single DNA
DSB using donor DNA with a transgene
can result in transgene insertion or gene
correction if the donor DNA contains
base-pair changes. (F) Repair of two
simultaneously introduced DNA SSBs 
by nicking Cas9 using donor DNA can
result in small insertion.
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target specific DNA binding ability when guided by
gRNAs. Targeting of dCas9-gRNA complex to specific
sites was shown to interfere with transcriptional elonga-
tion, RNA polymerase binding, or transcriptional factor
binding. This results in reversible repression of targeted
genes, referred to as CRISPR interference (CRISPRi) [58].
dCas9 can also be utilized to regulate endogenous gene
expression particularly when dCas9 fuses with effector
domains such as a transcriptional activation domain
VP64 or repression domain KRAB [34, 59, 60]. Multiplexed
recruitment of dCas9-activators results in a synergistic
effect of higher levels of gene activation [34, 59], and
dCas9-repressors enhance the repressive function of
CRISPRi [60]. dCas9 fused to epigenetic enzymes may
enable targeted epigenetic changes such as histone mod-
ifications or DNA methylation, as described with TALE
DNA-binding domains [61].
4.4  Genome scale knockout screens 
for target identification
For decades, desirable traits in CHO cells have been iden-
tified with screens and selection systems, implemented
after mutagenesis, drug treatment, or media optimiza-
tion. This process has enabled the identification of
improved cell lines and in a few cases, mutations under-
lying these traits [62]. The CRISPR/Cas9 system now pro-
vides a way to systematize the identification of mutations
conferring a desirable trait. Specifically, while most
CRISPR/Cas9 applications have targeted individual
genes, advances in array-based oligonucleotide library
synthesis [63] have recently enabled the development of
genome-wide loss-of-function and gene overexpression
screens [64–69]. For these screens, thousands of gRNAs
are synthesized in parallel on microarrays and introduced
into lentiviral transfer plasmids along with Cas9
(Fig. 3A–C). Viral infections can be titrated so that most
infected cells receive a single gRNA, thus allowing one to
conduct negative and positive screens on a population of
cells (Fig.  3D and 3E). Mutants exhibiting the desired
traits can be identified by quantifying gRNAs in the pop-
ulation of cells before and after the screen via next-gener-
ation sequencing (Fig. 3F and 3G). While these screens
are conceptually similar to RNA interference (RNAi)-
mediated screening, CRISPR/Cas9 genome-wide loss-of-
function screens usually completely inactivate the genes
and there are fewer ambiguities arising from residual
activity. Furthermore, different gRNAs against the same
gene tend to give more consistent phenotypes than dif-
ferent short-hairpin RNAs (shRNAs) in RNAi screens [65].
Thus CRISPR/Cas9 screens have recently been applied to
identify genes responsible for cancer drug resistance [65,
69] and mechanisms underlying toxin activity [68, 70]. In
theory, these approaches could be employed to identify
mutants for any desired trait for which a high-throughput
selection system can be implemented.
5  Experimental design
Genome editing of cells requires several steps including
target site selection, primer design, cloning of CRISPR/
Cas9 reagents, transfection, cell line generation and
analysis. An overview of the experimental steps is given
in Fig. 4 and will be described in detail below. 
5.1  Target site selection and primer design
For selection of a 20  bp target sequence there are two
main considerations: the presence of a 5’-NGG-3’ PAM
sequence directly downstream of the target sequence for
Streptococcus pyogenes Cas9 (SpCas9) and the mini-
mization of potential off-target activity. For this purpose,
several online target selection tools are available. For tar-
get selection in mammalian cells, one must consider the
various exons and splice variants for the gene of interest
(Fig. 4A). It is recommended to design at least two gRNAs
for each target locus and test their target modification
efficiency, as gRNAs occasionally may not work for
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packaging
(HEK293)
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AGGCCGGTACG
TACGCGGGAAC
Sequencing
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TTTAGGTAAGC
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TACGCGGGAAC
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Figure 3. Genome-wide screening using CRISPR/Cas9. Genome-wide
knockout, activation, and repression screens can be conducted. (A) To 
do this, gRNA constructs for all targets are synthesized in parallel on
microarrays. (B) RNA constructs are loaded into a lentiviral transfer plas-
mid, and (C) packaged into lentiviruses. (D) The lentiviruses, harboring all
possible gRNAs, are used to infect a population of cells. (E) The cells are
then subjected to a selection pressure. (F) gRNAs are sequenced before
and after the screen. (G) Positive and negative genetic changes can be
identified by searching for gRNA constructs that increase or decrease,
respectively, in the population over the course of the screen. 
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unknown reasons [55]. Online target selection tools assist
in identifying potential target sites in a genomic sequence
of interest and provide computationally predicted off-tar-
get sites for each identified target. Examples of these
tools are the CRISPR Design (http://tools.genome-engi-
neering.org) [55], the ZiFiTtargeter (http://zifit.partners.
org) [71] and the E-CRISP (http://www.e-crisp.org) [72]. At
the time of writing this manuscript, these tools were
unable to search for similarities in the CHO genome.
However, for genome engineering of CHO cells, the
CRISPy tool (http://staff.biosustain.dtu.dk/laeb/crispy) is
available [45]. This online bioinformatics tool provides a
precompiled database with identified target sites in the
CHO-K1 genome. In CHO-K1 genome there are 2 379 237
Cas9 targets with the format GN19NGG in CDS regions of
23  750 genes (ref-seq assembly GCF_000223135.1). For
increased targeting specificity, one may use the D10A
nickase mutant of Cas9 (Cas9n) together with a pair of
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Figure 4. Experimental overview of genome engineering. Genome engineering contains several experimental steps including: (A) Selection of the target
site that could be in the protein coding regions of a gene of interest. It is important to consider the potential splice variants of the gene of interest.
(B) Upon target site selection, oligonucleotides for gRNA construction can be designed and ordered in microtiter plates or spotted on arrays for high-
throughput cloning. (C) The gRNA can be cloned in a simple step with annealed oligonucleotides using ligation-free cloning and be delivered together with
Cas9 as DNA. For RNA delivery, expression vectors can be generated to facilitate in vitro transcription of Cas9 and gRNA. For protein delivery, the Cas9
protein can be purified and delivered together with in vitro transcribed gRNA. The U6 polymerase III promoter is often used to drive expression of the
gRNA. For Cas9 expression, the cytomegalovirus (CMV) vector is often applied. The nuclear localization signal (NLS) facilitates targeting of Cas9 to the
nucleus. Bgh encodes the bovine growth hormone poly adenylation signal. The T7 promoter can be applied for in vitro transcription.(D) The Cas9 and
gRNA reagents are introduced into cells during transfection or infection to modify the genomes. (E) Modified cells are isolated using FACS or limiting dilu-
tion, and isolated cells are expanded to create genome engineered monoclonal cell lines.(F) Different analytical assays apply preparation and digestion of
amplicons followed by gel separation that includes the Surveyor nuclease assay or restriction fragment length polymorphism (RFLP). Sequencing can be
applied for high-throughput screening in microtiter plates to obtain information about introduced DNA changes in cell pools or clonal cell lines.
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gRNAs, and the CRISPy tool also provides potential part-
ner gRNAs for nicking Cas9 compatible with CHO cells.
The selection of gRNAs regarding orientation and spac-
ing is critical and offsets between -4 and 100 bp are rec-
ommended [35]. In addition, CRISPy aids in primer design
for verifying cleavage efficiency at on-target sites and
computationally predicted off-target sites. Upon selection
of target sites, oligonucleotides for gRNA synthesis can
be designed. It is important to note that the PAM site is
required in the target locus but is not part of the 20 bp tar-
get sequence of the gRNA. Also, the U6 RNA polymerase
III promoter, often used to express the gRNA, prefers a
guanine (G) nucleotide as the first base of its transcript. In
cases where the target sequence does not contain a G as
the 20 bp nucleotide upstream of the PAM, a G can be
added to introduce G as the first base of the gRNA tran-
script [55]. For high-throughput cloning, oligonucleotides
can be delivered in microtiter plates or spotted on arrays
(Fig. 4B). 
5.2  Construction of CRISPR/Cas9 reagents
Depending on the genome engineering task, gRNAs can
be delivered as gRNA-expressing plasmids or as PCR
amplicons containing an expression cassette. The cloning
of gRNA expression plasmids can be done rapidly by
applying a single cloning step with a pair of partially com-
plementary oligonucleotides (Fig. 4C). The generation of
PCR amplicons is even faster and is well suited for large-
scale testing of gRNAs or generation of large knockout
libraries. Depending on the purpose of the genome edit-
ing event, the gRNA and Cas9 can be delivered as RNA
upon in vitro transcription or even as Cas9 purified pro-
tein together with in vitro transcribed gRNA (Fig. 4C) [73].
An overview of delivery methods applied in mammalian
genome editing including references is given in Table 1.
The most used promoter to drive expression of gRNAs in
mammalian cells is the RNA polymerase III U6 promoter.
Common promoters for driving the expression of Cas9 in
mammalian cells are the cytomegalovirus (CMV) promot-
er and the elongation factor 1-α (EF1-α) promoter. For
RNA delivery of Cas9 and gRNA, the T7 promoter is often
applied for in vitro transcription. Fusing 2A-GFP or antibi-
otic resistance genes to Cas9 can facilitate screening or
selection of transfected cells with Cas9 expression. Isola-
tion of cell populations with increasingly higher Cas9
expression levels can facilitate isolation of cells with
increased genome editing rates [74]. Increased efficiency
of genome editing may also result in a trade-off effect of
increasing non-targeted cleavage and mutagenesis
effects.
5.3  DNA repair templates
Generation of DNA repair templates is often based on
plasmid-based vectors with homology arms of varying
length. Often, the homology arms are longer than 500 bp.
The ssODNs require short homology arms of minimum
40 bp and can therefore be prepared without cloning [75].
They can be oriented in either the sense or the antisense
direction relative to the target locus. 
5.4  Engineered cell line generation
The CRISPR/Cas9 reagents aimed at modifying the
genome can be introduced by traditional transfection
methods including chemical transfection, electropora-
tion, nucleofection and by viral delivery depending on the
cell type and application (Fig. 4D, Table 1). The transfec-
tion process generally results in a heterogeneous mixture
of genomic modifications in the targeted cell pool, and
efficiencies are highly dependent on transfection effi-
ciency. Several assays are available to quantify and char-
acterize indels and modifications introduced. Isolation of
modified cells from the mixed population of wild type and
modified cells are often desired and can be performed by
fluorescence-activated cell sorting (FACS) or limiting dilu-
tions (Fig. 4E). It is important to note that different cell
types may respond differently to single cell isolation. The
isolated cells can then be expanded to establish new clon-
al cell lines. The assays described below can also be
applied to characterize the generated clones to identify
clones with desired genomic modifications.
5.5  Analysis of modifications
Different assays are available to monitor the heteroge-
neous mixture of mutations introduced by NHEJ or HDR
upon CRISPR/Cas9-mediated genome editing (Fig.  4F).
For detection of indels, two mutation screening assays
use the Surveyor nuclease the T7 endonuclease I, which
are two mismatch-recognizing nucleases. The enzymes
recognize heteroduplex DNA in an amplicon pool after
reannealing with wild type sequences and facilitate
selective digestion of mismatched duplex amplicons.
This facilitates estimation of the mutated fraction of an
amplicon pool [76, 77]. Some mutations can be deter-
mined using the restriction fragment length polymor-
phism (RFLP) method if a restriction site is introduced
during the genome editing process. With this method, the
amplicons are digested by selected restriction enzymes
and separated by size before analysis. The Surveyor
nuclease and RFLP assay has been applied in clone veri-
fication in several genome editing studies including
CRISPR/Cas9-mediated generation of mutated mice [78].
Genomic changes in a modified pool of cells or clones can
also be analyzed by Sanger sequencing. When sequenc-
ing amplicons with a heterogenous mixture of mutations,
subcloning can be used to isolate the different amplicons
before sequencing. For high-throughput identification of
genome modifications, deep sequencing can be applied
for direct sequencing of amplicons without subcloning.
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Combined with barcoding, amplicons from hundreds of
different cell pools or clones can be sequenced simul -
taneously using a benchtop sequencer like the Miseq
 (Illumina Inc.). 
6  Off-target analysis
Since Cas9 recognizes a target by simple Watson-Crick
base pairing rules, it is presumed that the off-target activ-
ity results as the nuclease binds a sequence with some
level of homology to the target sequence and subse-
quently induces a DSB. Off-target activity can lead to
alterations that have more or less serious consequences
for the cells. It can disrupt the normal cell function [79],
and cause unwanted chromosomal rearrangements such
as deletions, inversions and translocations [80–83].
A wide variety of assays exist to measure the extent to
which a given guide sequence exhibits off-target activity.
The most straightforward approach to analyze specific
off-target activity is based on an initial prediction of sites
in the genome that might be prone to off-target activity.
Available prediction tools incorporate combinations of
biological principles and factors that drive the Cas9-DNA
interactions in their prediction algorithms. These could
include information such as that the PAM proximal region
is crucial for target recognition and cleavage by Cas9 [25,
28] and tolerates a single base mismatch, that three to five
mismatches in the PAM distal region can be tolerated [34,
84, 85], and that a 5 nt seed region next to PAM is required
for Cas9 binding [86]. The off-target prediction is usually
followed by either gel-based assays such as T7 endonu-
clease I or Sanger- or deep-sequencing to look for off-tar-
get effects at the predicted sites, of which the sequenc-
ing-based approaches are more sensitive [49]. However,
contrasting results from this approach have been report-
ed [44, 49, 87]. 
Methods for genome-wide identification of off-target
activity exist. These methods are both based on Cas9
binding sites and Cas9 cleavage. Chromatin immunopre-
cipitation-sequencing (ChIP-seq) can assay Cas9 binding
sites. The nuclease is pulled down and the bound DNA
fragments are sequenced and mapped to their native
location in the genome [86, 88]. The Cas9 binding site
methods often lead to identification of false-positives, as
Cas9 does not always cleave the sites bound by dCas9.
Additional methods to assay off-target Cas9 cleavage
include integrase-deficient lentivirus (IDLV) at the DSBs
[89] and in vitro selection based on a DNA substrate
library [90]. The IDLV capture is much lower than the
actual mutation frequency; thus, many genuine off-target
sites are not detected [91]. For the in vitro selection, many
of the identified off-target sites do not exist in the genome
[90]. Newer, more sensitive genome-wide methods are
high-throughput, genome-wide translocation sequenc-
ing (HTGTS) [92], genome-wide, unbiased identification
of DSBs enabled by sequencing (GUIDE-seq) [93] and in
vitro Cas9-digested whole-genome sequencing
(Digenome-seq) [91]. Digenome-seq is the only method
not limited by chromatin accessibility. Even with sensi-
tive genome-wide identification of off-target activity, it is
still demanding to determine with certainty which muta-
tions are spontaneous and which are due to off-target
activity of the nuclease.
A good solution would be to minimize the effects of
off-target activity, and several strategies have been test-
ed. Adjusting the concentration as well as the ratio of
Cas9 to gRNA, changes the amount of off-target cleavage
[85]. Using paired nickases, as described earlier, does not
promote unwanted translocations or double the specifici-
ty of Cas9-mediated mutagenesis [34, 35]. The use of 3´
truncated gRNAs or gRNAs with two extra guanine
nucleotides at the 5´ end yields better on-/off-target ratios
[49, 90, 91], but at lower absolute on-target efficiencies. 
Using 5´ truncated gRNAs shows decreased mutagenic
effects and enhanced sensitivity to single or double mis-
matches at the DNA-RNA interface [94]. Fusion of cat-
alytically dCas9 to FokI nuclease improves the specificity
of genome editing [95, 96], and thereby decreases the off-
target activity. Selection of unique target sites that lack
any homologous sequence elsewhere in the genome can
also minimize off-target effects [49].
7  Past, present and future of CHO 
cell factory engineering via CRISPR/
Cas9-mediated genome editing
7.1  Past of CHO cell engineering
CHO cell engineering efforts have been forced to rely on
traditional methods because of the lack of genomic
sequence data. These methods included overexpression
of endogenous CHO or exogenous genes. RNA interfer-
ence mediated regulation of gene expression has also
been used to increase the time integral of viable cell
 concentration and/or specific productivity (q) [97, 98].
Targeted genome engineering for CHO cells has primari-
ly focused on knockout, which has been conducted by
HR and ZFNs [99–102]. Both alleles of the a1,6-fucosyl-
transferase (FUT8) were disrupted by HR in CHO-DG44
cells following screening of approximately 120 000 trans-
fectants [99]. Application of the ZFNs significantly
increased the targeting efficiencies of gene disruptions
up to >1%, which allowed isolation of knockout clones
from one 96-well plate of single-cell derived clones
[100–102]. Sequential rounds of ZFN-mediated gene dis-
ruptions achieved accumulation of knockouts on the
background of previously generated knockout clones,
enabling the generation of double and triple knockout
CHO cell lines [101]. 
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Site-specific integration of transgenes encoding
recombinant proteins has also been performed to circum-
vent random integration followed by extensive clone
screening for high producers. Site-specific recombinase-
based systems, including Cre/loxP and Flp/FRT, enabled
insertion of a gene of interest into the predefined specific
target sites where a high-level of transcription and ampli-
fiable capacity were warranted [103, 104]. The PhiC31/R4
integrase system was also successfully applied to place a
gene of interest into transcriptionally active pseudo attP
sites [105]. Moreover, homology-independent target-spe-
cific integration of short (<100 bp) oligonucleotides [106]
or linear transgenes [107] has been driven by ZFNs in
CHO cells. Of note, Cristea et al. achieved targeted inte-
gration and expression of large transgenes encoding anti-
body at FUT8 locus of CHO cells with the use of ZFNs or
TALENs following physiological selection for FUT8 knock-
out [107]. 
7.2  State of the art in CHO cell engineering –
toward facile genome engineering
In 2014 and 2015, we demonstrated successful applica-
tion of CRISPR/Cas9 for generating highly efficient gene
disruptions and gene insertions in CHO cells [45, 56].
Using Cas9 proteins from Streptococcus pyogenes, 18
gRNAs were used to target four genes. These resulted in
relatively high indel frequencies in the range of 7.6 to
47.3%, regardless of CHO host cell line (CHO-K1 or 
CHO-S), transfection method (nucleofection or chemical
transfection), culture mode (adherent or suspension), or
locus (C1GALT1C1, FUT8, MGAT1 or LDHA) [45, 56].
Most indels were single base pair insertions that resulted
in frame shift mutations. Current protocols are now
enabling the simultaneous disruption of up to three genes
with CRISPR/Cas9-based multiplexing. Simultaneous
introduction of multiple gRNAs and enrichment for trans-
fectants is yielding 58.8% of all clones harboring multiple
knockouts [48]. HDR-mediated integration of large gene
expression cassettes into desired loci was achieved in
CHO cells by combining the CRISPR/Cas9 system with
donor plasmids harboring short homology arms [56]. 
A  targeting efficiency of between 7.4 and 27.8% was
obtained depending on the target locus and CRISPR/Cas9
activity. Since HDR-based transgenesis is considered to
be a rare event in CHO cells due to their intrinsically low
levels of HDR [107], this result makes it worthwhile to
revisit the HDR-based targeted integration. Recent
genome engineering efforts via CRISPR/Cas9 conducted
in most common nonmammalian systems including
Escherichia coli [58, 108, 109] and Saccharomyces cere-
visiae [110, 111] reiterate the applicability and necessity
of this state of the art technology toward accelerated cell
factory construction. 
7.3  Future of CHO genome engineering – toward
rational design of mammalian cell factories
The CRISPR/Cas9 technology will be a valuable tool as we
aim to develop the next generation of CHO cell factories.
Advances in three areas will help this goal come to fruition,
namely, further refinements of the CRISPR/Cas9 technolo-
gy, increased understanding of the CHO genome, and
detailed characterization of cellular pathways.
First, future efforts will continue to improve the preci-
sion and targeting efficiency of CRISPR/Cas9. The pres-
ent CRISPR/Cas9 has a high genome editing success rate,
and nearly up to 100% of multigene mutation frequencies
were achieved in Escherichia coli [109] and Saccha-
romyces cerevisiae [111]. However, it still has a broad
range of genome editing activities (2.3 to 79%) obtained
in mammalian cells depending on the cell type, delivery
method and target locus [16]. Given the current status of
absence of reliable prediction rule for mutation rates,
increasing the mutation rates must be pursued to accel-
erate genome editing in CHO cells. For example, rational
design of highly active gRNAs [112] and engineered Cas9
[113] will enhance the functionality of the CRISPR/Cas9
system. The improved accessibility of Cas9 and gRNAs
by efficient delivery approaches through expression
 vector engineering or mRNA/protein delivery of
CRISPR/Cas9 components can also be easily implement-
ed. Instead, an efficient enrichment of cells with high
Cas9 expression levels [74] or genome editing events [114]
could provide another simple option for acquisition of
modified cells. In contrast with an acceptable frequency
of gene disruptions, the rate of HDR-mediated integration
of large transgenes remained relatively low, as a drug or
phenotypic selection process was required for the gener-
ation of targeted integrants [56]. In addition to the afore-
mentioned general approaches, methods to improve the
HDR:NHEJ ratio are needed because high nuclease activ-
ity does not necessarily ensure high rates of HDR. Lin et
al. recently reported interesting results showing that
chemically induced cell cycle synchronization and subse-
quent delivery of pre-assembled Cas9-guide RNA ribonu-
cleoprotein complexes achieved HDR-mediated genome
editing at levels up to 38% in human cells [115]. The reap-
plication of dominant NHEJ-driven knock-in approaches
[107] together with CRISPR/Cas9 will also broaden the
scope of knock-in strategies for rCHO cell construction. 
While improvements in the targeting efficiency are
being achieved, undesired off-target mutations can still
arise. In the area of cell culture engineering, unexpected
mutations may not be critical compared with therapeutic
applications, particularly when well-characterized genes
or sites are targeted. However, the potentially confound-
ing effects of off-target mutations may generate false-pos-
itive effects, thus obstructing evaluation of novel sites. We
anticipate that better understanding of the CRISPR/Cas9
system at structural and biochemical levels could over-
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come this issue. This will require improved approaches to
reduce off-target mutations of Cas9 (Section 6) and refine-
ment of bioinformatics tools for design of gRNA target
sites with minimized off-target effects (Section 5.1). 
Second, the establishment of improved Chinese ham-
ster and CHO cell line reference genomes will improve
genome editing efforts and subsequent in-depth analyses
of outcomes. The well-defined reference genomes will
allow us to analyze genome-wide off-target effects of Cas9
nucleases as well as structural variation analysis of CHO
cells (e.g., indels and chromosomal translocations) [116]
upon exposure to CRISPR/Cas9. Improvements in refer-
ence genome sequences will also decrease false-negative
rates in genome-scale knockout, activation, or repression
screening, thus helping to identify more candidate genes
that are essential for desired phenotypes. 
Third, computational models of metabolism [117], gly-
cosylation [118], signaling [119], DNA damage response
[120] and transcriptional regulation [121] will aid in the
design of novel expression hosts. These models, when
combined with ‘omics data (e.g. RNA-Seq or epigenome)
[122], will help to identify pathways that when engineered
will yield desired traits ranging from enhanced protein
secretion to the identification of ideal transgene inser-
tions sites ensuring high and stable expression of genes.
Given the homogeneity of transgene expression levels
observed in targeted integrants [56], site-specific integra-
tion of a gene of interest into any desired target sites could
lead to construction of production CHO cell lines assuring
sustainable and high expression levels in a short time. 
8  Concluding remarks
The advent of genomic sequences and genome editing
technologies makes genome-scale science for CHO cells
inevitable. Apart from the pros and cons of individual pro-
grammed nucleases, the cost-effective and simple
CRISPR/Cas9 system definitely offers several advantages
that industry would welcome. Together with improved
reference genomes for Chinese hamster and CHO cells,
the highly efficient CRISPR/Cas9 system is now ready to
address long-held questions inherent to CHO cells. Multi-
plexed genome engineering including gene knockouts,
gene knock-ins and controlled expression of target genes
will accelerate understanding of the molecular basis driv-
ing traits that make CHO cells a predominant mammalian
cell factory. This could ultimately lead to engineering of
the next generation of CHO cell factories.
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Chapter 2 
 
Knockout of single target genes 
 
 
The CRISPR/Cas9 tool is a major player in the process of transitioning from the traditional 
random approach of cell line development for therapeutic protein production towards a more 
rational engineering approach. Precise genome editing has long been the missing tool in 
mammalian cell line engineering, and with its tidy arrival we hope to catch up to the many existing 
tools for microbial cells to build synthetic gene networks 11. New methods and technologies, 
including gene editing, will help to characterize and modulate gene expression in biological 
context that is necessary to build synthetic gene networks with predictable activity. Gene editing 
with CRISPR/cas9 can be used for targeted mutagenesis of both coding and noncoding genetic 
regions, and for the insertion of transgenes at precise genomic locations.  
In this chapter and the following chapters, several studies demonstrating successful 
application of CRISPR/Cas9 genome editing for CHO cell engineering for various purposes is 
introduced, in an effort to contribute to the toolbox for CHO cell line development. This chapter 
is comprised of a book chapter describing a step-by-step method on how to generate a single gene 
knockout in CHO cells using the CRISPR/Cas9 genome editing tool. With the availability of CHO 
genome sequences and genome editing tools came the opportunity to knockout genes, making it 
possible to remove unwanted activities associated with these genes. Knockout of genes have since 
played an important role in improving culture performance, product quality and enabling gene 
amplification methods, among other beneficial attributes 12. With the emergence of the 
CRISPR/Cas9 genome editing tool 13,14, the process of knocking out genes in CHO cells has 
significantly improved 10. The tool is cheaper, more efficient, and relatively simple and flexible 
(allowing targeting of almost any gene) in comparison to other genome editing tools. With this in 
mind, it provides the opportunity to target and knockout a broader range of genes than in the pre-
CRISPR/Cas9 era. This significantly improves our ability to study more genes and their biological 
function, allowing us to identify further disadvantageous traits and reroute biological pathways to 
gain phenotypes more optimal for production of therapeutic proteins. 
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Chapter 7
Application of CRISPR/Cas9 Genome Editing to Improve 
Recombinant Protein Production in CHO Cells
Lise Marie Grav, Karen Julie la Cour Karottki, Jae Seong Lee, 
and Helene Faustrup Kildegaard
Abstract
Genome editing has become an increasingly important aspect of Chinese Hamster Ovary (CHO) cell line 
engineering for improving production of recombinant protein therapeutics. Currently, the focus is directed 
toward expanding the product diversity, controlling and improving product quality and yields. In this 
chapter, we present our protocol on how to use the genome editing tool Clustered Regularly Interspaced 
Short Palindromic Repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) to knockout engineering tar-
get genes in CHO cells. As an example, we refer to the glutamine synthetase (GS)-encoding gene as the 
knockout target gene, a knockout that increases the selection efficiency of the GS-mediated gene amplifica-
tion system.
Key words Chinese Hamster Ovary Cells, CRISPR/Cas9, Genome editing, Glutamine synthetase, 
Knockout, Recombinant protein production
1 Introduction
Chinese Hamster Ovary (CHO) cells are extensively used as a host 
cell system for the production of recombinant protein therapeu-
tics. The progress and success of CHO cell culture technology has 
long been depending on large-scale screening of highly productive 
cell lines and process optimization. Despite the established success 
of CHO cells, there are increasing demands to expand product 
diversity, control and improve product quality, and improve cellu-
lar production capacities. Advances in this area have been made by 
genetic engineering approaches including the repression or knock-
out of disadvantageous genes.
Knockout of genes has improved production of recombinant 
proteins in CHO cells and the performance of CHO production 
cells on several levels. Prolonging cell cultures by targeting pro- 
apoptotic genes, increasing product quality by targeting genes 
involved in glycosylation of proteins, and enabling amplification of 
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genes by targeting the dihydrofolate reductase (DHFR) gene are 
among the achievements using gene knockouts. An overview of 
genes targeted using gene knockout for improvement of CHO 
production cells was recently presented by Fischer et al. [1].
The bacterial clustered regularly interspaced short palindromic 
repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) gene edit-
ing tool has drastically improved the knockout of genes— making 
it easier, cheaper, and more efficient. CRISPR/Cas9 is a relatively 
simple genome editing system comprised only of the nuclease Cas9 
and a single guide RNA (sgRNA), which has shown to be highly 
applicable for genome editing in CHO cells [2]. In this system 
target recognition is enabled by a 20-nt target complementary 
sequence in the sgRNA, and a protospacer adjacent motif (PAM) 
sequence directly downstream of the target sequence [3]. The 
PAM sequence may differ between Cas9 orthologs [2]. The sgRNA 
guides the Cas9 nuclease to the target DNA, where it introduces a 
double strand break (DSB) [4]. The DSB can be repaired by the 
cells’ own DNA repair system. In CHO cells the most frequently 
used DNA repair pathway is the error-prone non- homologous end 
joining (NHEJ). Through the NHEJ pathway both dissected 
DNA ends are ligated directly without DNA-end resection, which 
may cause insertion or deletion of one or more base pairs—also 
known as indel formation. Indel formation can cause a frameshift 
in the coding region of genes, disrupting their translation and leav-
ing the genes dysfunctional. The Cas9 protein can be programmed 
to target any DNA sequence of interest that is followed by a PAM 
sequence, simply by changing the 20-nt target complementary 
sequence in the sgRNA.
In this chapter, we describe a general and robust platform 
for generating a single-gene knockout in CHO cells using the 
CRISPR/Cas9 genome editing tool. As an example, we refer to 
the gene glul, encoding glutamine synthetase (GS), as the target 
gene. However, the methods are general and can be used to knock-
out other genes or even to multiplex knockouts [5]. GS is the 
enzyme that converts glutamate and ammonia to glutamine, and 
without glutamine in the growth medium GS is essential for cell 
survival [6]. The widely used GS expression system ™ (Lonza) 
exploits the glutamine metabolism in mammalian cells, by using a 
transfected GS-encoding gene as a selectable marker as it permits 
growth in medium lacking glutamine. The system works well in 
cell lines that do not express sufficient GS to survive. In cell lines 
such as CHO cells, which express sufficient endogenous GS, the 
addition of the GS inhibitor methionine sulfoximine (MSX) is 
required to inhibit excess GS activity. Increasing the MSX concen-
tration can result in gene amplification and increased productivity 
[7]. It is desirable to eliminate the endogenous GS-encoding gene 
from CHO cell lines to improve the selection stringency and effi-
ciency of the GS system in CHO cells [8].
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2 Materials
 1. Target sequence analysis software, e.g., CRISPy tool available 
for free online.
 2. Glycerol stock of E. coli transformed with sgRNA expression 
plasmid (from Ronda et al. [9]).
 3. 2× YT medium.
 4. Kanamycin.
 5. 500 mL baffled Erlenmeyer shake flask.
 6. Sterile pipette tips.
 7. Incubator with shaker, 37 °C, 250 rpm.
 8. Plasmid midi- or maxiprep kit (Machery-Nagel).
 9. Sterile Milli-Q water.
 10. NanoDrop 2000 (Thermo Scientific).
 11. PCR primers for amp lification of sgRNA backbone (for design 
instructions see Subheading 3.2.2).
 12. Primers containing the sgRNA sequence (for design instruc-
tions, see Subheading 3.2.3).
 13. Phusion U polymerase (Thermo Scientific).
 14. 5× HF Buffer (Thermo Scientific).
 15. dNTPs.
 16. PCR tubes.
 17. Thermocycler.
 18. Fast Digest DpnI enzyme (Thermo Scientific).
 19. 10× Green Buffer (Thermo Scientific).
 20. 1 kb DNA ladder.
 21. 1% agarose gel: 1 g agarose powder (Bio-Rad) dissolved in 
100 mL 1× TAE buffer (Sigma).
 22. Gel chamber and power source.
 23. PCR and gel purification kit (Machery-Nagel).
 24. 10× NEBuffer 4 (New England Biolabs).
 25. Heat block.
 26. USER enzyme (New England Biolabs).
 27. 10× BSA (New England Biolabs).
 28. 1.5 mL eppendorf tubes.
 29. Mach1 competent E. coli cells (Thermo Scientific).
 30. Heat block, 37 °C, 300 rpm.
 31. Table top centrifuge.
 32. Sterile spatula.
2.1 sgRNA 
Expression Plasmid 
Construction
Knockout Generation in CHO Cells using CRISPR/Cas9
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 33. LB-kanamycin plates: 15 g/L Agar, 10 g/L Tryptone, 10 g/L 
NaCl, 5 g/L Yeast Extract, 50 μg/mL kanamycin.
 34. 10 mL bacterial culture tubes.
 35. Plasmid miniprep kit (Machery-Nagel).
 36. Access to Sanger sequencing facility.
 37. Sequencing primers.
 38. Sequence analysis software (e.g., CLC Main Workbench).
 1. Glycerol stock with E. coli transformed with GFP 2A peptide- 
linked Cas9 expression plasmid (from Grav et al. [5]).
 2. Ampicillin.
 3. LB-ampicillin agar plates: 15 g/L Agar, 10 g/L Tryptone, 
10 g/L NaCl, 5 g/L Yeast Extract, 60 μg/mL ampicillin.
 1. CHO-S cells (Life Technologies).
 2. NucleoCounter NC-200 Cell counter (ChemoMetec).
 3. Growth medium: CD CHO medium (Life technologies) sup-
plemented with 8 mM L-glutamine (Lonza).
 4. 15 or 50 mL centrifuge tubes.
 5. 6-well plate, flat bottom (Corning #351146).
 6. Humidified incubator, 37 °C, 5% CO2, 120 rpm.
 7. OptiPro™ SFM reduced serum medium (Life Technologies).
 8. FreeStyle™ MAX reagent (Life Technologies).
 9. sgRNA expression plasmid generated in Subheading 3.2.
 10. GFP 2A peptide-linked Cas9 expression plasmid prepared in 
Subheading 3.3.
 1. Quick extract (Epicentre).
 2. 2× Phusion Master Mix (Thermo Scientific).
 3. Primers (for design see Subheading 3.5).
 4. 10× NEBuffer 2 (New England Biolabs).
 5. T7 endonuclease (New England Biolabs).
 6. 4% E-Gel (Invitrogen #G501804) or equivalent.
 7. Mother E-base (Invitrogen).
 1. Fluorescence-activated cell sorter.
 2. 384-well plates, flat bottom (Corning #3542).
 3. FACS sorting medium: CD CHO medium (Life Techno-
logies) supplemented with 8 mM L-glutamine (Lonza), 1% 
Antibiotic- Antimycotic 100× (Gibco), and 1.5% HEPES (Life 
Technologies).
2.2 Prepare GFP 2A 
Peptide-Linked Cas9 
Expression Plasmid
2.3 Transfection 
of CHO-S Cells
2.4 Analysis of Indel 
Generation: T7 
Endonuclease Assay
2.5 Generation 
of Clonal Cell Lines: 
Fluorescence- 
Activated Cell Sorting 
(FACS)
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 4. FACS tubes.
 5. 30 μm cell strainer.
 6. Celigo cytometer or microscope.
 7. Humidified incubator, 37 °C, 5% CO2, no shake.
 8. 96-well plates, flat bottom (Corning #351172).
 9. Clone expansion medium: CD CHO medium (Life Techno-
logies) supplemented with 8 mM L-glutamine (Lonza), 1% 
Antibiotic- Antimycotic 100× (Gibco), and 1 μL/mL Anti- 
clumping agent (Life Technologies #0010057AE).
 10. 96-well plates, V-Shaped (Greiner bio-one #651161).
 11. Breathable plastic bag.
 1. Primers from Subheading 3.5.
 2. 2× Phusion Master Mix (Thermo Scientific).
 3. DNA quick extract from Subheading 3.6.
 1. 12-well plates, flat bottom (Corning #351143).
 2. 125 mL shake flask (Corning #431143).
 3. DMSO (Sigma-Aldrich #472301).
 4. Cryotubes.
3 Methods
The following section is a general protocol that we use for single 
knockouts in our lab. To make the protocol easier to follow, we 
refer to the GS-encoding gene as an example of a specific target. 
The protocol can be used to target other genes, and can easily be 
adapted to multiple knockouts [5]. An overview of the protocol is 
shown in Fig. 1.
 1. Go to http://staff.biosustain.dtu.dk/laeb/crispy/.
 2. Search for your target gene by name, id or symbol, e.g., the 
GS- encoding gene glul. Be aware of that there can be multiple 
genes annotated to encode one protein (see Note 1).
 3. A selection of different target sequences will be displayed. You 
can sort them according to the number of exact matches (pref-
erably one) and see where the different target sequences are 
located in relation to exons and introns (see Note 2). The target 
sequence is followed by a PAM sequence (5′-NGG-3′) in the 
target gene, as shown in Fig. 2a.
2.6 Analysis of Gene 
Modifications: Sanger 
Sequencing
2.7 Expansion 
of Clones
3.1 Identification 
of Target Site 
and sgRNA Primer 
Design
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 4. Design sgRNA primers using your selected target sequence 
from Subheading 3.1. The target sequence minus the PAM 
sequence is the only varying region when designing primers 
and constructing the sgRNA plasmids for different target 
sequences, as described in Fig. 2b.
 1. Request the sgRNA plasmid from Ronda et al. [9] and gener-
ate a bacterial glycerol stock (or prepare it from scratch follow-
ing the method described in the publication).
 2. Use the tip of a sterile pipette tip and scrape the bacterial stock, 
add the pipette tip to 100–200 mL of 2× YT medium supple-
mented with 50 μg/mL kanamycin, and incubate overnight at 
37 °C with shaking at 250 rpm.
 3. Isolate plasmid DNA using a plasmid midi- or maxiprep kit, 
resuspend at 1 μg/μL in Milli-Q water. Measure the concen-
tration using Nanodrop 2000.
 1. Use the sgRNA plasmid map, and design and order uracil- 
containing primers to amplify the sgRNA backbone. The prim-
ers should amplify the sgRNA backbone so that it acquires 
overhangs after Uracil-Excision Specific Reagent (USER) 
treatment that is compatible for USER fusion with the over-
hangs of the annealed primers from Subheading 3.2.3, as 
described in Fig. 2b. Alternatively, apply primers previously 
published [9].
3.2 sgRNA Plasmid 
Construction
3.2.1 Prepare sgRNA 
Backbone Plasmid
3.2.2 Amplify sgRNA 
Backbone
Identify target sequence 
in gene of interest
Construct sgRNA
expression plasmid
Transfect GFP_2A_Cas9 
and sgRNA
Single cell sort for GFP 
positive cells using FACSExpand clones
Sample & extract 
genomic DNA
Analyse gene 
modifications
Verify 
knockouts
Make a cell bank
of clones
5’-GNNNNNNNNNNNNNNNNNNNNGG-3’ U6 promoter
target 
sequence
sgRNA 
scaffold
termination 
signal
sgRNA plasmid
Cas9
2A
GFP
+ -
WASTE SINGLE CELLSORT
DSB by CRISPR Cas9 
and GFP expression 
Fig. 1 Schematic outline of the experimental setup for the method described in this chapter
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U6 
promoter
target 
sequence
sgRNA 
scaffold
termination 
signal
sgRNA plasmid
NNNNNNNNGNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNForward sgRNA primer
Reverse sgRNA primer NNNNNNNNNNNNNNNNNNNNNNNNCNNNNNNNNNNNNNNN
NNNNNNNNGNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNCNNNNNNNNNNNNNNNNNNNNNNNN
Annealed 
sgRNA primers
U6 
promoter
sgRNA 
scaffold
termination 
signal
PCR amplified
backbone
NNNNNNNNUNNNNNNNNNNNN
NNN
NN
UNN
NNN
N
+
USER treatment
Anneal primers
PAM
NGG
Target sequence
N (19) + G
A
B Target complementary sequence G+N (19)
GNNNNNNNNNNNNNNNNNNNAGG
CNNNNNNNNNNNNNNNNNNN TCC
NNNNNNNNNNN- 3’
NNNNNNNNNNN- 5’
5’ -NNNNNNNNN
3’ -NNNNNNNNN
Fig. 2 An outline of the target gene and target sequence, and a schematic overview of how to construct the 
sgRNA expression plasmid. (a) An outline of the target gene showing the target sequence (5′-G+N(19)-3′) and 
the PAM sequence (5′-NGG-3′) in relation to each other. (b) Schematic overview of the sgRNA plasmid con-
struction described in Subheading 3.2. A simple way to construct your sgRNA plasmid is by ordering your 
target complementary sequence as primers. You can keep your sgRNA “constant” and just exchange the target 
complementary sequence. The primers for the target sequence are designed to anneal and give rise to over-
hangs that match overhangs generated after USER treatment of the amplified sgRNA backbone. In this case, 
the following uracil containing primers would be used for amplifying the backbone: Fwd: AGCTAGAAA 
UAGCAAGTTAAAATAAGGC and Rev.: ACAAGATAUATAAAGCCAAGAAATCGA. After assembly of the annealed 
primers and the amplified sgRNA backbone upon USER enzyme treatment, you will attain the complete sgRNA 
expression construct
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 2. Mix the following components in a PCR tube:
 – 10 μL 5× HF buffer.
 – 1 μL dNTPs (10 mM).
 – 2.5 μL Primer forward (10 μM).
 – 2.5 μL Primer reverse (10 μM).
 – 0.5 μL Phusion U polymerase.
 –  1 μL sgRNA plasmid template (1.7 ng/uL) (prepared in 
Subheading 3.2.1).
 – 32 μL Milli-Q water.
 3. Place the PCR tube in thermocycler, and run the following 
program (as shown in Table 1).
 4. Treat the sgRNA backbone amplicon with DpnI enzyme to 
remove methylated DNA by mixing the following components:
 – 44 μL of the sgRNA backbone PCR reaction mixture.
 – 5 μL 10× Green buffer.
 – 1 μL Fast Digest DpnI enzyme.
 5. Incubate the mixture at 37 °C for 1 h, this will degrade meth-
ylated DNA.
 6. Run the PCR product on a 1% agarose gel alongside a 1 kb 
DNA ladder.
 7. Cut out the band at approximately 4.2 kb and purify the PCR 
product using a PCR and gel purification kit.
 1. Mix the following components in an Eppendorf tube:
 – 10 μL 10× NEBuffer 4.
 – 10 μL sgRNA Forward primer (100 μM).
 – 10 μL sgRNA Reverse primer (100 μM).
 – 70 μL Milli-Q water.
3.2.3 Annealing Primers 
for sgRNA Construct
Table 1 
PCR program to amplify the sgRNA backbone
Temperature (°C) Time (min) Number of cycles
98 00:30  1
98 00:10 35
57 00:30
72 01:15
72 10:00  1
4 ∞  1
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 2. Incubate the mixture at 95 °C for 5 min on a heat block, turn 
off the heat block, and leave the mixture on the heat block 
overnight for gradual cooling. Store at −20 °C.
 1. Mix components in a PCR tube according to Table 2, including 
a negative control (backbone only).
 2. Incubate the mixed reactions at 37 °C for 40 min, and 25 °C 
for 30 min. Store at −20 °C.
 1. Add 1.5 μL of USER reaction to 15 μL competent E. coli cells 
in an Eppendorf tube and incubate on ice for 30 min.
 2. Heat shock at 42 °C for 30 s.
 3. Return to ice and keep it there for 1 min.
 4. Add 1 mL 2× YT medium to the Eppendorf tube and incubate 
the mixture at 37 °C for 1 h at 300 rpm shake.
 5. Pellet the cells at 2000 × g for 3 min.
 6. Remove the supernatant, resuspend the pellet in 100 μL 2× YT 
medium, and plate it using a sterile spatula on a pre-warmed 
(37 °C) kanamycin agar plate.
 7. Incubate the plates upside down at 37 °C overnight.
 1. Pick a colony using a pipette tip and transfer it to 4 mL 2× YT 
medium supplemented with 50 μg/mL kanamycin in a 10 mL 
bacterial culture tube.
 2. Shake cells at 250 rpm at 37 °C for 5 h.
 3. Isolate plasmid DNA using a plasmid miniprep kit and use this 
for sanger sequencing. Use a primer for sequencing that 
anneals before the U6 promoter and covers the target sequence, 
to make sure your sgRNA expression cassette does not contain 
any mutations using a sequence analysis software, e.g., CLC 
Main Workbench.
3.2.4 Assembly 
of Backbone and sgRNA 
Insert
3.2.5 Transformation 
of sgRNA Plasmid in E. coli
3.2.6 Analyze 
and Prepare sgRNA 
Plasmid
Table 2 
Components of reaction for assembly of backbone and sgRNA insert
Component Negative control, μL sgRNA reaction, μL
Backbone 1 1
Annealed sgRNA primers – 7
10× BSA 0.5 0.5
NEBuffer 4 0.5 0.5
USER enzyme 1 1
Milli-Q water 7 –
Knockout Generation in CHO Cells using CRISPR/Cas9
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 4. Grow a midi- or maxiprep culture of the correct transformant 
by inoculating 100–200 mL of 2× YT medium supplemented 
with 50 μg/mL kanamycin with 1 mL culture from step 2. 
Incubate overnight at 37 °C with shaking at 250 rpm.
 5. Isolate plasmid DNA using a midi- or maxiprep kit. Resuspend 
plasmid DNA at approximately 1 μg/μL in sterile Milli-Q 
water. Measure the concentration using Nanodrop 2000. Use 
this product for transfection.
 1. Request the GFP 2A peptide-linked Cas9 expression plasmid 
(GFP_2A_Cas9) plasmid from Grav et al. [5], and generate a 
bacterial glycerol stock (or prepare it from scratch following 
the method described in the publication).
 2. Use the tip of a sterile pipette tip and scrape the bacterial stock, 
add the pipette tip to 100–200 mL of 2× YT medium supple-
mented with 60 μg/mL ampicillin, and incubate overnight at 
37 °C with shaking at 250 rpm.
 3. Isolate plasmid DNA using a plasmid midi- or maxiprep kit, 
resuspend 1 μg/μL in sterile Milli-Q water. Measure the 
 concentration using Nanodrop 2000. Use this product for 
transfection.
 1. Use healthy (above 95% viability) CHO-S cells at a low 
passage.
 2. Count cells using a NucleoCounter.
 3. Harvest 1.5–2 × 106 cells (for a single transfection in 1 × 6 
well), spin down cells at 200 × g for 5 min, and remove the 
supernatant.
 4. Wash cells with preheated CD CHO medium supplemented 
with 8 mM glutamine (no anti-clumping agent), spin down at 
200 × g for 5 min, and remove the supernatant.
 5. Inoculate cells at 5–6 × 105 cells/mL in 1 × 6 well with pre-
heated growth medium.
 6. Incubate cells at 37 °C, 5% CO2, and shake at 120 rpm for 
1 day.
 1. Count cells and inoculate cells at 1 × 106 cells/mL in 3 mL 
preheated growth medium in a 6-well plate.
 2. Use a total amount of 3.75 μg of plasmid (1:1 (w/w) of sgRNA 
plasmid and Cas9 expression plasmid). If you want to use mul-
tiple sgRNAs, see Note 3.
 3. Gently mix plasmids with 60 μL OptiPRO™ SFM reduced 
serum medium.
 4. Dilute 3.75 μL FreeStyle™ MAX reagent in 60 μL OptiPRO™ 
SFM reduced serum medium. Mix gently and add to plasmid 
premix (step 3).
3.3 Prepare the GFP 
2A Peptide- Linked 
Cas9 Expression 
Plasmid
3.4 Transfection 
of CHO-S Cells
3.4.1 Day 0: Washing 
and Seeding Cells 
for Transfection
3.4.2 Day 1: Transfection
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 5. Incubate for 5 min.
 6. Gently add transfection mix to the cells from step 1.
 7. Incubate cells at 37 °C, 5% CO2 and shake at 120 rpm for 
2 days.
 1. Harvest 50 μL cells 2 days after transfection, spin down at 
1000 × g, remove the supernatant, and add 20 μL quick extract 
and incubate at 65 °C for 15 min followed by 95 °C for 5 min. 
Store at −20 °C.
 2. Design primers using, e.g., NCBI Primer-BLAST tool (http://
www.ncbi.nlm.nih.gov/tools/primer-blast/) so that a prod-
uct between 600 and 1000 bp will be amplified. This product 
should span the selected target sequence in your target gene. 
The T7 endonuclease will cleave the product where an indel is 
present when hybridized to wild-type sequence. Design your 
primers so that the PCR product after cleavage will give bands 
of different sizes that are separable on an agarose gel.
 3. Mix the following components in a PCR tube (prepare one for 
quick extract of the transfected pool of cells and one for quick 
extract from CHO-S cells):
 – 10 μL 2× Phusion Master Mix.
 – 1 μL Primer Forward (10 μM).
 – 1 μL Primer Reverse (10 μM).
 – 1 μL DNA template (quick extract from step 1).
 – 7 μL Milli-Q water.
 4. Place the PCR tube in a thermocycler, and run the following 
program as outlined in Table 3:
 5. Run 5 μL of the PCR product next to a 1 kb DNA ladder on a 
1% agarose gel. There should be only one clear band (if not 
redo and/or troubleshoot your PCR).
 6. Transfer 10 μL to a new PCR tube.
 7. Place the PCR tube in a thermocycler and run the following 
T7 endonuclease annealing program as outlined in Table 4.
 8. Divide the PCR product into two PCR tubes (5 μL in each 
tube).
 9. Mix the components for the following two reactions (T7+ and 
T7−) as outlined in Table 5.
 10. Incubate the PCR tubes for 30 min at 37 °C.
 11. Load the products on a 4% E-Gel or equivalent, and run for 
approximately 30 min. Your results should be similar to what is 
shown in Fig. 3a.
3.5 Optional: T7 
Endonuclease Assay 
to Check if Your 
sgRNA Works
Knockout Generation in CHO Cells using CRISPR/Cas9
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Table 4 
T7 endonuclease annealing program
Temperature (°C) Time (min) Number of cycles
95 05:00  1
95 00:01  5
−2 s−1
85 00:01 300
−0.2 s−1
4 ∞
Table 5 
Components of T7+ and T7− reactions
Component T7+, μL T7– (negative control), μL
10× NEBuffer 2 1 1
T7 endonuclease 0.5 –
PCR product 5 5
Milli-Q water 3.5 4
Table 3 
PCR program for T7 endonuclease assay
Temperature (°C) Time (min) Number of cycles
98 00:30  1
98 00:10 10
68 00:30
−1 per cycle
72 00:30
98 00:10 20
58 00:30
72 00:30
72 05:00  1
4 ∞  1
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 1. Two to three days after transfection, prepare wanted number 
of 384-well flat-bottom plates (see Note 4) with 30 μL FACS 
sorting medium.
 2. Strain cells through a 30 μm cell strainer into a FACS tube.
 3. Using a FACS, sort for GFP-positive single cells into one or 
more pre-warmed (37 °C) 384-well plates. If a FACS is not 
available, an alternative method can be used (see Note 5).
 4. Spin plates at 200 × g for 5 min to make sure cells reach the 
medium.
 5. Place cells in a breathable plastic bag (to limit evaporation), 
and incubate cells at 37 °C, 5% CO2, no shake for 10 days.
 6. Check for surviving cells using a microscope or Celigo cytom-
eter. Cell count should preferably be around >1000 in a well or 
confluency >50%.
3.6 Generation 
of Clonal Cell Lines 
Using FACS
Fig. 3 Analysis of genome modifications. (a) T7 endonuclease assay of a pool of cells 2 days after transfection, 
showing that a sgRNA complementary sequence to a selected target site is capable of generating indels. The 
samples are analyzed on a 4% E-Gel, where the two first lanes (1 and 2) are not treated with T7 endonuclease, 
and the two last lanes (3 and 4) are treated with T7 endonuclease. Samples in lane 2 and 4 are transfected 
with GFP_2A_Cas9 and a sgRNA, while the other two samples are un-transfected. After T7 endonuclease 
treatment, the un-transfected sample shows two bands, while the transfected sample shows two additional 
bands at expected sizes, designated by arrows. A result like this shows that a selected sgRNA is capable of 
generating indels at the target site. The percentage of indels generated in this case is estimated to 9.3, by 
using ImageJ software. (b) An example of sanger sequencing analysis of a target sequence region. The align-
ment shows that out of four sequences, in this case, there are one sequence with an indel of −10, one with an 
indel of +1, and two that still have the wild-type sequence (no indel)
Knockout Generation in CHO Cells using CRISPR/Cas9
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 7. Carefully pipette up and down three times and transfer cells to 
a 96-well flat-bottom plate with 180 μL of clone expansion 
medium.
 8. After 4 days, check plates in microscope. When the clones have 
a confluency >50%, carefully pipette up and down three times 
and transfer 50 μL cell suspension to a 96-well V-shaped plate.
 9. Spin down the V-shaped 96-well plate at 1000 × g for 5 min, 
remove the supernatant, add 20 μL quick extract, resuspend 
the pellets, and move them to PCR tubes or plates. Incubate at 
65 °C for 15 min and 95 °C for 5 min. Store at −20 °C.
 1. Mix the following components in a PCR tube (per clone you 
have generated):
 – 10 μL 2× Phusion Master Mix.
 – 1 μL Primer Forward (10 μM).
 – 1 μL Primer Reverse (10 μM).
 – 1 μL DNA template (quick extract from Subheading 3.6).
 – 7 μL Milli-Q water.
 2. Place the PCR tube in thermocycler, and run the following 
program as shown in Table 6.
 3. Run the PCR product on a 1% agarose gel, cut out the band 
with the expected amplicon size, and purify it using a gel 
and PCR purification kit. Measure the concentration using 
Nanodrop 2000.
3.7 Analysis of Gene 
Modifications: Sanger 
Sequencing
Table 6 
PCR program for analysis of gene modifications
Temperature (°C) Time (min) Number of cycles
98 00:30  1
98 00:10 10
68 00:30
−1 per cycle
72 00:30
98 00:10 20
58 00:30
72 00:30
72 05:00  1
4 ∞  1
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 4. Sequence the product using the forward primer designed for 
the T7 endonuclease assay (see Note 6). Mix primer and puri-
fied PCR product according to the instruction provided by the 
sequencing service you use. We discuss application of alterna-
tive methods to analyze gene modifications in Subheading 4 
(see Note 7).
 5. Analyze your sequencing results using a sequence analysis soft-
ware, e.g., CLC Main Workbench and align the results to the 
wild-type target sequence (e.g., the GS sequence). The results 
should be similar to what is shown in Fig. 3b.
 1. Select clones with indels that lead to a frameshift, which indi-
cates that you have rendered the gene dysfunctional. Even if 
the analysis shows there is a frameshift, it is important to verify 
that it is a real knockout, e.g., by western blotting (see Note 8) 
and/or a functional assay (see Note 9).
 2. Move the selected clones from the 96-well plate when >90% 
confluent to a 12-well flat-bottom plate, maintain in the 
12-well plate until confluent, and then move to a 6-well flat-
bottom plate, when confluent seed in a 125 mL shake flask at 
3 × 105 cells/mL.
 3. Take out the samples you need and bank the clones, using 107 
cells in 1 mL conditioned medium with 5–10% DMSO. Freeze 
in a Styrofoam box at −80 °C the first 24 h before moving to 
permanent storage at −180 °C.
4 Notes
 1. When selecting a sgRNA sequence to target the gene of inter-
est, it is important to be aware that there can be several genes 
annotated for the same protein that may be isoforms or pseu-
dogenes. When this is the case you could either select a sgRNA 
specific for each of the genes, select a sgRNA that matches all 
of the genes, or select sgRNAs based on expression levels of 
the gene variants.
 2. Examples of sgRNAs in CRISPy with exact match in each of the two 
glul gene variants in the CHO-K1 genome (GCF_000223135.1) 
are “GGCCCAGGGAAGCCATCGGAAGG” (GeneID:100, 
689,337) and “GGCCTCCTCGATGTGCCTGGTGG” 
(GeneID:100,764,163), or that matches both genes (in the 
3′-end) are “GAGAAGGCATGTGCGGACGATGG.” When 
selecting your target sequence, you should consider the vari-
ous exons and splice variants for the gene of interest, and which 
target position will most likely make a break that leaves the 
gene dysfunctional. If opportunity allows it, it is a good idea 
3.8 Expansion 
of Clone Candidates
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to test a minimum of two different sgRNAs. Always  remember 
that the annotation of some genomes can be incomplete at 
the time of analysis, and it is always important to validate your 
knockout, either by a Western Blot (see Note 8) and/or a 
functional assay (see Note 9). The CRISPy tool takes the pres-
ence of a 5′-NGG-3′ PAM sequence directly downstream of 
the target sequence for Streptococcus pyogenes Cas9 (spCas9) 
into consideration. If you are using a different Cas9 ortholog, 
there might be different requirements to your PAM sequence 
that you need to consider.
 3. When using multiple sgRNAs, the weight ratio between the 
Cas9 expression plasmid and sgRNA plasmids is still (1:1). The 
weight ratio between the different sgRNAs is also (1:1). For 
instance, if you use three different sgRNAs the weight ratio 
should be (1:1:1). Another recommendation when multiplex-
ing gene knockouts is to use deep sequencing when analyzing 
the gene modifications, as explained in Note 6.
 4. The number of 384-well plates necessary for sorting depends 
on your FACS sorting efficiency. It is important to use strin-
gent settings so that you only sort one cell per well. Depending 
on your sorting efficiency (how many wells get a single cell 
sorted into it) and survival (how many single cells survive), you 
can adjust the number of plates you sort. If your sorting effi-
ciency is around 30%, two 384-well plates should give a suffi-
cient number of knockout cells to choose among.
 5. Limiting dilution is an alternative way to single cell sort your 
cells, if you do not have access to a FACS [10]. In this case you 
will need to screen more clones, as you cannot enrich for 
GFP_2A_Cas9 expressing cells. When applying limiting dilu-
tion it is sufficient to use a plasmid expressing Cas9 that is not 
linked to GFP with a 2A peptide.
 6. If your coverage is not good when only using the forward 
primer, you can also use the reverse primer for sequencing, or 
design new sequencing primers. The Sanger sequencing 
method is very simple, but not optimal. You might experience 
some unclear sequencing result, due to, e.g., mixed indels on 
different alleles. Select only the clones that show clear sequenc-
ing results indicating a frameshift; otherwise, it is necessary to 
use one of the alternative methods described in Note 7. When 
potential functional knockout clones are selected, we recom-
mend applying an additional primer set for verification.
 7. TOPO™ cloning-based sequencing and deep sequencing are 
alternative methods that can be used to analyze gene modifica-
tions in greater detail. A description of how to perform these 
analyses can be found in Ronda et al. [9]. Both methods can 
reveal if you have an indel on one or more alleles of your 
 targeted gene. However, TOPO cloning-based sequencing 
Lise Marie Grav et al.
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requires a much higher extent of screening than deep sequencing. 
It is therefore recommended to use deep sequencing analysis 
when analyzing gene modifications from multiplexed 
 knockouts, as it minimizes the work load and gives a higher 
coverage. When potential functional knockout clones are 
selected, we recommend applying an additional primer set for 
verification.
 8. Even though you see clear gene modifications in your analysis, 
the protein could still be expressed in an intact or truncated ver-
sion. A simple way to ensure that you have disrupted the protein 
expression is to perform a Western Blot of your putative clones, 
using an antibody against target gene. In the case of a GS knock-
out, you can use an antibody against GS as shown in Fig. 4.
 9. In addition to ensuring that you have lost the protein expres-
sion, it is important to ensure that you have acquired the 
wanted phenotypic change. As in the case of a GS knockout, a 
simple test is to grow the cells in the presence and absence of 
glutamine. If the cells die in the absence of glutamine (and not 
in the presence), you likely have a functional knockout.
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Fig. 4 Knockout validation. An example of a western blot of cell lysates from a 
putative GS knockout (KO) clone in lane 1 and wild-type CHO-S in lane 2, which 
were analyzed with anti-GS antibody (Abcam ab 49873) and anti-vinculin anti-
body (Sigma-Aldrich V9131). Anti-vinculin is used as a loading control. The puta-
tive GS knockout in lane 1 shows no band at the expected size of GS (45 kDa), 
while the wild-type shows a band at the expected size of GS, indicating that GS 
is not expressed in this putative GS knockout
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Chapter 3 
 
Knockout of multiple genes simultaneously 
 
 
Here we present an efficient way of removing several genes simultaneously in order to speed up 
rational cell line development processes in a more cost-effective manner, as generation of a single 
knockout clone is rather time-consuming. In the past decades, genetic engineering of CHO 
production host cells has focused on the manipulation of single target genes 12. However, changes 
in cellular phenotypes are most likely not the result of altering the expression of a single gene but 
rather of a plethora of genes involved in the same or different pathways. It is expected that 
engineering multiple genes and eventually entire signalling pathways will have a higher 
probability to significantly improve phenotypic outcomes. 
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1  Introduction
Chinese hamster ovary (CHO) cells are widely used in the
biopharmaceutical industry as a host for the production of
complex pharmaceutical proteins. Thus, genome engi-
neering of CHO cells for improved productivity and prod-
uct quality is of great interest.
In biotechnology and medical research, generating
desirable genomic traits in mammalian cell lines is often
highly valuable. Traditionally, genome editing has been
performed mainly by conventional gene targeting strate-
gies based on homologous recombination [1]. However,
the low frequency of spontaneous breakage of chromoso-
mal DNA increases the need for nucleases to generate
site-specific DNA double strand breaks (DSBs). Genome
editing nucleases including meganucleases, zinc-finger
nucleases (ZFNs), transcription activator-like effector
nucleases (TALENs), and the more recent clustered regu-
larly interspaced short palindromic repeats (CRISPR)/
CRISPR-associated (Cas) system have paved the way for
rapid and efficient induction of DSBs at defined genomic
sites, leading to site-specific gene manipulations by non-
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homologous end joining (NHEJ) repair or homology-direct-
ed repair (HDR) [2]. We have previously shown that the
CRISPR/Cas protein 9 (Cas9) genome editing tool is very
efficient in CHO cells by generating NHEJ-mediated gene
disruptions in two genes involved in glycosylation: fuco-
syltransferase 8 (FUT8) and COSMC encoding the
C1GALT1-specific chaperone 1 [3]. In this system, a sin-
gle-guide RNA (sgRNA) directs the Cas9 nuclease to
cause DSBs in matching target DNA sequences if they are
adjacent to short sequences known as protospacer adja-
cent motifs (PAMs) [4, 5]. The target site specificity is
determined by 20-base pair (bp) sequences at the 5’ end of
the sgRNA that form base pairs with desired target DNA
sequences [4, 5]. This technology can edit multiple target
sequences simultaneously by simply expressing multiple
sgRNAs together with a single Cas9 nuclease, which con-
fers multiplex genome engineering [5–9]. Additionally, a
recent study provides a simple method to increase
genome editing frequencies by ZFNs and CRISPR/Cas9
via 2A peptide-coupled co-expression of nuclease and flu-
orescent protein followed by FACS enrichment of cell pop-
ulations with high nuclease expression levels [10]. Up to
now, multiple knockout of genes was shown to be feasible
in CHO cells through the sequential application of differ-
ent pairs of ZFNs [11, 12]. Successive transfection and
screening of knockout cell lines achieved generation of
triple gene knockout cell lines at frequencies of >1% [12]. 
In this study, we explore the potential of the
CRISPR/Cas9 system to generate several gene disrup-
tions simultaneously by multiplexing. Our goal was to
accelerate the genome editing process during cell line
generation and this study focused on the development of
an efficient multiplexing process for CHO cells. To facili-
tate enrichment of cells with generated indels, a vector
with green fluorescent protein (GFP) reporter linked via a
2A peptide to Cas9 was constructed and transfected cells
were sorted with fluorescence-activated cell sorting
(FACS). Deep sequencing was applied to analyze the
genome editing efficiencies at both on-target and off-tar-
get sites for three target genes, FUT8, Bcl-2 homologous
antagonist killer (BAK) and Bcl-2-associated X (BAX).
Selected engineered cell lines were shown to be unable to
fucosylate and to be resistant to apoptotic inducers, thus
confirming a functional knockout of FUT8, BAK and BAX.
These results support the conclusion that application of
this multiplexing process leads to the successful genera-
tion of genetic and functional triple knockout CHO cell
lines. 
2  Materials and methods
2.1  Plasmid construction and sgRNA target design
Cloning of the GFP_2A_Cas9 was performed with seam-
less uracil-specific excision reagent (USER) cloning to
insert GFP_2A directly upstream of the Cas9 reading
frame in pJ607-Cas9 [3]. The uracil-containing primers
are listed in Supporting information, Table S1 and PCR
(98°C for 2 min; 35 times: 98°C for 10 s, 60°C for 45 s, 72°C
for 40 s/5 min; 72°C for 5 min) was performed with the X7
DNA polymerase [13]. Subsequent to DpnI (Thermo Fish-
er Scientific, Waltham, MA) treatment of the backbone
fragment (pJ607-Cas9), amplicons were purified from 1%
agarose TAE gel using NucleoSpin® Gel and PCR Clean-
up kit (Macherey-Nagel, Düren, Germany). The two PCR
products were mixed and treated with USER enzyme
(New England Biolabs, Ipswich, MA) according to the
manufacturer’s recommendations. Subsequent to USER
enzyme treatment, the reaction mixture was transformed
into Escherichia coli One Shot® Mach1TM competent 
cells (Life technologies, Thermo Scientific, Rockford, IL)
according to standard procedures. Transformant cells
were selected on 100  µg/mL ampicillin LB plates. The
sequence of the construct was verified by sequencing
and purified plasmid was obtained using the Nucleo -
Bond® Xtra Midi kit (Macherey-Nagel) according to the
manufacturer’s recommendations. The online bioinfor-
matics tool “CRISPy” was applied for sgRNA target selec-
tion for BAK and BAX [3]. For FUT8, the sgRNA3_F was
selected based on a previous study [3]. The BAK, BAX and
FUT8 target sites are presented in Supporting informa-
tion, Table S2. The sgRNA expression vectors were
 constructed as previously described [3]. The oligos for
sgRNA construction are listed in Supporting information,
Table S3.
2.2  Cell cultivation and transfections
CHO-S suspension cells obtained from Life Technologies
were grown in CD CHO medium supplemented with
8 mM L-glutamine and 1 µL/mL anti-clumping agent (Life
Technologies). Cells were expanded in Corning vent cap
shake flasks (Sigma-Aldrich, St. Louis, MO) in a humidi-
fied incubator at 120 rpm, 37°C and 5% CO2. Cell growth
was monitored using the NucleoCounter NC-200 Cell
Counter (ChemoMetec, Allerod, Denmark) and cells were
passed into fresh medium every two to three days with
seeding densities at 3 to 4 × 105 cells/mL. Cells were
washed and seeded at 5 to 6 × 105 cells/mL without anti-
clumping agents one day prior to transfection. Cells were
transfected with expression vectors encoding Cas9 or
GFP_2A_Cas9 and sgRNA targeting FUT8, BAK and/or
BAX. For each sample, a density of 1 × 106 cells/mL in a
six multi-well plate (BD Biosciences, San Jose, CA) or in
125 mL flasks were transfected with a total of 3.8 µg or
17.7  µg of DNA respectively using FreeStyleTM MAX
reagent together with OptiPRO SFM medium (Life Tech-
nologies) according to the manufacturer’s recommenda-
tions. Transfections with pmaxGFP® vector (Lonza, Basel,
Switzerland) were applied as control for transfection effi-
ciencies. Anti-clumping agent (1.5  µL/mL) was added
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one day after transfection. For comparison of Cas9 and
GFP_2A_Cas9 efficiencies, transfected cells were har-
vested on day 3 after transfection. For multiplexing, cells
were harvested on day 2 after transfection, before or after
FACS. For each sample 500 000 cells were harvested.
2.3  Isolation of fluorescent-positive cells with FACS
A FACSJazz (BD Biosciences) was used to bulk sort cells
from selected transfections. Before cell sorting, cells were
prepared by centrifugation at 100 g for 5 min and resus-
pended in 1  mL fresh medium. The cells were filtered
through a 40 µm cell strainer to achieve single cell sus-
pension and transferred to a FACS-compatible tube. Flu-
orescent-positive cell populations were gated based on
non-transfected wild-type CHO-S cells. From the multi-
plexed samples, 500 000 fluorescent-positive cells were
isolated followed by single cell sorting into 96-well U-bot-
tom plates (BD Biosciences). For single cell sorting, one
cell was seeded per well in 200 µL 80% CD CHO medium
supplemented with 8 mM L-glutamine, and 1% penicillin-
streptomycin and 20% 20 µm filtered spent medium. After
10 days, anti-clumping agent was added to each well with
colonies at a final concentration of 2 µL/mL. At day 14, the
colonies were moved to 96-well flat-bottom plates (BD
Biosciences) for further expansion. Confluent colonies
were split and replicated plates were seeded and har-
vested for deep sequencing analysis when close to con-
fluent. Genomic DNA was extracted from cell pellets (cell
pools and clonal cells) using QuickExtract DNA extraction
solution (Epicentre, Illumina, Madison, WI) according to
the manufacturer’s instructions.
2.4  Deep sequencing analysis
Deep sequencing was performed on a MiSeq Benchtop
Sequencer (Illumina, San Diego, CA). Libraries were pre-
pared based on Illumina 16S Metagenomic Sequencing
Library Preparation with some modifications. Genomic
regions flanking target genomic sites were amplified
using Phusion Hot Start II HF Pfu polymerase (Thermo
Fisher Scientific) by touchdown PCR (95°C for 5  min; 
10 times: 95°C for 45 s, 69–59°C (–1°C/cycle) for 30 s, 72°C
for 45 s; 20 times: 95°C for 45 s , 59°C for 30 s, 72°C for 45 s;
72°C for 10  min), with primers containing overhang
sequences compatible with Illumina Nextera XT index-
ing (forward primer overhang: TCGTCGGCAGCGTCAG
ATGTGTATAAGAGACAG, reverse primer overhang:
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG).
PCR primers are listed in Supporting information, Table S4.
After PCR amplification, amplicons were purified using
AMPure XP beads (Beckman Coulter, Brea, CA). Illumina
Nextera XT Index (Illumina #FC-131-1001) sequencing
adapters were integrated into the amplicons by PCR
(98°C for 3 min; 8 times: 95°C for 30 s, 55°C for 30 s, 72°C
for 30 s; 72°C for 5 min). The final libraries were purified
once again before quantification. The purified libraries
were quantified with the Qubit® dsDNA BR Assay kit
(Life Technologies; #Q32850), and the product size within
the library was verified by 2% agarose gel. Sequencing
was performed as a 151 paired-end run. Sequence data
were analyzed using custom python code that compared
the sequence data with the expected wild-type sequence
from the CHO genome [3]. In short, the sequence data
were searched for high similarity to the expected wild-
type genomic sequences and then analyzed for the poten-
tial presence and size of an indel. The final result is a
spreadsheet with a row for each target or off-target, which
states how often we see the wild-type, how often we see
an indel and what size that indel is.
2.5  Off-target site prediction
Off-target sites were predicted using custom python code
that compared the targets with all other potential targets
in the CHO genome (ref-seq assembly GCF_000223135.1).
Off-targets were then scored based on the following cri-
teria: (i) the first 5 bp immediately adjacent to the PAM
sequence: cutoff value of 0; (ii) the number of mismatch-
es in the first 13 bp: cutoff value of up to 1; and (iii) the total
number of mismatches including number of mismatches
in first 13 bp: cutoff value of up to 5. From the scoring, the
15 highest potential off-target sites for each of the FUT8,
BAK and BAX sgRNA were selected (Supporting infor-
mation, Table S5). 
2.6  Re-sequencing of genomic regions flanking
sgRNA target sites
Genomic regions flanking the sgRNA target site for FUT8,
BAK and BAXwere amplified from genomic DNA extracts
using DreamTaq DNA polymerase (Thermo Fischer Sci-
entific) by touchdown PCR (95°C for 5 min; 10 times: 95°C
for 45  s, 69–59°C (–1°C/cycle) for 30  s, 72°C for 45  s; 
20 times: 95°C for 45 s, 59°C for 30 s, 72°C for 45 s; 72°C
for 10 min) using PCR primers listed in Supporting infor-
mation, Table S6. The PCR products were purified from
1% agarose TAE gel with the NucleoSpin® Gel and PCR
Clean-up kit (Macherey-Nagel). Each purified PCR prod-
uct was Sanger sequenced with the corresponding for-
ward primer using EuroFins sequencing service (Eurofins
Scientific, Luxembourg). 
2.7  Analysis of Bak and Bax protein level
Five million cells were harvested and re-suspended in a
fresh lysis buffer (10 mM Tris-HCl, pH 7.4, 100 mM NaCl,
2.5 mM MgCl2, 0.5% Triton X-100, supplemented with 1×
Roche protease inhibitor cocktail). The lysate was cen-
trifuged at 12 000 g at 4°C for 10 min, and the soluble
lysate was reduced using DTT. 15 µL of the reduced solu-
ble lysates were separated on 4–12% Bis-Tris NuPAGE®
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gel (Life technologies) in 1× MES buffer, followed by trans-
fer to nitrocellulose membranes using iBlot® dry blotting
system (Life Technologies). Membranes were blocked
with 5% dry skimmed milk diluted in 1× PBS and 0.1%
Tween20 for 1 h, and further probed with anti-Bak (Sigma
Aldrich, B5897) or anti-Bax (Abcam, ab32503) antibodies
at 1:2000 dilutions overnight. The blots were then probed
with a HRP-conjugated donkey anti-rabbit IgG secondary
antibody (1:5000) for 50 min and detected using Amer-
sham ECL detection system (GE Healthcare Life Sci-
ences, Buckinghamshire, UK). As a loading control, the
membranes were re-probed with an anti-Vinculin anti-
body (Sigma Aldrich, V9131) at 1:1000 dilution and a
mouse IgG secondary antibody (1:5000).
2.8  Phenotypic analysis of FUT8 knockout cells 
A lectin stain was performed to analyze the phenotypic
change of FUT8 knockout cells. Cells were seeded in a 
96-well tissue culture treated black/clear® microplate
(Greiner Bio-one, Frickenhausen, Germany) and incubat-
ed for 45 min at room temperature in medium containing
20 µg/mL fluorescein-Lens culinaris agglutinin (F-LCA,
Vector Laboratories, Peterborough, UK) and NucBlue®
Live ReadyProbes® Reagent (Life Technologies). Cells
were then washed three times with fresh culture medium
followed by complete removal. Celigo Imaging Cell
Cytometer (Nexcelom Bioscience, Lawrence, MA) was
used to measure fluorescence using the mask + target1
application. The blue and green fluorescence channels
were used as mask and target1 respectively. 
2.9  Glycoprofiling
Exponentially growing cells were seeded at 1 × 106 cells/mL
in 250 mL Corning vent cap shake flasks (Sigma Aldrich).
Four days after seeding, 40 mL supernatant was harvest-
ed and centrifuged at 2000 g for 15 min. The supernatant
was filtered using sterile Nalgene rapid flow 0.2 µm SFCA
filter (Thermo Scientific). Proteins contained in the super-
natant were concentrated by three to four cycles of cen-
trifugation at 4000 g at room temperature for 10 min in
Amicon Ultra column with 3000 Da cutoff, until 1 mL was
left in column. N-glycans from retained proteins were
released and fluorescently labeled with GlykoPrep Rapid
N-Glycan kit (ProZyme Inc., Hayward, CA) according to
the manufacturer’s instructions using 2-aminobenzamide
(2-AB) as a fluorescent label. Labeled N-glycans were ana-
lyzed on LC-MS. LC-MS System was a Thermo Ultimate
3000 HPLC with fluorescence detector coupled on-line to
a Thermo Velos Pro Iontrap MS. Separation was per-
formed on a BEH Glycan column 100 mm × 2.1, 1.7 µm
(Waters, Milford, MA) and solvents: A: 100% acetonitrile,
B: 50  mM ammonium formate, pH 4.4 adjusted with
formic acid and filtered 0.2 µm. Separation gradient from
39% buffer A to 47% buffer A over 16 min at 0.5 mL/min
flow-rate. Fluorescence detector set to high power lamp
and 360 nm excitation, 428 nm emission. MS settings:
fullscan: 700–2000 m/z, source fragmentation 60 V, polar-
ity negative. All annotated sugar structures are peaks
with correct mass and at least a signal to noise value of
20:1 calculated with the Chromeleon software (Thermo
Scientific). Almost all annotated sugar structures were in
the plus 300 S/N intensities. 
2.10  Apoptosis analysis
Exponentially growing cells were seeded at 3 to 
4 × 105 cells/mL into polystyrene transparent square 
96-half-deepwell microplates with sandwich cover
(Enzyscreen, Leiden, Netherlands) containing 250 µL cul-
ture medium and the culture plates were incubated on the
Multitron cell (INFORS HT, Bottmingen, Switzerland) at
300 rpm in humidified 5% CO2 at 37°C. To induce apopto-
sis, 10 µg/mL actinomycin D (Sigma Aldrich) was added
to the culture on day 3. After 24 h cultivation in the pres-
ence of actinomycin D, 15 000 cells were transferred to 
96-well tissue culture-treated black/clear® microplates
(Greiner Bio-one), and caspase activity was measured
using the Homogeneous Caspases Assay kit (Roche,
Basel, Switzerland) according to the manufacturer’s
instructions. Briefly, caspase substrate labeled with Rho-
damine 110 was added and incubated for 1 h at 37°C. Free
Rhodamine 110 resulting from cleavage by active caspas-
es was measured by microplate reader (Synergy Mx,
BioTek Instruments, Inc., Winooski, VT). 
2.11  Transient expression of antibody 
and quantification
For transient expression of antibody, cells were transfect-
ed with expression vector encoding rituximab and cell
growth was measured daily as described in Section 2.2.
Cell suspension was harvested daily and centrifuged at
4000 g for 5 min and supernatant was kept for rituximab
quantification. Rituximab quantification was performed
using an Octet RED96 (Pall, Menlo Park, CA, USA). Protein
A biosensors were equilibrated in sample diluent buffer
(PBS containing 0.1% BSA and 0.02% Tween-20) and rit-
uximab was measured for 120 s at 30°C. Absolute con-
centrations of rituximab were calculated by comparison
with a calibration curve generated from a dilution series
of human IgG (GENSA01006, VWR, Dublin, Ireland).
Regeneration of biosensor tips between measurements
was performed in 10 mM glycine pH 1.7.
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3  Results 
3.1  Facilitation of enrichment for genome-edited
cells via GFP 2A peptide-linked Cas9
expression vector combined with FACS
The overall aim of this study was to: (i) accelerate the gen-
eration of engineered CHO cell lines with multiple gene
disruptions; and (ii) lower number of clones screened for
isolation of triple knockout cell lines. To facilitate this, an
expression vector with GFP 2A peptide-linked to CHO
codon-optimized Cas9 [3] was constructed for identifica-
tion and enrichment of the Cas9 expressing cells when
combined with FACS (Supporting information, Fig. S1).
The 2A peptide leads to coupled co-expression of GFP
and Cas9 nuclease, which are driven by a single promot-
er. Therefore cells that are fluorescent after transfection
indicate concurrent expression of Cas9 nuclease [10]. To
test the method, the glycosylation enzyme Fut8 and the
two pro-apoptotic proteins, Bak and Bax, were selected
for disruption based on industrial relevance and previous
characterization [11, 12]. 
Three sgRNA expression vectors were constructed to
target FUT8, BAK and BAX. To compare the indel gener-
ating efficiency of GFP_2A_Cas9 to the previous charac-
terized Cas9 expression vector, CHO-S cells were trans-
fected with the vectors encoding Cas9 or GFP_2A_Cas9
together with sgRNAs targeting either FUT8, BAK or
BAX. The indels generated at the target sites were inves-
tigated by deep sequencing (Fig. 1A). The GFP_2A_Cas9
expression vector was shown to be functional and gener-
ated close to the same amount of indels at the sgRNA tar-
get sites in FUT8, BAK and BAX as Cas9.
To test the functionality of the GFP_2A_Cas9 expres-
sion vector in multiplexing and in FACS enrichment of
cells with genome editing events, CHO-S cells were trans-
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Figure 1. Validation of the GFP 2A peptide-
linked Cas9 expression vector. (A) The
graph shows the frequency of indels gener-
ated at FUT8, BAK and BAX sgRNA target
sites upon transient transfection of Cas9
and GFP_2A_Cas9, together with the
respective sgRNAs. The percentage of
indels is measured from deep sequencing
of amplicons covering the target sites in the
genome of transfected CHO-S cells harvest-
ed three days after transfection. The data
are generated from two biological repli-
cates. (B) The graph shows the percentage
of indels  generated at FUT8, BAK and BAX
sgRNA target sites upon transient transfec-
tion of GFP_2A_Cas9 and the three respec-
tive  sgRNAs simultaneously. The indels are
measured from deep sequencing of
 amplicons covering the target sites in the
genome of transfected cells before and after
FACS two days after transfection. Low
 sgRNA shows indels generated from
 transfection of GFP_2A_Cas9 to each 
of the sgRNAs in the molar ratio of
1:(0.8/0.8/0.8). High sgRNA shows 
indels generated from transfection of
GFP_2A_Cas9 to each of the sgRNAs in the
molar ratio of 1:(2.4/2.4/2.4). The results
from two biological replicates are shown.
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fected with the vectors encoding GFP_2A_Cas9 and
 sgRNAs against FUT8, BAK and BAX simultaneously.
Two different molar ratios between GFP_2A_Cas9 and
sgRNA expression vectors were selected to test the effect
of relative molar ratios of GFP_2A_Cas9 and sgRNA on
efficiency during multiplexing. The selected ratios were
1:(0.8/0.8/0.8) as used previously [3] and 1:(2.4/2.4/2.4) to
increase sgRNA. Two days after transfection, the cell
pools were FACS sorted for fluorescent cells. From each
sample, both bulk sorting and single cell sorting was
 performed to acquire both a GFP-enriched population 
and GFP-positive single cells. The indels generated at
FUT8, BAK and BAX sgRNA target sites in the enriched
bulk-sorted cell populations were analyzed by deep
sequencing (Fig. 1B). Despite the discrepancy observed
between the two low sgRNA replicates, the amount of
sgRNA is not likely to limit the frequency of genome edit-
ing events.
In particular, FACS enrichment of the CHO-S cells
transfected with a high sgRNA to GFP_2A_Cas9 plasmid
ratio resulted in a large enrichment of cells with generat-
ed indels at the three genomic sites with an average of
11% before enrichment and 68% after enrichment. These
data demonstrate the feasibility of GFP_2A_Cas9 expres-
sion vector and FACS enrichment for CRISPR/Cas9-medi-
ated multiplex genome engineering.
3.2  Analysis of off-target sites for FUT8, 
BAK and BAX sgRNAs
The high number of genome editing events in the
enriched cell pool led us to investigate whether potential
off-target sites were being modified as well. Bioinformat-
ics analysis comparing the FUT8, BAK and BAX sgRNA
target sites to other sequences in the genome allowed us
to predict the highest potential off-target sites from scor-
ing the number of mismatches (Supporting information,
Table S5). To analyze the genome editing efficiencies at
these potential off-target sites, deep sequencing of 15 dif-
ferent off-target sites for each sgRNA was performed
(primers given in Supporting information, Table S4). Com-
parisons of genome editing efficiencies of the predicted
off-target sites were performed from pools of cells treated
with GFP_2A_Cas9 only and GFP_2A_Cas9 together with
the three sgRNAs before and after FACS enrichment
(Supporting information, Table S7). From the deep
sequencing analysis, no significant off-target modifica-
tions were observed at the investigated sites in the
enriched cell pool despite on-target genome editing effi-
ciencies at 66, 66 and 76% for FUT8, BAK and BAX,
respectively (Table 1). The observed low mutation levels
at potential off-target sites support the reliability of the
current multiplexing process. 
3.3  Generation and characterization of single,
double and triple gene-disrupted CHO-S 
cell lines
Single cells from each of the four indel-enriched cell pop-
ulations (analyzed in Fig. 1B) were expanded to generate
clonal cell lines and resulted in 187 colonies. To analyze
the indels generated at the FUT8, BAK and BAX loci of
these clones, deep sequencing was performed (Support-
ing information, Table S8 and S9). From the 187 clones, 
90 clones were discarded based on failed or unclear deep
sequencing data yielding 97 clones with clear genotypes
(Supporting information, Table S8 and S9). Of the 97 ana-
lyzed clones, 36 clones showed no indels in FUT8, BAK or
BAX while four, 23 and 34 clones showed indels in one,
two or three genes, respectively (Fig. 2A). 
Table 1. Off-target analysis of the 15 most potential off-target sites for each of the sgRNAs in multiplexed and FACS-enriched cell populations
FUT8_on target 66.3% BAK_on target 66.3% BAX_on target 75.8%
FUT8_off1 0.2% BAK_off1 0.1% BAX_off1 0.1%
FUT8_off2 0.1% BAK_off2 0.2% BAX_off2 0.2%
FUT8_off3 0.2% BAK_off3 0.1% BAX_off3 N/Aa)
FUT8_off4 0.2% BAK_off4 0.2% BAX_off4 0.6%
FUT8_off5 0.2% BAK_off5 0.2% BAX_off5 46.3%b)
FUT8_off6 0.0% BAK_off6 N/Aa) BAX_off6 0.2%
FUT8_off7 0.1% BAK_off7 0.2% BAX_off7 0.7%
FUT8_off8 0.1% BAK_off8 0.4% BAX_off8 0.2%
FUT8_off9 0.1% BAK_off9 0.4% BAX_off9 0.1%
FUT8_off10 N/Aa) BAK_off10 N/Aa) BAX_off10 0.1%
FUT8_off11 0.1% BAK_off11 0.1% BAX_off11 0.1%
FUT8_off12 0.2% BAK_off12 0.2% BAX_off12 0.1%
FUT8_off13 0.7% BAK_off13 0.2% BAX_off13 0.1%
FUT8_off14 0.2% BAK_off14 0.1% BAX_off14 0.1%
FUT8_off15 0.1% BAK_off15 0.2% BAX_off15 0.7%
a) N/A indicates that no PCR products were obtained from samples.
b) The high indel frequency observed in this sample is also observed in the GFP_2A_Cas9 only sample.
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One potential BAK and BAX double knockout cell line
and two potential FUT8, BAK and BAX triple knockout
cell lines were selected for further characterization.
Primers were designed to verify the indels generated at
the three sgRNA target sites, and to facilitate analysis of
a larger region surrounding the target site compared to
the deep sequencing primers. The flanking regions sur-
rounding the FUT8, BAK and BAX target site were ampli-
fied, gel purified and Sanger sequenced (Supporting infor-
mation, Table S10). The purified bands are presented 
in Supporting information, Fig.  S2. Alignment of the
sequencing data was performed (Supporting information,
Fig. S3, S4 and S5) which verified the deep sequencing
data obtained for the three clones (Supporting informa-
tion, Table S11). 
To investigate whether the genome modifications
introduced by CRISPR/Cas9 genome editing technology
resulted in a functional knockout, three knockout cell lines
with validated genotypes were further analyzed for pro-
tein levels and their functions. Western blot analysis
revealed no detectable Bak and Bax protein levels in one
BAK and BAX double knockout cell line and two FUT8,
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Figure 2. Characterization of multiplexed single cell sorted clones upon
FACS enrichment. (A) Distribution of the number of clones with indels gen-
erated in none (wild-type), one, two or three of the targeted genes (FUT8,
BAK and BAX) upon multiplexing with GFP_2A_Cas9 and the respective
sgRNAs. The number of genes with indels is measured by deep sequencing
of amplicons covering the three sgRNA target sites in 187 single cell sorted
clones upon FACS enrichment. Only data for 97 of the clones that had clear
deep sequencing data are shown. The data include clones generated upon
low and high ratio of GFP_2A_Cas9 to sgRNAs and both biological repli-
cates. (B) Cell lysates from CHO-S, CHO-S (conditioned) and three select-
ed clones are analyzed with anti-Bak, anti-Bax, or anti-Vinculin antibodies.
The predicted molecular weight of Bak and Bax is 23 kDa and 20 kDa,
respectively. Vinculin is used as a loading control. (C) Analysis of apoptosis
in multiplexed single cell sorted clones. Caspase activities are measured
upon cultivation with apoptosis inducer, actinomycin D, for 24 h. Black
bars, no actinomycin D; gray bars, 10 µg/mL actinomycin D. The activity of
each clone is normalized by that of the wild-type CHO-S cells in the
absence of actinomycin D. Average value of triplicates ± SD is shown. 
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BAK and BAX triple knockout cell lines (Fig. 2B, Lane 3–5
for Bak; Lane 8–10 for Bax). Truncated Bak and Bax pro-
teins were not observed either, which confirmed suc-
cessful knockout of BAK and BAX via frameshift muta-
tions in the exons yielding no full-length Bak and Bax pro-
teins. 
Since Bak and Bax regulate the intrinsic apoptotic
pathway through mitochondrial permeabilization leading
to cytochrome c release and subsequent activation of cas-
pase cascade [11, 14], double knockout of BAK and BAX
is expected to render cells resistant to apoptosis. When
cells lacking Bak and Bax were treated for 24 h with pro-
apoptotic transcription inhibitor, actinomycin D, which is
known to induce cytochrome c release from mitochondria
and cell death [15], caspase activation hardly occurred. In
contrast, wild-type CHO-S cells and one clonal cell line
without indels in FUT8, BAK and BAX (conditioned wild-
type CHO-S) showed significant induction of caspases in
the presence of actinomycin D (Fig. 2C). 
The phenotypic change caused by disruption of Fut8
was assessed by a lectin stain and glycoprofiling of
secreted proteins from FUT8, BAK and BAX triple knock-
out cell lines. Since the enzyme activity of Fut8 is respon-
sible for transferring fucose to core oligosaccharides, cells
lacking the Fut8 enzyme activity do not bind LCA that
selectively recognizes fucosylated plasma membrane pro-
teins [3, 12]. The two knockout cell lines harboring the
knockout of Fut8 showed no F-LCA binding, whereas
both wild-type cells and one BAK and BAX double knock-
out cell line were completely stained with F-LCA
(Fig. 3A). Comparison of the glycoprofiles of all secreted
proteins from wild-type CHO-S cells, one BAK and BAX
double knockout cell line and one FUT8, BAK and BAX
triple knockout cell line, showed clear differences in the
Re
la
tiv
e A
bs
or
ba
nc
e
Time (min)
1
2
3
4
5
6
7
8
9
10
11
12
13
CHO-S
BAK (-13) BAX (-2)
B
Green fluorescence intensity
- F
-LC
A
Ce
ll C
ou
nt
+ 
F-
LC
A
CHO-S CHO-S (conditioned)
BAK (-13)
BAX (-2)
FUT8 (-2,-23) 
BAK (-19,-14)
BAX (+88)
FUT8 (+59)
BAK (+1)
BAX (+1)
99.1 %
0.2 %
99.0 %
0.2 %
99.7 %
0.1 %
4.2 %
0.6 %
1.8 %
0.1 %
A
FUT8 (-2,-23) BAK (-19,-14) BAX (+88)
Figure 3. Characterization of glycosylation of multi-
plexed single cell sorted clones. (A) Lectin staining
characterized by alteration of green fluorescence
intensity upon incubation with F-LCA. The figure
shows the representative images of triplicate experi-
ments and the percentages of F-LCA positive cells are
shown as the average value of the triplicates (n = 3).
(B) Glycoprofiling of all proteins in pooled super-
natants from duplicate cultivations of CHO-S, the
double knockout cell line BAK (-13) BAX (-2) and the
triple knockout cell line FUT8 (-2,-23) BAK (-19,-14)
BAX (+88). The upper panel shows the chro-
matograms of the released and fluorescent labeled
glycoforms of the secreted proteins from the three
cell lines respectively. The numbers indicate the peaks
of the different glycoforms, which are presented in the
lower panel. Blue square with black outline, N-acetyl-
glucosamine; green circle with black outline, man-
nose; yellow circle with black outline, galactose; red
triangle with black outline, fucose; purple diamond
with black outline, N-acetylneuraminic acid.
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amount of fucosylated and non-fucosylated glycoforms
(Fig.  3B and Supporting information, Table S12). In the
FUT8, BAK and BAX triple knockout cell line, the main
peaks of the fucosylated glycoforms (peaks 5 and 7) were
not present and the main peaks of non-fucosylated glyco-
forms (peaks 4 and 6) were increased. The analysis con-
firmed the loss of Fut8 enzyme activity in the triple
 knockout cell line as expected. Taken together these data
demonstrate a highly efficient method for generation of
genetic and functional multiple knockout CHO cell lines
using multiplexing with CRISPR/Cas9.
3.4  Cell culture performance of double 
and triple knockout CHO-S cell lines 
To evaluate the effect of multiple knockouts on culture
performance, the generated double and triple knockout
cell lines were cultivated together with wild-type and
conditioned wild-type CHO-S cells. In accordance with
the apoptosis inhibition (Fig. 2C), the double and triple
knockout cell lines harboring knockout BAK and BAX
were found to delay viability drop, resulting in extended
culture longevity compared to CHO-S cells (Fig. 4A). Sub-
sequently, the capability to produce recombinant thera-
peutic proteins was assessed by transient expression of
antibody constructs encoding rituximab for three days
(two biological replicates). The cell growth and product
titer was measured daily and the raw data are presented
in Supporting information, Table S13. From the viable cell
concentration (Supporting information, Fig. S6) and the
production of rituximab (Supporting information, Fig. S7),
the productivity of the five cell lines was calculated
(Fig. 4B). The double and two triple knockout cell lines
were capable of producing rituximab comparable to those
from wild-type CHO-S cells, and even better for two of the
clones.
4  Discussion 
With the availability of CHO cell lines and Chinese ham-
ster genome sequences, extensive genetic manipulation
and genomic analysis of CHO cells has become possible,
which has lead us to engineer CHO cells via sequence-
specific approaches [16, 17]. Here, we have developed an
efficient multiplexing platform for CHO cells via simulta-
neous transient expression of sgRNAs together with 
co-expression of GFP and Cas9 nuclease. To avoid a
potential decrease in Cas9 activity by being fused to GFP,
a linker peptide harboring the 2A peptide was applied to
couple GFP to Cas9. The use of a self-cleaving 2A peptide
allows stoichiometric co-expression of 2A peptide-linked
proteins from the same transcript following post-transla-
tional cleavage [10, 18]. Thus, the cleavage of GFP from
Cas9 is expected to yield wild-type Cas9 and free GFP at
comparable levels, which can be used for sorting trans-
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Figure 4. Growth profiles and productivity of multiplexed single cell sort-
ed clones from batch cultures. (A) Viable cell concentration and viability.
CHO-S, CHO-S (conditioned) and three selected clones are cultivated in
shake flasks with seeding densities at 4 × 105 cells/mL. The error bars show
the deviation between data points from each biological replicate (n = 2).
(B) Productivity upon transient expression with antibody expression plas-
mid. The productivity is calculated from the growth of the cell lines and
the amount of secreted rituximab protein during cultivation for three days
after transient transfection. The center line represents the average of the
biological replicates (n = 2). 
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fected cells. FACS enrichment for fluorescence-positive
cells achieved isolation of cell populations with high
genome editing events, which allowed for the simultane-
ous generation of single, double, and triple gene knockout
clones in a single round of transfection and clone genera-
tion. Notably, 57 out of 97 single cell sorted clones (effi-
ciency = 58.8%) harbored multiple knockouts, in which
59.6% of clones were triple knockout clones, demonstrat-
ing the efficiency of CRISPR/Cas9 genome editing in mul-
tiplexing. The resultant multiple knockout CHO cell lines
showed the expected phenotypes with the practical
industrial relevance including enhanced culture lifespan
and capability to produce non-fucosylated proteins
(Figs. 3 and 4A). In particular, stable production of highly
active non-fucosylated antibodies [19] can be achieved
from knockout CHO cell lines lacking Fut8, which will be
executed in future studies.
By virtue of its simple, fast, and highly efficient multi-
gene knockout capability, this platform can offer distinct
advantages over current targeted methods as well as tra-
ditional methods for CHO cell line engineering including
overexpression or introduction of new genes, RNA inter-
ference-mediated knockdown or regulation of gene
expression [20, 21]. Permanent gene modifications
through transient expression of sgRNA and Cas9 nucle-
ase abolish the need for a lengthy selection process with
a limited number of available selection markers when
compared to traditional methods. This feature enables us
to exclude the addition of expensive selection markers
during cell cultivation for sustainable expression of
exogenous transgenes while reducing metabolic burdens
caused by expression of selection marker genes. The high
frequency of gene disruption can reduce screening time
and effort dramatically by generating independent knock-
out clones from less than one 96-well plate of single cell
sorted clones. In comparison to previous triple knockout
CHO cell line generation using ZFNs [12], the present
platform is fast and efficient in regard to the one-step gen-
eration of multiple gene knockout CHO cell lines. The
application of CRISPR/Cas9 technology also benefits from
the straightforward, rapid, and low cost of sgRNA design
compared to other genome editing nucleases. 
Multiplex genome engineering with transfection of
separate sgRNAs against each target site in a pool has
advantages and disadvantages compared to all-in-one
vector systems containing multiple sgRNA and Cas9
nuclease expression cassettes [8, 9]. Co-transfection of
multiple plasmids can cause a lower transfection efficien-
cy and variable targeting efficiency at individual target
sites due to dilution of each construct and uncoupled
expression levels from separate entities. Nevertheless,
this was not the case in this study as shown by the high
and comparable genome editing efficiency at the three
genomic sites after FACS enrichment (Fig.  1B). It can
rather be exploited for various combinatorial multiplexing
through co-transfection of several sgRNAs without con-
struction of single vectors every time for particular com-
binations. Introduction of more sgRNAs could expand this
system further, thus it will be valuable to investigate how
many target sites can be dealt with at once. 
Although CRISPR/Cas9 technology generates on-tar-
get modifications specifically, off-target mutations can
also occur as reported in previous studies in mammalian
cells [22–26]. Based on the recent progress on off-target
analysis, the potential off-target sites for each sgRNA
were predicted by extending our previous bioinformatics
tool, CRISPy (Section 2.5), followed by deep sequencing
analysis aiming at the top 15 candidate off-target sites
(Table 1). Interestingly, no off-target mutations were
observed even after FACS enrichment, which supports
the high fidelity of the present system. The application of
a CHO genome-oriented bioinformatics tool for design of
sgRNA target sites with the minimal number of possible
off-target sites could facilitate multiplex genome engi-
neering while minimizing the risk of off-target mutations.
Furthermore, multiplexing with the use of Cas9 nickase
can also be utilized to improve on-target specificity of
Cas9 [26, 27].
Our study provides a simple and efficient platform for
multiplex genome engineering of CHO cells. With the
advent of improved CHO genome characterization and
global gene expression profile, it will not be confined to
knockout of well characterized genes, but may be har-
nessed for multiple gene integration [10] and transcrip-
tional control of endogenous genes [28, 29] in CHO cells
through slight modifications. The multiple modifications
of industrially-relevant genes will improve the production
of biopharmaceuticals and enhance the understanding of
the gene network underlying protein production.
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3.2 Applicability and future perspectives 
A major issue of eukaryotic expression systems is the continuous acidification of culture medium 
due to accumulation of lactate, which is generated by the conversion of pyruvate by the lactate 
dehydrogenase (LDH). The complete knockout of the LDH-A gene has been shown to be lethal 
for CHO cells 15, which could the case for several other genes as well. However, a recent study 
by Hefzi et. al 16 successfully managed to knockout LDH-A by simultaneously knocking one or 
more of the four genes PDK1, PDK2, PDK3 and PDK4, using the multiplexing technique 
presented in this chapter. The resulting CHO cells were devoid of lactate dehydrogenase activity, 
an achievement previously believed to be impossible. With this testimony that the impossible can 
be made possible, it is clear that this multiplexed genome editing technique will completely 
transform our ability to study and engineer more complex biological problems. 
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Chapter 4 
 
Site-specific knockin of transgenes 
 
 
This chapter presents a platform for site-specific gene integration in CHO cells mediated by 
CRISPR/Cas9 and homology-directed DNA repair pathway, where the use of antibiotics is 
avoided. Site-specific integration of genes provides a point of control in the development of 
recombinant protein producing CHO cells by avoiding position effect variation and phenotypic 
heterogeneity associated with random gene integration. The technique allows the use of 
predetermined loci in the genome where, for example, the gene expression levels and stability 
have been assessed over time. Resulting in predictable levels of protein production and 
accelerated cell line generation. The need to screen thousands of clones will no longer be 
necessary if sufficient production levels can be achieved in this controllable manner. Site-specific 
integration into precise genomic locations is also necessary in order to characterize the function 
of regulatory elements in mammalian cells in their natural chromosomal position. 
      We opt to avoid the use of antibiotics in this study, as it has been shown that the expression 
of antibiotic selection markers can occupy a substantial amount of the protein production 
machinery 17. Additionally, by avoiding the use of antibiotic selection we do not limit the use of 
the platform to the number of antibiotic selection markers that are available.  This opens up for 
the possibility to consequently target several additional loci in the genome. Avoiding the use of 
antibiotics will possibly increase the control and predictability of the platform,  as any changes to 
the environment cells are grown in can increase the genetic plasticity 18. 
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ABSTRACT: Targeted gene integration into site-speciﬁc loci can be
achieved in Chinese hamster ovary (CHO) cells via CRISPR/Cas9
genome editing technology and the homology-directed repair
(HDR) pathway. The low efﬁciency of HDR often requires antibiotic
selection, which limits targeted integration of multiple genes at
multiple sites. To improve HDR-mediated targeted integration,
while avoiding the use of selection markers, chemical treatment for
increased HDR, and ﬂuorescent enrichment of genome-edited cells
was assessed in CHO cells. Chemical treatment did not improve
HDR-mediated targeted integration. In contrast, ﬂuorescent
markers in Cas9 and donor constructs enable FACS enrichment,
resulting in a threefold increase in the number of cells with HDR-
mediated genome editing. Combined with this enrichment method,
large transgenes encoding model proteins (including an antibody)
were successfully targeted integrated. This approach provides a
simple and fast strategy for targeted generation of stable CHO
production cell lines in a rational way.
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Introduction
The extensive use of Chinese hamster ovary (CHO) cells as a
production host for complex therapeutic proteins, has long been
based on random integration, large-scale screening for highly
productive cell lines and process optimization (Kim et al., 2012). In
order to meet industrial requirements, such as high and stable
transgene expression, and increasing demands for new therapeutic
proteins, CHO cell line engineering is transitioning into a
more rational and targeted approach (Nielsen and Borth, 2015).
The ability to make targeted modiﬁcations of the CHO genome
drastically improved with the bacterial clustered regularly
interspaced short palindromic repeat (CRISPR)/CRISPR-associated
protein 9 (Cas9) gene editing system, which is based on the
generation of double-strand breaks (DSBs) at desired locations in
the genome and consequent gene modiﬁcation using the DNA
repair pathways, non-homologous end joining (NHEJ), or
homology-directed repair (HDR) (Lee et al., 2015a). It allows for
the direct manipulation of existing genes as well as insertion of new
genes into desired genomic locations.
NHEJ is the predominant form of DNA repair in CHO cells
(Mansour et al., 2008), causing a low efﬁciency of CRISPR/Cas9-
mediated targeted gene insertions by HDR. This makes isolation of
clones with targeted gene insertions time-consuming and labor
intensive, creating a desire for more efﬁcient approaches to
accelerate genome engineering. We recently demonstrated efﬁcient
and precise targeted integration of a gene cassette (3.7 kb in size)
into site-speciﬁc loci in CHO cells, using CRISPR/Cas9 genome
editing system and donor plasmid harboring homology sequences
(Lee et al., 2015b). It is a simple method, providing a high
percentage of clones with targeted gene insertions based on HDR
and antibiotic selection. There are a few drawbacks with our
previous method: antibiotic selection is not desired in an industrial
setting due to high costs, selection genes are available in a limited
number—making it difﬁcult to employ this method for multiple
integrations, and selection genes can potentially impose a further
metabolic burden on the cells (Veraitch and Al-Rubeai, 2005). It is
thus attractive to have efﬁcient marker-free systems.
In order to avoid using antibiotic selection, we tested two
approaches: chemical treatment and FACS enrichment; aiming to
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enhance HDR efﬁciency or to enrich targeted integrants resulting
from HDR events (Fig. 1A). To investigate which approaches are
most effective with regard to improving targeted integration
efﬁciency, we used short DNA fragments (a BamHI restriction site
with linker sequences, 15 bp in total) as gene of interest (GOI). This
construct allows for deep sequencing analysis to determine the
relative ratio of Cas9-induced DSBs being repaired by the NHEJ
versus HDR pathway (Fig. 1B).
The efﬁciency of HDR-mediated genome editing in human cells
has previously been increased several fold by chemical treatment for
inhibition of NHEJ (Chu et al., 2015; Maruyama et al., 2015) or cell
cycle synchronization to select for HDR (Lin et al., 2014). We
therefore chose the DNA ligase IV inhibitor Scr7 (Chu et al., 2015;
Maruyama et al., 2015) and the G2/M cell cycle inhibitor lithium
chloride (LiCl) (Ha et al., 2014) as chemical additives to test their
effects on CRISPR/Cas9-mediated genome editing in CHO cells.
Based on previous studies (Chu et al., 2015; Ha et al., 2014;
Maruyama et al., 2015), we chose ﬁve concentrations of Scr7
(0.1, 1, 5, 10, and 20mM) and 10mM LiCl. Scr7 inhibited cell
growth of CHO cells in a dose-dependent manner, while cell
viability was maintained (Supplementary Fig. S1). Highest
insertion efﬁciency was reported upon treatment with 1mM Scr7
in human cells (Chu et al., 2015; Maruyama et al., 2015). The use of
10mM LiCl was validated in CHO cell cultures to induce cell
cycle arrest at the G2/M phase (Supplementary Fig. S2) while
maintaining cell viability (Ha et al., 2014).
CHO cells were transfected with GFP_Cas9 and sgRNA
expression vectors together with donor plasmids targeting two
endogenous target sites, COSMC (C1GALT1C1) and FUT8
(Supplementary Table SI). Chemical additives were applied before
and/or after transfection, and deep sequencing of target sites was
performed (Methods). Transfection efﬁciency was estimated to be
approximately 90% for replicates of both target sites in controls
without chemical treatment (Supplementary Fig. S3). The use of
Scr7 concentrations above 5mM decreased transfection efﬁciency,
in particular by 25–50% with 20mM Scr7 regardless of the timing
of the treatment. Severe cell clumping was observed in the samples
with 20mM Scr7, and likely led to the large difference in
transfection efﬁciency between the two target sites and replicates.
LiCl slightly reduced transfection efﬁciency (!20%), while it was
unaffected by pre-treatment (condition 3). We observed an average
of 35.7/32.0% indel (NHEJ) frequencies (light gray) and 1.8/0.9%
targeted integration (HDR) frequencies (black) at COSMC and
FUT8 target sites, respectively in the absence of chemical additives
(Fig. 1C and D). It corresponds to NHEJ versus HDR ratio of 20 and
35 at the two target sites, indicating a preference toward NHEJ. The
HDR frequency was only enhanced at FUT8 in the presence of 1mM
Scr7 after transfection, but it was ineffective at COSMC. Overall, we
observed no signiﬁcant increase in HDR efﬁciency upon Scr7 and
LiCl treatment (Fig. 1C and D, HDR fold), but rather negative effects
on total editing including both NHEJ and HDR. The negative effects
could be due to decreased transfection efﬁciency. However, 1mM
Scr7 and 10mM LiCl before transfection did not lead to increase in
HDR frequencies despite similar levels of transfection efﬁciency.
This limited effect may arise from the refractory nature of CHO cells
against chemical manipulation of DNA repair pathways caused by
different kinetics of DSB repair. Recent studies also reported
minimal effects of chemical treatment in mammalian systems,
suggesting context or cell line dependent responses to these
treatments (Pinder et al., 2015; Song et al., 2016). Genetic
manipulation of key molecules of NHEJ/HDR (Ismail et al., 2015;
Kim et al., 2001; Lambert and Lopez, 2000; Mansour et al., 2008)
and investigation of alternative NHEJ pathways (Ceccaldi et al.,
2015; Mateos-Gomez et al., 2015) could perhaps unveil the
underlying mechanism.
Our second approach is based on a previous study where we
show that CRISPR/Cas9 targeted cells are enriched via a GFP-
labelled Cas9 expression vector combined with FACS, resulting in
cell populations with high genome editing events (Grav et al., 2015).
By applying two ﬂuorescent proteins, GFP 2A peptide-linked Cas9
and donor DNA expressing mCherry, we can enrich cells transfected
with both Cas9 and donor DNA that are likely to be exposed to
genome editing events. Since mCherry is placed outside the
homology regions of the donor DNA, it is not integrated upon
correct targeting of the donor plasmids to the desired locus via HDR
(Fig. 1B).
Fluorescent enrichment resulted in a threefold increase in the
number of cells with HDR-mediated genome editing at the two
target sites relative to non-enriched samples, yielding HDR
frequencies of !7% (Fig. 1E). NHEJ frequencies up to 85% were
also achieved upon enrichment, but no effects were observed in
control samples without sgRNAs. Time course analysis from day 0
to 5 after enrichment showed no signiﬁcant changes in HDR and
NHEJ frequencies, revealing that genome editing events occurred
within 48 h post-transfection. Overall, these data demonstrate the
feasibility of efﬁcient isolation of genome-edited cells with targeted
integration.
To assess the effect of ﬂuorescent enrichment on targeted
integration of longer DNA fragments, we inserted large transgenes
encoding model proteins, erythropoietin (EPO, 2.1 kb in size
excluding homology arms), or antibody (Rituximab, 5.1 kb in size
excluding homology arms) into COSMC (Fig. 2A). Successful
targeted integration of transgenes in enriched pool of cells was
veriﬁed by 50/30 junction PCR targeting genome-donor boundaries
(Fig. 2B, Lanes 4 and 8). We then isolated non-ﬂuorescent clonal
cells from each enriched pool of cells for EPO or Rituximab, in
which 62% or 80% of cells were both mCherry and GFP negative.
Selection of non-ﬂuorescent clonal cells excludes many cells with
randomly integrated donor DNA and facilitates a screening process
to select proper targeted integrants, as only the transgene
expression cassettes inside homology regions can be inserted
through HDR. 81 EPO and 76 Rituximab clonal cells were acquired
from six 96-well plates of single cell sorted clones (i.e., Sorting
survival rate of 10.5% or 9.9%). One out of 81 EPO clonal cells and
one out of 76 Rituximab clonal cells were veriﬁed as correct targeted
integrants (Supplementary Table SIII) by out–out PCR using a
primer set targeting outside of the homology arms (Fig. 2C, Lane 2:
EPO, amplicon size of 3.7 kb, Lane 4: Rituximab, amplicon size of
6.8 kb) compared with non-targeted cells (Fig. 2C, Lanes 1 and 3:
amplicon size of 1.6 kb). The generated targeted integrants
harbored the same copy number of transgenes compared to a
mCherry expressing targeted integrant at the same locus that was
derived from the previous selection-dependent method (Clone #1,
Lee et al., 2015b) (Fig. 2D). The Rituximab construct consists of two
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Figure 1. The effect of chemical treatment or fluorescent enrichment on NHEJ-directed indel generation and HDR-directed targeted integration in CHO cells. (A) Schematic
illustration of two approaches for increasing targeting efficiency including chemical treatment (i and ii) and fluorescent enrichment (iii). The donor plasmid contains target GOI,
BamHI restriction site with additional linker sequence flanked by homology arms and a mCherry expression cassette outside homology arms. In GFP_Cas9 expression plasmid, GFP
is linked via a 2A peptide to Cas9. (B) Experimental schematic of detection of genome editing. Upon DSB generation and subsequent HDR-mediated targeted integration of GOI,
targeted genomic regions were PCR-amplified with primers that anneal outside of the homology arms. Targeted deep sequencing of the PCR products was performed using MiSeq.
The percentage of wild type sequences (dark gray), NHEJ-directed indel sequences (light gray), and sequences corresponding to precise insertion of target GOI (black) are
illustrated in the bar plot. (C and D) Analysis of genome editing events upon chemical treatment. Cells were treated with five different concentrations (0.1, 1, 5, 10, and 20mM) of Scr7
(C) or 10 mM concentration of LiCl (D) immediately after transfection (denoted by 1), both before and after transfection (denoted by 2), or before transfection only (denoted by 3) (See
Methods). Genomic DNA harvested 2 days after transfection was subjected to deep sequencing analysis as shown in panel B. (E) Analysis of genome editing events upon
fluorescent enrichment. After 2 days of transfection, cells were FACS sorted for mCherry and GFP fluorescent positive populations (day 0), followed by 5 incubation days. Time
course analysis of genome editing events was performed on genomic DNA as described earlier. NHEJ and HDR fold change indicates the relative percentage values of indel and
targeted integration rate, compared to control samples transfected with GFP_Cas9, sgRNA, and donor plasmid without chemical treatment or fluorescent enrichment—set at 100%.
Results of approximately 50,000–230,000 sequencing reads from two biological replicates are shown.
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Figure 2. Application of fluorescent enrichment for targeted integration of large transgenes encoding model proteins. (A) Schematic illustration of the targeting strategy. The
donor plasmids contain expression cassettes of two model proteins, EPO or antibody (Rituximab), as described in Figure 1A. Integration events were analyzed using primer sets that
anneal either inside and outside (50/30 junction regions) or outside of the homology arms. (B and C) Detection of integration events upon fluorescent enrichment using 50/30 junction
PCR (B) or out–out PCR (C). Genomic DNA harvested from enriched pool of cells was analyzed for 50/30 junction regions. After single cell sorting, genomic DNA harvested from clonal
cells was analyzed for regions outside of the homology arms (Lanes 2 and 4 in C). Lanes 1 and 3 in C serve as a negative control, using genomic DNA of a pool of cells transfected with
only GFP_Cas9 and donor plasmid to provide PCR products of wild type COSMC locus. M, 1 kb DNA ladder (D) Relative copy number of transgenes in clonal cells with targeted
integration. Target amplicon regions on genomic DNA are depicted. Genomic DNA of COSMC targeted integrant expressing mCherry (Lee et al., 2015b) was used as reference. The
error bars represent the standard deviations (n¼ 3).
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expression cassettes encoding either heavy or light chains, thus
twofold higher copy number was observed. Targeting results
comparable to those obtained from the previous integration
platform supports the reliability of the current integration platform.
In this way, we not only shorten the clone generation time, but
also generate clonal CHO cell lines with site-speciﬁc, marker-free
(no antibiotic selection required), and clean (no unwanted DNA
present) targeted integration of transgenes from one 96-well plate of
single-cell derived clones, offering several advantages over the
previous method. Improvement in HDR efﬁciency through small
molecule screening (Yu et al., 2015) or transient modulation of DNA
repair proteins (Chu et al., 2015) could fully optimize targeted
gene insertion in CHO cells. Taken together, the present platform
has the huge potential to accelerate targeted generation of stable
CHO production cell lines. It could ultimately lead to a rational
construction of CHO production cell lines assuring stable high
expression levels in a short time when combined with the selection
of ideal transgene insertion sites.
Methods
Plasmid Construction
GFP_Cas9 and sgRNA expression vectors used in this study were
constructed as described previously (Supplementary Table SI).
Donor plasmids harboring BamHI or model protein-encoding genes
were constructed via uracil-speciﬁc excision reagent (USER)
cloning method (Lund et al., 2014) using primers listed in
Supplementary Table SII. For construction of donor plasmids
harboring BamHI, four PCR ampliﬁed DNA parts including
50 homology armwith BamHI sequence at 30 end, 30 homology arm,
mCherry expression cassette, and backbone were assembled with
USER enzyme (New England Biolabs, Ipswich, MA). The EPO donor
plasmid was made of six DNA parts that include 50 and 30 homology
arms, EF-1a promoter, EPO-BGH pA, mCherry expression cassette,
and backbone. The antibody (Rituximab) construct was assembled
using seven DNA bricks: 50 and 30 homology arms, EF-1a promoter,
heavy chain-BGH pA, light chain expression cassette (EF-1a—light
chain—BGH pA), mCherry expression cassette, and backbone. The
length of each 50 and 30 homology arm was set at 750 bp. Plasmids
used as PCR templates for EPO and antibody parts have previously
been described (Kol et al., 2015). Puriﬁed plasmid was obtained
using NucleoBond Xtra Midi EF (Macherey-Nagel, D€uren,
Germany) according to manufacturer’s instructions following
sequence veriﬁcation.
Cell Culture and Transfection
CHO-S cells were grown in CD CHO medium supplemented with
8mM L-glutamine (Life technologies, Thermo Scientiﬁc, Rockford,
IL) and cultivated in Corning vent cap shake ﬂasks (Sigma–Aldrich,
St. Louis, MO) in a humidiﬁed incubator at 120 rpm, 37!C, and
5% CO2. Cell growth and viability was monitored using the
NucleoCounter NC-200 Cell Counter (ChemoMetec, Allerod,
Denmark) based on two ﬂuorescent dyes, acridine orange and
DAPI for the total and dead cell populations, respectively. Cells at a
concentration of 1" 106 cells/mL were transfected with donor
plasmid, expression vectors encoding GFP_Cas9, and/or sgRNA
targeting the integration site at a ratio of 1:1:1 (w:w:w).
Transfection was performed in 6- or 12-well plates (BD Biosciences,
San Jose, CA) with a total of 3" 106 cells and 3.75mg of DNA or
1" 106 cells and 1.25mg of DNA, respectively using FreeStyleTM
MAX reagent together with OptiPRO SFM medium (Life
Technologies) according to the manufacturer’s recommendations.
Transfection efﬁciency was measured based on % population of
mCherry-positive cells using the maskþ target 1 application on
Celigo Cell Imaging Cytometer (Nexcelom Bioscience, Lawrence,
MA) as described previously (Lee et al., 2015b).
Cell Cycle Analysis
The cell cycle was analyzed using a Celigo Cell Imaging Cytometer.
Cells were incubated with culture media containing various
concentrations (1, 5, 10, 15, and 20mM) of LiCl (Sigma–Aldrich)
for 24 h, followed by Vybrant1 DyeCycleTM Green stain (ﬁnal stain
concentration of 10mM, Thermo Fisher Scientiﬁc) for 60min in the
dark according to manufacturer’s instructions. Approximate
10,000–15,000 cells were analyzed using the Expression Analysis
application on Celigo.
Chemical Treatment
Three treatment conditions were tested in this study: (i) cells were
incubated with Scr7 (0.1, 1, 5, 10, and 20mM, ApexBio, Houston,
TX) or LiCl (10mM) for 48 h after transfection; (ii) cells were
treated with Scr7 or LiCl for both 24 h before transfection and 48 h
immediately after transfection; and (iii) cells were treated with Scr7
or LiCl for 24 h before transfection, washed to remove the chemical
upon transfection, and then incubated without any chemical for an
additional 48 h until analysis.
Fluorescent Enrichment
A 48 h post-transfection, cells were bulk sorted for both mCherry
and GFP positive cell population using a BD FACSJazz cell sorter
(BD Biosciences, San Jose, CA) according to a previous study
(Grav et al., 2015). Bulk sorted cells were maintained in 80%
CD CHO medium supplemented with 8mM L-glutamine, and
1% Antibiotic-Antimycotic (Life Technologies) and 20% 20mm
ﬁltered spent medium for 1–2 weeks in order to make them restore
and further expand before single cell sorting. Single cell sorting was
performed as described previously (Grav et al., 2015) upon gating
for mCherry and GFP negative cell population to exclude cells with
randomly integrated donor DNA.
Genomic DNA Extraction and PCR Amplification of
Target Region
Genomic DNAwas extracted from cell pellets (cell pools and clonal
cells) using QuickExtract DNA extraction solution (Epicentre,
llumina, Madison, WI) according to the manufacturer’s instruc-
tions. GeneJET Genomic DNA Puriﬁcation Kit was used for genomic
DNA preparation for copy number analysis, as described below.
50/30 junction PCR was carried out using DreamTaq DNA
2522 Biotechnology and Bioengineering, Vol. 113, No. 11, November, 2016
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polymerase (Thermo Fisher Scientiﬁc) by touchdown PCR (95!C for
2min; 10": 95!C for 30 s, 65–55!C [#1!C/cycle] for 30 s, 72!C
for 2min; 30": 95!C for 30 s, 55!C for 30 s, 72!C for 2min; 72!C for
5min). Out–Out PCR was performed using Phusion High-Fidelity
PCR Master Mix (Thermo Fisher Scientiﬁc) by touchdown PCR
(98!C for 30 s; 10": 98!C for 10 s, 68–58!C [#1!C/cycle] for 30 s,
72!C for 1min [BamHI], 2min [EPO], or 3min 30 s [Rituximab];
30": 98!C for 10 s, 58!C for 30 s, 72!C for 1min [BamHI], 2min
[EPO], or 3min 30 s [Rituximab]; 72!C for 10min). PCR primers
are listed in Supplementary Table SII.
Deep Sequencing Analysis
Deep sequencing analysis of PCR products was performed on a
MiSeq Benchtop Sequencer (Illumina, San Diego, CA) using the
protocol described previously (Grav et al., 2015). As described in
Figure 1B, PCR amplicons for deep sequencing were generated from
the out–out PCR products to avoid amplifying the donor plasmids.
Quantitative Real-Time PCR (qRT-PCR) for Copy
Number Analysis
Relative copy number of transgenes was determined using Brilliant
III Ultra-Fast SYBR1 Green QPCR Master Mix (Agilent Technolo-
gies, Santa Clara, CA) on Mx3005P qPCR System (Agilent
Technologies) as described previously (Lee et al., 2015b). Target
genomic regions including EF-1a, BGHpA, and Vinculin were
ampliﬁed using primers listed in Supplementary Table SII that were
validated by melting curve analysis and agarose gel electrophoresis.
A delta–delta threshold cycle (DDCT) method was applied using a
COSMC targeted integrant expressing mCherry (Clone #1) in which
mCherry coding sequence is ﬂanked by EF-1a promoter and
BGHpA sequences (Lee et al., 2015b), as calibrator. As unknown
samples harbored coding sequences ﬂanked by the same EF-1a
promoter and BGHpA sequences, EF-1a promoter and BGHpA
amplicons were used as target GOI for comparative quantiﬁcation.
Vinculin was used as an internal control gene for normalization.
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4.3 Applicability and future perspectives 
Using CRISPR/Cas9 for site-specific integration of genes provides a completely new and 
extremely flexible way to integrate genes in the genome. It allows targeting of several more 
annotated loci than previous genome-editing tools, which lets us test many more genomic 
locations for potential suitability for stable and high transgene expression. Not being limited by 
the number of available selection markers also opens the possibility to insert genes in many 
different loci in the same system. This provides a huge advantage if there is a need to express 
different genes at different levels, which often is the case for genes working in consort with each 
other. The efficiency that we have managed to reach in this study, is still quite low and requires 
screening of a significant number of clones. However, if coupled with recombinase-mediated 
cassette exchange (RMCE) landing pads, as demonstrated in Chapter 5, the targeted integration 
site becomes re-usable, leaving the current efficiency more than sufficient.  
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Chapter 5 
 
Minimized clonal variation for improved comparative 
systems biology studies 
 
 
In this chapter, we present a study where we have combined site-specific gene integration with a 
recombinase-mediated cassette exchange (RMCE) method to create isogenic clones. In order to 
study and understand the effect of genes or elucidate why it is difficult to produce certain proteins, 
it is necessary to utilize systems that are comparable. Immortalized cell lines, like CHO, are 
known for their inherent genomic instability, making it difficult to assess the effect different 
transgenes impose on the cells. The necessity to use isogenic cells for comparative studies is due 
to the difficulty in distinguishing if an observed change in phenotype is related to the actual 
introduction of a transgene to the CHO cells, or if it simply transpires from clonal variation. 
      A transcriptomics analysis is performed on the isogenic clones generated in the study, to 
illustrate the applicability of the technique for comparative studies like differential gene 
expression. Transcriptomics is the study of the complete set of transcripts generated by the 
genome, and is one of the most sensitive omics tools due to the fundamentally stochastic process 
of gene expression, and is highly influenced by phenotypic variation. Presenting an ideal case to 
test the applicability of isogenic cell lines in this setting. 
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Abstract!
Mammalian' cell' lines,' such' as' Chinese' hamster' ovary' (CHO)' cells,' are' widely' used' to' stably' express'
transgenes( for( the( production( of( complex( biopharmaceuticals.( Nevertheless,( the( effect( of( recombinant(
protein( expression( on( the( cell( is( difficult( to( investigate# using# current# cell# line# development# platforms,#
possessing( high( genomic( and( phenotypic( diversity.( It( hampers( comparative( transcriptomic( approach( for(
discovery* of* potential* engineering* targets* for* the* generation* of* CHO* cell* lines* with* improved* protein*
production(performance.(Here,(we(present(a(cell(line(development(platform(where(the(genetic(background(
that$ may$ influence$ large$ transcriptional$ variation! is# minimized,# allowing# us# to# study# the# impact# of# any#
transgenes( on( the( global( transcriptome( of( mammalian( cells.& The& platform& cell& line& was& developed& by&
clustered) regularly) interspaced) short) palindromic) repeats) (CRISPR)/CRISPR!associated) protein) 9) (Cas9)!
mediated' site!specific' integration'of'a' landing'pad' for' recombinase!mediated'cassette'exchange' (RMCE).'
Upon! RMCE% we% created% derivative% subclones% stably% expressing% four% commercially% relevant% recombinant%
proteins,*which*show*an*extraordinary*comparability*in*growth*and*transcript*levels*of*transgenes*across*all*
subclones.* We* further* use* these* isogenic* cell* lines* to# examine# their# exact# transcriptional# response# to#
recombinant+proteins+and+observe+ low+variation+ in+global+transcriptomic+ levels+based+on+RNA!sequencing)
data.%We%also%observe%little%variation%in%phenotypic%behaviour%and%global%gene%expression%within%producer$
clones' that' are' grown' in' unchanged' environmental' conditions' for' three' months.' Thus,' this' cell' line'
development*platform*enables*robust*comparative*studies*of*transgene*effect*on*the*cell.*The*platform*has*
potential) to) accelerate) the) discovery) and) verification' process' of' CHO' cell' line' engineering' targets'when'
combined)with)omics)techniques.!
!
Introduction!
Stable' expression' of' transgenes' in' mammalian' cells' is' crucial' for' both' basic' biological' studies' and'
biotechnology,-especially-for-the-production-of-biopharmaceuticals.-Nowadays,-the-preferred-choice-for-the-
production*of*biopharmaceuticals*is*CHO*cell*lines.*Current*mammalian*cell*line*development*platforms*are*
based& on& random& integration& of& transgenes& into& the& genome,& yielding& clones& exhibiting& a&wide& range$ of$
expression,*growth*and*stability*characteristics,*referred*to*as*a*clonal*variation.*This*clonal*heterogeneity*
obliges( researchers( to( do( time!consuming) and) labour!intensive' screening' to' find' cell' lines' with' desired'
performance*1."!
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The$phenomenon$of$clonal$variation$can$originate$from$different$sources.$It$can$be$partly$explained$by$the$
plasticity)of)CHO)genomes,)which)is)reflected)in)frequent)chromosomal)rearrangements,)high)mutation)rates)
and$ genome% instability% 2,3." Genomic" variation" also" occurs" due" to" random" integration" of" vectors" with"
transgenes,) which) can) be) inserted) in) multiple) copies! in# different# genomic# loci.# This# variation# is# often#
explained)as)the)“position)effect”,)and)emphasize)the)importance)of)genomic)environment)surrounding)the)
transgene(4."Moreover,"upon"random"integration"transgene"cassette"can"be"rearranged,"affecting"the"original"
vector'elements,'which'may'confer'unpredictable'expression'of'the'transgene'(Lee'et'al.,' in'preparation).'
Another(source(of(heterogeneity(is(non!genetic'variation'due'to'epigenetics,'stochastic!gene$expression$and$
changing' environmental' conditions' 5." Currently," clonal" variation" is" a" barrier" that" hinders" our" ability" to"
understand)the)biology)of)CHO)cell)lines.)!
One$of$the$fundamental$questions,#which#remains#to#be#answered#in#the#CHO#field,#is#what#impact#a#specific#
transgene(has(on( the(cell.( Elucidation(of( the(cell’s( response( to(a( transgene( is( crucial( for( the(discovery(of(
potential) engineering) targets) to) improve)CHO) cell) protein) production)performance.* Cell* line* engineering*
approaches) based) on) transient) transgene) expression) and) random) chromosomal) integration,) introduce)
experimental+biases+and+are+not+ reproducible+ 6." Thus," there" is" a"need" for#a# robust# cell# line#development#
platform)to)study)the)cell’s)response)to)specific)transgene)expression.)!
Recent& advances& in& mammalian& genome& engineering& technologies& provide& new& opportunities& for& the&
development*of*platforms*to*assess*the*impact*of*transgenes%on%the%cell.%Systems%for%site!specific'integration'
of#transgenes#allows#the#generation#of# isogenic#cell# lines#with# low#genomic#variation#and#predictable#and#
stable' transgene' expression' 7." The" first# generation# of# targeted# integration# approaches# is# based# on# site!
specific' recombination'and'RMCE,'and'have'been'widely'used' for'genetic'modification' 8." These"methods"
employ' recombinases' that' recognize! specific' recombinase!attachment( sites( and( can( mediate( targeted(
excision(or( integration(of( large(transgenic(cassettes( into(mammalian(cell( lines( (up(to(27(kb(9).#As#second!
generation) targeted) integration" tools," programmable" endonucleases," such" as" CRISPR/Cas9," have" been"
employed.)CRISPR/Cas9)has)been)successfully)used)for)site!specific'integration'of'transgenes'in'mammalian'
cells,&particularly& in&CHO& 7,10!However,(when(using(CRISPR/Cas9( there( is(a( risk(of(aberrant( recombination(
events&around&the&cut&site&and&off!target&effects,&while&recombinase!based&genome&editing&is&highly&specific&
11."!
Several'site!specific'recombinases'have'been'described'and'used'for'engineering'of'mammalian'genomes.'
The$most$ commonly$ used$ recombinase$ is$ the$ P1$ bacteriophage!derived& Cre,& that& mediates& site!specific'
recombination+ between+direction!sensitive'DNA' sequences" named" loxP." Alternative" systems" employ" Flp!
recombinase+with+FRT!sites%or%Bxb1!recombinase+with+att!sites%8,12!By#using#a#pair#of#heterotypic#sites#for#a#
particular) recombinase,) site!directional+ RMCE+ can+ occur.+ In+ RMCE+ systems,+ the+ master+ cell+ line+ (MCL)+
contains(a(marker(gene(flanked(by(recombination(sites(commonly(referred(to(as(a(“landing(pad”.(The(MCL(
can$then$be$used$to$insert$any$genes$of$interest%into%the%landing%pad%by%exchanging%it%with%the%marker%gene.%!
Several'studies'apply'recombinase!mediated'targeted'integration'in'CHO'cell'lines.'The'Flp/FRT!system&has&
been$used$to$generate$cell$lines$expressing$either$monoclonal$antibodies$(mAbs)$13–15!and$antibody$fragments$
16,"or"other"recombinant"proteins,"such"as"erythropoietin"(EPO)"17,"tissue"plasminogen"activator"18,"secreted"
alkaline'phosphatase'18,"bone"morphogenic"protein"2"11!and$G!protein(coupled(receptors(19."Analogous"to"
Flp/FRT!system,'Cre/lox!recombinase+system+has+been+used+to+generate+mAb!expressing)CHO)cell) lines)20."
Initially,)RMCE)platforms)were)developed)by)random)integration)of)the)landing)pad)into)the)genome.)In)some)
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cases,&primary&screening&was&performed&for&the&selection&of&parental&clones&with&the&highest&expression&level& 
of#the#marker#(fluorescent,protein,17,"surface"marker"13!or#antibody#14),#in#order#to#preselect#transcriptionally# 
active'integration'site.'The'site!specific'integration'of'RMCE'landing'pad'into'predefined'loci'is'an'evident' 
improvement*of*the*RMCE*platform.*Targeted*integration*ensures*that*the*landing*pad*will*not*disrupt*any" 
coding'genes'or'essential'genetic'elements,'which'can'have'phenotypic'consequences.'By'using'CRISPR/Cas9!
mediated' homology!directed' integration' and' fluorescent' enrichment' Flp/FRT!! and$ Bxb1/att!landing' pad' 
master'cell'lines'were'created'and'used'for'efficient%generation%of%mAb!expressing)cell)lines)21."!
The$ use$ of$ RMCE!based& site!specific' integration' platform' allows' faster' cell' line' generation' compared' to' 
traditional)random)integration)approach,)and)has)already)been)adopted)by)industry.)It)has)been)employed) 
by#Pfizer#to#speed#up#the#process#of#mAbs#development,'allowing'early'assessment'of'mAb'candidates'14,22." 
Interestingly,, it, has, been, shown, that, RMCE!derived& clones,& expressing& similar& monoclonal! antibodies* or* 
antibody)fragments,)can)have)different)productivity)22,16."However,"only"one"study"went"beyond"descriptive" 
analysis' of' clone' performance,' and' tried' to' reveal' the' cause' of' different' productivity' between' clones' 
expressing)two)similar)antibody)fragments)by)proteomics)analysis)23.!
In# this# study,#we#developed#a#platform# for# the#generation$of$ isogenic$CHO!S"cell" lines" (isoCHO)" to" reveal" 
changes(in(the(transcriptome(caused(by(recombinant(protein(expression.(By(CRISPR/Cas9!mediated'targeted' 
integration) of) a) landing) pad) for) Cre/lox! RMCE,& we& created& master& cell& lines& (MCLs)& with& a& stable& and!
homogeneous)expression)of)reporter)fluorescent)protein.)Upon)RMCE)and)fluorescence!activated(cell(sorting( 
we#generated#derivative#stable#producer#cell#lines,#expressing#four#recombinant#proteins:#etanercept#(ETC),# 
EPO,%growth/differentiation%factor%5%(GDF5)#and#C1#esterase#inhibitor#(C1INH).#A#set#of#isogenic#producer#cell# 
lines,' which' were' genetically' identical' aside' from' the' expressed' gene' of' interest' (GOI),' showed' highly' 
comparable*growth*and*transcript* levels*of*transgenes.*This*cell* line*development*platform(allowed(us(to( 
evaluate' the' transcriptomic' response' to' transgenes' by' comparative' transcriptome' analysis,' while' 
overcoming*effects*accrued*by*clonal*variation*in*CHO*cells.!
Results'!
Stable' master' cell' lines' generated' using' CRISPR/Cas9' and' a' pre!selected$ target$ locus.$ To# facilitate# the# 
construction)of)stable)recombinant)CHO)cell)lines)in)a)more)controlled)manner,)we)established)a)two!stage& 
approach'using'CRISPR/Cas9!mediated'targeted'integration'followed'by'RMCE. For the first stage of 
targeted integration,&we&selected&a&genomic&region&located&close to essential& genes,&to&potentially&avoid 
subsequent(loss(of(transgenes and transcriptional(silencing. Based on our previously published method for  
CRISPR/Cas9!mediated'homology!directed'targeted'integration#7, we"inserted"the"RMCE"“landing(pad”(into 
the$preselected$site,$creating$a$MCL$for$the$second$stage$of$cell$line$generation$(RMCE$with$GOIs).$To$ensure$ 
that$the$GOI$only$will$be$expressed$from$our$target&locus&upon&RMCE,&we&introduced&loxP/lox2272!sites%24!
flanking(the(mCherry(reporter(gene((Fig.(1a).(The(EF!1α#promoter#(EP)#driving#the#mCherry#expression#and# 
the$polyA$signal$are$consequently$located&outside&lox!sites,&creating&a&promoter/polyA&trap&for&the&incoming& 
promoterless)GOI)upon)co!transfection+with+Cre+recombinase+(Fig.+1b).+This+ensures+that+expression+of+the 
GOI only$ occurs$ upon$ exchange$ with$ mCherry.$ After$ CRISPR/Cas9!mediated' targeted# integration# of# the# 
landing'pad,'selection,'fluorescence!activated(single(cell(sorting(and(clone(expansion, 13(clones(having(high  
confluency)in)96!well$plates$were$identified$as$junction$PCR!positive.)Among)the)targeted)integrants,)seven) 
clones'!contained)!one$!copy%!of#!the$Cherry'expression'cassette'(Fig.'1c).'Out'of'two'further'characterized'!
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!!
Fig.% 1% |% Targeted% integration% of% landing% pad% into% preselected% locus% using% CRISPR/Cas9% and% RMCE! strategy.) (a)! Schematic)
representation"of"the"targeting"strategy"of"the"landing"pad"into"the"preselected"target"locus."The"donor"plasmid"contains"the"landing"
pad$with$loxP!(34bp)'and'lox2272!(34bp)'sequences'flanking'mCherry'gene.'EF!1α#promoter#and#BGHpA#polyA#is#located#outside#the#
lox$ sequences% allowing% for% both% promoter% and% polyA% trapping% upon% RMCE.% (b)$ Schematic) of) RMCE) strategy:) co!transfection+ of+
promoterless)RMCE)donor)+)CRE)recombinase)ensures)the)incoming)gene)of)interest)(GOI))will)only)be)expressed)when)exchanged)
with%mCherry%in%the"genomic"landing"pad."(c)!Relative(copy(number(of(mCherry(regions(in(clonal(cells.(The(plot(shows(the(relative(
copy%number%of%mCherry%in%all%targeted%cell%lines%verified%by%junction%PCR,%in%comparison%to%reference%sample%COSMC!mCherry'from'
Lee#et#al#7."The"error"bars"represent"the"standard"deviations"of"technical"replicates"(n≥3)."(d)!Stability(of(mCherry(gene(expression(
tested%over%an%eight!week$period$measured$by$qRT!PCR,%for%two%selected%one%copy%clonal%cell% lines.%The%error%bars%represent%the%
standard'deviations'of'technical'replicates'(n=3).!
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clones,(showing(highly(stable(mCherry(expression(after(an(eight!week$long$cultivation$period$(Fig.$1d),$one$
clone&(isoCHO!EP)$was$selected$as$the$MCL$based$on$homogenous)and)high) levels)of)mCherry)expression)
(Supplementary-Fig.-S1-and-Table-S1).!
!
Isogenic)subclones)expressing)therapeutic)proteins)show)similar)growth)and)low)transcriptional)variation.)
To#generate#a#set#of#isogenic#subclones!from%the%master%cell%line,%we%cloned%four%promoterless%vectors%for%
RMCE%with%GOIs%encoding%recombinant%proteins%ETC,%EPO,%GDF5,%or%C1INH.%After%co!transfections+of+RMCE+
donor%vector%and%Cre!recombinase+into+isoCHO!EP,$we$single$cell$sorted$mCherry!negative"cells"to"enrich"for"
cells%that%have%exchanged%mCherry%with%the%incoming%GOI%from%the%RMCE%donor%vector,%using%isoCHO!EP#as#
gating&control.&For&each&GOI&exchange,&we&verified&exchange&with&GOI&in&generated&subclones&using&insert&
PCR$with$primers$aligning$outside(the( lox!sequences'and'sequenced'the'products.'We'selected'12'clones'
(three&clones&for&each&GOIs)&for&further&analysis.&To&study&the&growth&behaviour&of&these&subclones,&batch&
cultures(in(shake(flasks(were(performed.(All(12(subclones(derived(from(isoCHO!EP#displayed#highly#similar#
growth'phenotypes'(Fig.'2a).'On'day'four'in'late'exponential'phase,'cells'were'harvested'for'RNA!sequencing)
to#capture#the#transcriptome#for#further#analysis#of#the#variations#between#all#subclones#expressing#different#
recombinant'proteins'(dataset'1).'Based'on'the'transcriptomics'data,'highly'comparable'relative'transgene'
expression)levels)were)observed)within)biological)replicates)(three)clones)expressing)the)same)GOI))(Fig.)2b),)
which%was%confirmed%by%qRT!PCR$(Supplementary#Fig.#S2).#The#reproducibility#among#the#biological#replicates#
were$evaluated$following$guidelines$for$technical$replicates$25,"with"Spearman"R2>0.9%(Supplementary%Fig.%
S3).% % To% assess% the% variation% in# global# gene# expression#between# subclone# sets# expressing# different#GOIs,#
principal( component( analysis( (PCA)( of( the( transcriptomics( data,( excluding( transgene( expression,( was(
performed.)Little)variation)in)the)gene)expression)profiles)of)the)isoCHO!EP#subclones&is&observed:&the&first&
principal(component((PC)(accounts(for(only(25%(of(the(variation(and(the(second(PC(accounts(for(13%(of(the(
variation.) The) variation) in) PC1) is) clearly) explained) by) GDF5) expressing) subclones,) as) they) provide) the)
separation*according#to#PC1#(Fig.#2c).#To#further#assess#the#variation#in#all#genes#expressed#in#the#subclones,#
differential*gene*expression*(DGE)*analysis*was*performed*on*the*dataset*1*(Supplementary*Fig.*S4a).*Only*
160$out$of$a$ total$of$12646$tested$genes$ (1.27%)$were$significant(differentially(expressed,( indicating(very(
similar' gene' expression' profiles' of' all' 12' clones.' From' these' data,' we' can' conclude' that' our' two!stage&
isogenic(cell(lines(generation(platform(facilitated(efficient(generation(of(highly(reproducible(subclones%with%
low$variations$in$phenotypes$and$transcriptomes.$!
!
Isogenic)subclones)show)high)stability) in)growth)and)transcriptome)during)three)months)of)cultivation.)
Generation)of)clones)by)the)traditional)approach)of)random)integration)of)the)GOI)into)the)genome%of%cells%
often&results& in&unstable&clones&that&show&loss&of&expression&over&time.&Therefore,&we&were& interested& in&
studying)how)the)generated)clones)behaved)in)long!term%culture.%For%the%analysis,%six%isoCHO!EP#subclones#
expressing) ETC) and)C1INH)were! cultivated* up* to* three*months* by* passaging* three* times* a*week,*with* a*
cryopreservation-at-each-passage.-Upon-completion,-the-cryopreserved-cultures-from-the-beginning-of-the-
maintenance(culture((0(months),(mid!culture'(1.5'months)'and'end'of'culture'(3'months)&were&thawed&and&
cultivated*in*batch*cultures*simultaneously.*Unfortunately,*one*biological*replicate*of*both*ETC*and*C1INH!
was$ lost$ after$ 1.5$months$ and$were$ therefore$ not$ included$ in$ the$ batch.$ The$ viable$ cell$ densities$ were$
analysed(revealing(almost"no"variation"in"growth"irrespective"of"product"or"time"of"harvest"indicating"very"
stable'and'similar'growth'of'the'subclones'(Fig.'3a).'From'the'batch'cultures,'cells'were'harvested'in' late!
exponential!!phase&!!for!!RNA!sequencing!!analysis'!(dataset'2).!!!RNA!sequencing)!revealed!!low!!variation!!!in#!
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!Fig.2&|&Isogenic&subclones&generated&by&RMCE&show&low&variation&in&phenotypes&and&transcriptomes.!(a)!Viable'cell'densities'of'
isoCHO!EP#subclones!expressing)ETC,)EPO,)GDF5)or)C1INH.)The)error)bars)of)each)line)represent)the)standard)deviations)of)three)
isogenic(subclones(expressing(the(same(GOI((n=3).((b)!Relative(levels(of(transgene(expression,(as(measured(in(transcripts(per(kilobase(
million&(TPM)!of#ETC,#EPO,#GDF5#or#C1INH#producing#subclones#sampled#at#day#4#in#late#exponential#phase.#The#error#bars#represent#
the$standard$deviations$of$three$isogenic$clones$expressing$the$same$GOI$(n=3).$(c)!PCA$of$whole$transcriptome$data$from$isoCHO!
EP#subclones"expressing"ETC,"EPO,"GDF5"or"C1INH"sampled"at"day"4"in"late"exponential"phase."!
!
relative(transgene(expression(levels(over(the(time(in(culture,(indicating(stable(expression(of(GOIs(from(the(
integration)site)(Fig.)3b).)PCA)of)the)transcriptomics)data)(not!including(transgenes)(reveal(little(variation(in!
subclone)populations)over)time)with)PC1)explaining)only)23%)of)the)variation)and)PC2)16%)of)the)variation.)
Clustering+!was$!observed!!for!!each%!biological!!replicate,!!indicating(!that$!the$!largest(!variation!!is#!between$!
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!Fig.3&|&Long!term%stability%of%gene%expression%in%isogenic%subclones.!(a)!!Viable'cell'densities'of'isoCHO!EP#subclones#expressing#ETC#
and$C1INH$cultivated$upon$thawing$of$cells$harvested$after$0,$1.5$and$3$months$in$culture.$The$error$bars$represent#the#standard#
deviations* of* three* (0* and* 1.5*months)* or* two* (3*months)* subclones* expressing* the* same*GOI* (n=2!3).$ (b)! Levels& of& transgene&
expression)over)time)of)isoCHO!EP#ETC#and#C1INH#expressing#clones#cultivated#upon#thawing#of#cells#harvested#after#0,"1.5"and"3"
months'in'culture'as'measured'in'transcripts'per'kilobase'million'(TPM).'The'error'bars'represent'the'standard'deviations'of'three%(0%
and$1.5$months)$or$two$(3$months)$subclones$expressing$the$same$GOI$(n=2!3).$(c)!PCA$of$whole$transcriptome$data#from#isoCHO!
EP#subclones#expressing#ETC#or#C1INH#cultivated#upon#thawing#of#cells#harvested#after#0,#1.5#and#3#months#in#culture.#Clustering$is$
observed(within(each(biological(replicate(of(ETC(producing(subclones((E1,(E2,(E3)(and(C1INH(producing(subclones#(C1,#C2,#C3),#and#
no#clustering#observed#due#to#time#in#culture.!!
!
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individual(subclones((Fig.(3c).(The(gene(expression(of(biological(replicates(was(deemed!as#reproducible,#with#
Spearman( R2>0.90% (Supplementary% Fig.% S5).% From! the$ DGE$ analysis$ of! subclones! producing! the$ same%
recombinant+protein+(Supplementary+Fig.+S4b),+only+10+out+of+12932+tested+genes+(0.08%)+were+differentially+
expressed'over'the'three'months'period'of'passaging.'This' indicates'very' low'changes'in'gene'expression'
levels%over%long!term%cultivation.)Moreover,)only)4)out)of)12935)tested)genes)(0.03%),)including)transgenes,)
were$detected$as$differentially$expressed$when$comparing$the$ETC$cultures$at$0,$1.5$and$3$months$versus$
the$C1INH$cultures$at$the$same$time$points$(Supplementary$Fig.$S4c),"indicating"a"low"or"similar"effect"of"ETC"
and$C1INH$expression$on$the$transcriptome$in$these$cells.$Together,$the$data$indicate$that$the$generated$
clones'behave'very'similarly'and'show'low'transcriptomic'changes'over'time.'''!
!
Different(responses(to(transgene%expression%levels%from%same%promoters%in%same%target%site.%To#facilitate#
analysis'of'the'direct'impact'of'different'transgenes'on'the'transcriptome,'we'aimed'to'generate'a'MCL'with'
higher&basal&expression&levels&of&mCherry/GOIs,'potentially'imposing'a'larger'burden'on'the'cells'by'increased'
expression)of)therapeutic)proteins.)We)created)a)new)donor)vector)for)targeted)integration)of)the)landing)
pad,%where%the%full%length%human%EF!1α#promoter#is#replaced#with#a#commercial#composite(promoter((CP)(
consisting(of(mouse(CMV(enhancer,(minimal(human(EF!1α#and#HTLV#RU5’#5’UTR#region.#After#CRISPR/Cas9!
mediated'targeted'integration,'selection,'single'cell'sorting'and'clone'expansion,'11'targeted'integrants'with'
high$ confluency$ in$ 96!well# plates#were# verified#by# junction#PCR.#Among# the# verified# targeted# integrants,#
seven%clones%contained%one%copy%of%the%mCherry%expression%cassette%(Fig.%4a).%Of%two%selected%clones,%both%
showed'stable'mCherry'expression'after'an'eight!week$long$cultivation#period#(Fig.#4b).#One#clone#(isoCHO!
CP)$was$selected$as$a$new$master$cell$line$based$on$homogenous$mCherry$expression$(Supplementary$Table$
S2)$and$that$it$showed$about$1.8$times$higher$mCherry$expression$level$than$isoCHO!EP#(Supplementary#Fig.#
S6).%!
!
Similar'to'isoCHO!EP,$isoCHO!CP#was#used#to#generate#subclones#expressing#four#recombinant#proteins#by#
RMCE.& In& addition,& non!producing* subclones* of* both* isoCHO!EP# and# isoCHO!CP#were# generated# by# low!
frequency) recombineering) of) loxP! and$ lox2272! sites% in% the" absence" of" a" RMCE" donor" vector." For" each"
recombination+event,+subclones+were+verified+by+insert+PCR+and+sequencing+of+inserted+GOI.+15+clones+(three+
clones' expressing' each' GOIs' and' three' non!producer( clones)( derived( from( isoCHO!CP#were# selected# for#
further#analysis.#To#study#the#growth#behaviour#of#these#subclones,#batch#cultures#were#performed.#Of#the#
isoCHO!CP#subclones,#the#three#EPO#and#three#GDF5#subclones#grow#similar#as#non!producing* isoCHO!CP#
subclones.* Interestingly,* C1INH* and* ETC* expressing* clones# grow# to# slightly# lower# maximum# VCDs#
(Supplementary-Fig.-S7a).-On-day-four-in-late-exponential-phase,-cells-were-harvested-for-RNA!sequencing)to)
analyse'the'variation'in'transcriptome'of'all'15'subclones'(dataset'3).'From'the'RNA!sequencing)data,)highly)
comparable*relative*expression*levels*were*observed*within*each#set!of#ETC#and#GDF5,#while#larger#error#bars#
were$observed$within$the$EPO$and$C1INH$expression$clone$sets$(Supplementary$Fig.$S7b).$However,$qPCR$
showed' lower' variation' in' gene' expression' among" the" EPO" and" C1INH" clones" (Supplementary" Fig." S8)."
Unexpectedly,, only, EPO, expression, levels, were, increased, by, 1.7, fold, in, isoCHO!CP# clones# compared# to#
isoCHO!EP#(Fig.#4c).#The#expression#level#of#ETC,#GDF5#and#C1INH#were#similar#in#both#isoCHO!EP#and#isoCHO!
CP#clones.!
!
Large&transcriptional&variation&observed&in&relation&to&increased&protein&expression&and&clonal&variation&
between&MCLs.&To#study# the#variation# in#global#gene#expression#between#subclones#expressing#different#
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GOIs%at%different%expression%levels,$PCA$of$the$transcriptomics$data$from$the$15$subclones$was$performed$
(dataset'3).'PCA'of'gene'expression'data'from'isoCHO!CP#subclones,#not#including#transgenes,#display#slightly!
higher&variation&between&subclones&than&dataset&1,&resulting&in&PC1&explaining$33%$of$the$variation$and$PC2$
explaining!!12%$!of#!the$!variation(!(Fig.&5a).&!The$!gene!!expression!!of!!biological(replicates(was(compared(and!
!
!
!
!
!
Fig.%4|%Generation%of%clones%with%composite%promoter.!(a)!Relative(copy(number(of(mCherry!transgene(in(clonal(cells.(The(plot(shows(
the$relative$copy$number$of$mCherry$in$of$all$targeted$cell$lines$verified$by$junction$PCR,$in$comparison$to$reference$sample!COSMC!
mCherry'from'Lee'et'al'7."The$error$bars$represent$the$standard$deviations$of$technical$replicates$(n≥3).$(b)!Stability(of(mCherry(gene(
expression)tested)over)an)eight!week$period$measured$by$qRT!PCR.%The%error%bars%represent%the%standard%deviations%of%technical%
replicates*(n=3).*(c)!Relative(levels(of(transgene(expression(in(isoCHO!EP#and#isoCHO!CP!derived&subclones,&measured&by&qRT!PCR,%
normalized+ to+ average+ value+of+ isoCHO!EP# subclones.# The#error# bars# represent# the# standard#deviations#of# three# isogenic# clones#
expressing)the)same)GOI$(n=3).!
!
deemed$to$be$reproducible$with$Spearman$R2>0.90%(Supplementary%Fig.%S9).%A%large%amount%of%differentially%
expressed'genes' (DEGs)'were'observed'when'comparing'all' five'groups'of'subclones' (Supplementary'Fig.'
S4d),&4622&DEGs&out&of&a& total&of&12967#tested#genes# (35.6%).# #With#a# log# fold#change#cut!off#at#1.5,# the#
number'of'DEGs'is'reduced'to'229'(5%).'To'check'if'the'increase'in'DEG'between'isoCHO!CP#subclones#could#
be#due#to#the#increase#in#EPO#productivity,#we#compared#the#gene#expression#of#all!subclones)excluding)EPO)
producers)(Supplementary)Fig.)S4e).)This)yielded)a)much)lower)number)of)DEGs:)137)out)of)a)total)of)12967)
tested%genes%(1.1%).%Interestingly,%this%smaller%set%of%DEGs%completely%overlap%in%terms%of%gene%identity%with%
the$DEGs$identified%in%dataset%1.%!
!
We#did#some#further#analysis#of#the#DEGs#identified#when#including#EPO#producers#in#the#comparison,#to#see#
if#the#DEGs#were#related#to#the#increased#transgene#expression.#DEGs#with#human#homologs#were#subjected#
to# enrichment# analysis# of# canonical# pathways# showing# that# DEGs# are# most# enriched# in# mitochondrial#
dysfunction,, oxidative,phosphorylation,, and,EIF2, signalling, canonical, pathways, (Supplementary, Fig., S10).,
Analysis(of(non!redundant(gene(interaction(networks(shows(that(the(most(represented&cellular&functions&in&
our$set$of$DEGs$are$molecular$transport,$post!translational)modification,)protein)synthesis,)lipid)metabolism)
and$cell$signalling.$!
a cb
iso
CH
O*
EP
iso
CH
O*
CP
iso
CH
O*
EP
iso
CH
O*
CP
iso
CH
O*
EP
iso
CH
O*
CP
iso
CH
O*
EP
iso
CH
O*
CP
ETC
EPO
GDF5
C1INH
Protein
MCL
W
ee
k=
0
W
ee
k=
8
W
ee
k=
0
W
ee
k=
8
CO
SM
C*
m
Ch
er
ry
iso
CH
O*
CP A2 A5 A6 A7 C3 C4 C5 C6 D9 D1
2
Re
la
tiv
e=
m
Ch
er
ry
ex
pr
es
sio
n
Re
la
tiv
e=
m
Ch
er
ry
co
py
=n
um
be
r
Re
la
tiv
e=
ge
ne
=e
xp
re
ss
io
n
isoCHO*CP
A2
- Chapter 5 -
70
!
To#assess#clonal#variation,#we#compared#subclones#expressing#ETC#and#C1INH#derived#from#both#isoCHO!EP#
and$isoCHO!CP#together#with#their#respective#non!producing*clones*(dataset*4).*PCA*shows*a*clear*separation*
between&subclones&based&on&which&MCL&they&originate&from.&They&are&separated&by&the&PC1&that&accounts&
for$77%$of$the$variation$(Fig.$5b).$The$PC2$only$accounts$for$4%$and$the$distance$between$subclones$derived$
from%the%same%MCL.%When%comparing%subclones%from%different%MCLs%(Supplementary%Fig.%S4g),%6884%out%of%
a"total"of"13031"genes"(52,8%),"including"transgenes,"were"identified"as"differentially%expressed.%With%a%log%
fold%change%cut!off#at#1.5,#the#DEG#are#reduced#to#1100#(8,4%).#The#DEG#analysis# indicates#a#high#level#of#
clonal& variation& between& the& two&MCLs,& even&when& the& same& locus& in& the& CHO!S" genome"was" used" for"
targeting(when(generating"both"MCLs."!
!
!
Fig.% 5% |% Variation% within% subclone% populations.! (a)$ PCA$ of$ whole$ transcriptome$ data$ from$ isoCHO!CP# subclones#
expressing)ETC,)EPO,)GDF5)or)C1INH)and)non!producer(subclones(sampled(at(day(4(in(late(exponential(phase.((b)!PCA$
of#whole# transcriptome#data# from# isoCHO!EP#and# isoCHO!CP# subclones#expressing#ETC#or#C1INH#and#non!producer(
subclones)sampled)at)day)4)in)late)exponential)phase.)!
!
!
Discussion!
Traditionally,, mammalian, cell, lines, are, generated, by, random, integration, of, transgenes, leading, to, large,
uncontrollable% variations% in% growth% and% transgene% expression% levels.% Random% integration% creates% a% high%
diversity)of)clones,)which)can)be)beneficial) in) the)search) for)high)producing)clones) 3."However," the" large"
clonal% variation% complicates% transcriptomics% data% analysis% due% to% difficulties% in% deciphering% which%
transcriptional+ changes+ are+ originating+ from+ transgene+ expression+ and+which+ are+ originating+ from+ clonal+
variation( 26." Here" we" present" a" platform" for" generating" isogenic" cell" lines" using" CRISPR/Cas9!mediated'
targeted' integration' combined' with' RMCE' for' improved' transcriptomic' analyses' by' minimizing' clonal'
variation(interference.(!
With% CRISPR/Cas9!mediated' targeted& integration& of& a& landing& pad& for& subsequent& recombineering& of&
transgenes,)we)have)established)a)two!stage&approach&for&the&generation&of&isogenic&transgene&expressing&
clones.(CRISPR/Cas9(allows(flexible(selection(of(target(sites(for(landing(pad(integration(in(the(first(step(of(the(
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approach.( Our( selected( target( site( close to( essential( genes( exhibited( both( stable( mCherry( expression) 
and) stable) expression) of) GOIs) over) 1.5) to) 3) months) of) cultivation.) A) similar) strategy) for) the 
selection)of)target#sites#between#essential#genetic elements#has#been#applied#in#yeast#27. Our"preliminary 
finding might&suggest&that&this&strategy&will&be&a&successful&selection&criteria&for&target&sites&in&CHO&cells as 
well.#The second'step'of'our'approach'allows'fast'and'reproducible'generation'of'cell'lines'originating'from 
the'same master'cell'line'that'only'differ'in'the'transgene'coding'sequence,'without'the'use'of'antibiotic 
selection'by' enriching(for(non!mCherry'expressing&clones&with&FACS&upon&RMCE.!
Combination)of)CRISPR/Cas9!mediated'targeted'integration'with'RMCE'has'also'been'proposed'by'Inniss'et  
al.,%which%integrated%a%Bxb1/att!and$Flp/FRT!landing'pad'into'the'Fer1L4'site'of'CHO!K1#genome#21."In"their" 
approach, they( recombined( GFP( and( Thymidine( kinase( genes( from( the( landing( pad( with( incoming  
promoterless)blasticidin)resistance)gene)and)genes)encoding)IgG)heavy)chain)(HC))and)light)chain)(LC) driven 
by#CMV#promoters.#In#their#system,#a#selection#with#blasticidin#was#required#upon#RMCE.#Selection pressure 
applied'after'RMCE'exchange'could'lead'to'some'perturbations'in'the'cell'3,"which"could%explain the variable 
levels%of%expression% in%RMCE derived&clones&reported& in&their&study.&The&design&of&RMCE&  promoter/polyA 
trap%without%resistance%gene%in%our%study%hinders%the%expression%of%GOI%from%possible%random%integration,%
allowing( the( generation# of# isogenic# clones# with# highly# comparable# phenotypes# while# avoiding# the# use# of 
additional(antibiotic(selection(step. Due( to( the( efficient( generation( of( recombineered( mCherry( negative 
clones'with'FACS'and'high'stability'of'expression'in'the'established'system,'we'propose'that'removal'of'neoR  
gene$during$RMCE$could$be$feasible$by$moving$the$ lox2272!site%downstream%of%the%neoR%gene%before% its%
polyA& tail.& Removal& of& the& NeoR& marker& could& potentially& release& move& transcriptional& and& translational  
capacity'for!growth'and'protein'production'in'the'host'cell' line'as'observed'previously'28."In"addition,"this" 
could&facilitate&re!use$of$neoR$selection$marker$for$efficient$future$targeted$integration$events.!
With!our$two!staged'approach,'the'generated'subclones'expressing'ETC,'EPO,'GDF5'and'C1INH'show'very' 
similar'growth'profiles'between'biological replicates'as'well as'between'different'transgene expressing 
clones'(Fig.'2a'and'Supplementary'Fig.'S6).'Although'corresponding*recombinant*proteins*differ*in size*and* 
post!translational)modifications,)their)expression)in)the)MCLs)did)not)seem)to)affect)the)growth,)even)when) 
the$expression$level$of$EPO$was$increased.$It$is$possible$that$the$respective$level$of$transgene expression)was 
not$high$enough$to$repress$the$growth$as$growth$repression$is$typically'regarded'as'a'trait'of'high!producing  
CHO$cell$lines.$The$similar$growth$might$also$be$due$to$a$mild$impact$of$RMCE$on$the$MCLs$phenotype$or the 
subcloning*of*CHO!S"cells during%the%first%CRISPR!mediated'targeted'integration'step.'CRISPR!mediated' 
targeted' integration'of'mCherry' into'COSMC'site' in'the'same'CHO!S"cells"as"used" in"this"study"generated" 
clones'with'different'growth'profiles'while'showing'similar'mCherry'expression(levels(7."This"could"indicate" 
that$the$CHO!S"cells"used"as"a"starting"point"in"both"studies"contain"high"variation"of"growth"among"the"cells" 
or#that#the#CRISPR!mediated'genome'editing'in'combination&with&antibiotic&selection&introduced&the&growth 
variation(observed(in(Lee(et(al.,(2015.(Furthermore,(Ko(et(al. shows(that(subclones(of(a(mAb(producing(clone  
displays(a(wide(variety(in(growth,(titer(and(product(quality!29."This"might"be"due"to"random"integration"of" 
transgene(in(unstable(regions(in(the(parental(clone(population.!
Large&challenges&in&transcriptomics&studies&arises&from&the&plasticity&of&CHO&cell&genomes&and&the&cell’s&easy& 
adaptation!to#environmental#changes.#It#was#therefore#surprising#to#us#that#the#isoCHO!EP#clones#expressing# 
ETC$and$C1INH$showed$high$stability$in$their$transcriptome$over$3$months$in$culture.$This$could$be explained 
by#the#constant#culture#conditions#and#stability#of#the#integration#site.#There#was#no#indication#of#drift#in#the
#
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transcriptome,- as-would-be-expected-due- to- the- large- variation-observed- in- the-genome-over- long- term-
culture'30."!
The$ recent$ advances$ in! obtaining( large!scale& data& sets& for& CHO& cells& including& transcriptomics& allow&
researchers'to'improve'their'understanding'of'the'basic'biology'of'CHO'cells'underlying'recombinant'protein'
production.+To#reveal#the#impact#of#expressed#transgenes#on#the#global%transcriptomic%levels,%DEG%analysis%
was$performed.$The$transcriptomic$data$showed$a$low$variation$of$the$transcriptome$among$the$subclones$
originating(from(the(same(MCL((isoCHO!EP#or#isoCHO!CP).%Especially%the%isoCHO!EP#!derived&clones&showed&
few$DEGs!(about'1%).'We'expect'that'the'low'variation'obtained'is'due'to'the'two!stage&approach&applied&
to# generate# the# isogenic# clones,#which# resulted# in# similar# transgene# expression# levels# among# clones# and#
similar'growth'profiles.'Especially'the'low'variation'in!growth'facilitate'easier'transcriptomics'comparisons'
as#subclones#might#be#experiencing#the#same#nutrient#depletion#and#thereby#the#same#environmental#impact#
on#their#transcriptome#over#time#in#culture.#For#future#studies,#it#would#be#interesting#to#analyse#if#the#clones#
indeed%show%similar%uptake%of%nutrients%and%excretion%of%bi!products.*!
The$ transcriptomic$ analysis$ of$ C1INH$ and$ ETC$ producing$ clones$ together$ with$ non!producing* clones*
originating( from( isoCHO!EP# and# isoCHO!CP# showed# low# variation# among# the! subclones) originating) from)
either& isoCHO!EP# and# isoCHO!CP,$ indicating$ a$ low$ or$ similar$ effect$ of$ ETC$ and$ C1INH$ expression$ on$ the$
transcriptome, in, these, cells., On, the, contrary,, large, variation,was, observed, between, the, two, groups, of,
isogenic(cell(lines(originated'from'different'MCLs'(Fig.'5b).'This'indicates'that'even'the'two'MCLs'with'similar'
growth' profiles' could' have' quite' different' transcriptomic' profiles,' as' similar' subclones' derived' from' the'
different(MCLs(display(a(large(amount(of(DEGs((52,8%).(A(similar$observation$was$reported$in$Orellana$et.$al,$
showing( that( two( cell( lines( originated( from( the( same( cell( pool( have( 58%( of( DEGs( despite( only( modest(
differences)in)growth)rate)26."With"such"high"degree!of#variation,#it#is#almost#impossible#to#use#transcriptomics#
data$to$identify$potential$engineering$targets$without$minimizing$clonal$variation,$as$was$performed$in$our$
study.'!
The$ higher$ level$ of# EPO$ expression$ in$ isoCHO!CP!derived& clones& allowed& us& to& further$ investigate$ the$
transcriptional+impact+of+EPO+expression+in+the+cell+lines.+Increase+in+EPO+productivity+was+coupled+to+large+
transcriptional+ changes,+ especially+ in+ mitochondrial+ dysfunction,+ oxidative+ phosphorylation,+ and+ EIF2+
signaling'pathways.'Mitochondrial*dysfunction*and*oxidative*phosphorylation*are*highly*interconnected*and*
are$both$shown$to$be$down!regulated,*indicating*that*the*“metabolic*effort”*from*these*pathways*has*been*
rerouted'to'protein'production.'Down!regulation+of+oxidative+phosphorylation(genes(was(also(reported(in(
producer(HEK239(cultures(31."EIF2"signaling"is"known"to"be"involved"in"global"translational"control"and"has"
previously+been+shown+to+regulate+translation+and+protein+production*in*CHO*cells*32."The"most"represented"
cellular' functions' in' our' set' of' DEGs' were' molecular' transport,' post!translational) modification,) protein)
synthesis,) lipid)metabolism)and)cell) signaling.!These%are%all% cellular% functions%we%would%expect% to%change%
when%protein%production%is%increased,%indicating%that%the%increase%in%DEG%could%be%explained%by%the%increased%
expression)of) EPO.) Extended)analysis) of) the) gene)networks) and) their)major) regulators) could% lead% to% the%
discovery*of*interesting*engineering*targets*for*improving*protein*expression*levels.!
In#summary,#the#presented#cell#line#generation#approach#minimizes#clonal#variation#in#CHO#cells,#making#it#
optimal(for(comparative(studies(such(as(DGE(analysis.'It'can'be'applied'in'numerous'studies'ranging'from'
multi!omics& studies,& studying& the& effect& of&media& supplementations& and& the& impact& of& specific& genes& or&
genetic'elements.'The'platform'can'be' further'advanced'by' inserting' the' landing'pad' into'multiple$ sites,$
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combining(it(with(inducible(promoters(or(promoters(of(different(strengths,(in(order(to(study(multiple(genes(
in#coherence#to#each#other.!
Methods!
Plasmids( and( plasmid( construction.( GFP_2A_Cas9+ and+ sgRNA+ vectors+ were+ constructed+ as+ described+
previously%33."sgRNA"target"sequence"was"designed"manually"after"selection"of"target&loci.&Donor&plasmids&
with%RMCE%landing%pad%and%promoterless%RMCE%vectors%were%constructed%via%uracil!specific'excision'reagent'
(USER)' cloning' method.' The' donor' plasmids' harboring' the' RMCE' landing' pad' was' made' of' seven' PCR'
amplified)DNA)parts,)including$5’$and$3’$homology$arms,$the$promoter$(EF!1α#(EP)#or#composite#promoter#
(CP)),&mCherry&coding&sequence&with&loxP!sequence'at'5’'end'and'lox2272!sequence'at'3’'end'and'BGHpA,'
NeoR% expression% cassette% (pSV40!NeoR!SV40pA),) ZsGreen1!DR# expression# cassette# (pCMV!NeoR!BGHpA)'
and$backbone.$Plasmids$used$as$PCR$templates$for$EF!1α#sequence,#NeoR#and#ZsGreen#expression#cassettes#
have%been%described%previously%7."Plasmid"lox!mCherryOri)with)loxP!mCherry!lox2272!BGHpA&DNA&part&was&
constructed*in!house&by&USER&cloning,&the&template&used&for&mCherry&amplification&have&previously&been&
described(7."The"composite"promoter"(CP)"was"amplified"from"pDRIVE5!GFP!2"plasmid&included&in&Invivogen’s&
PromTest™*kit*(version*#*13F06!MM).$Promoterless$RMCE$vectors$was$made$of$two$parts,$the$backbone$and$
GOI$(ETC,$EPO,$GDF5,$C1INH)$with$loxP!sequence'at'5’'end'and'lox2272!sequence'at'3’'end.'Plasmids'used'as'
PCR$templates$for$ETC,%EPO%and%C1INH%have%previously%been%described%34–36."The"plasmid"with"the"coding"
sequence' for' human' GDF5' was' ordered' via' GeneArt' and' codon' optimized' for' CHO,' sequence' listed' in'
Supplementary$ Table$ S3.$ Primers$ are$ listed$ in$ Supplementary$ Table$ S4.$ Assembled$ PCR$ fragments$were$
transformed+ into+ E.# coli! Mach1& competent& cells& (Life& Technologies).& All& constructs& were& verified& by&
sequencing) and) purified) using) NucleoBond) Xtra) Midi) EF) (Macherey!Nagel)$ according$ to$ manufacturer’s$
instructions.**For*Cre*recombinase*expression,*Sigma!Aldrich(PSF!CMV!CRE$recombinase$expression$vector$
was$used$directly$(OGS591).!
Generation) of) RMCE) master) cell) lines) using) CRISPR/Cas9.) CHO!S" cells" (Thermo" Fisher" Scientific)" were"
maintained( in( CD( CHO( medium( supplemented( with( 8( mM( L!Glutamine* (Thermo* Fisher* Scientific)* and*
cultivated*in*125*mL*Erlenmeyer*flasks*(Corning*Inc.,*Acton,*MA),*incubated*at*37°C,*5%*CO2!at#120#rpm#and#
passaged' every' 2!3" days." Cell" growth" and" viability#was#monitored# using# the# NucleoCounter# NC!200# Cell#
Counter((ChemoMetec).(Cells(at(a(concentration(of(1(x(106!cells/mL(were(transfected(with(donor(plasmid(and(
vectors(encoding(GFP_Cas9(and(sgRNA(targeting( the( integration(site(at(a( ratio(of(1:1:1( (w:w:w)( in"6!well$
plates'(BD'Biosciences)'using'FreeStyleTM!MAX$transfection$reagent$(Thermo$Fisher$Scientific)$according$to$
the$manufacturer’s$recommendations.$Stable$cell$pools$were$generated$by$seeding$cells$in$CELLSTAR$6$well$
Advanced(TC(plates((Greiner(Bio!one)"on"day"3"after"transfection"in"medium"containing"G418"(500"mg/mL;"
Sigma!Aldrich).* During* selection* with* G418,* medium* was* exchanged* every* 3–4" days." After" 2" weeks" of"
selection,*cells*were*detached*with*TrypLE*(Life*Technologies)*and*adapted*to*grow*in*suspension&in&non!
tissue&treated&plates&or&Erlenmeyer&flask&depending&on&cell&concentrations.&For&clonal&selection,&cell&pools&
were$ subjected$ to$ single$ cell$ sorting$ using$ a$ BD$ FACSJazz$ cell$ sorter$ (BD$ Biosciences),$ and$ GFP$
negative/mCherry.positive.clones.were! isolated.*Single*cells*were*seeded* in* flat!bottom%Corning%384!well$
plates'(Sigma'Aldrich)'in'30'µl'of'CD'CHO'medium,'supplemented'with'8'mM'L!Glutamine,+1.5%+HEPES+(Gibco)+
and$1x$Antibiotic!Antimycotic)(Gibco).)14)days)after)single!cell$sorting,$the$entire"volume"of"sub!confluent)
clones'was'transferred'to'180'µl'of'CD'CHO'medium'supplemented'with'1x'Antibiotic!Antimycotic)(Gibco))in)
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flat!bottom%96!well$plates$using$an$epMotion$5070$liquid$handling$workstation$(Eppendorf).$Subsequently,$
cells%were%expanded%in#suspension#and#verified#by#fluorescent#level#analysis,#junction#PCR#and#qRT!PCR.%!
Fluorescent+level+analysis.+The$generated$mCherry$expressing$colonies$were$analyzed$by$a$Celigo$Imaging$
Cell$Cytometer$(Nexcelom$Bioscience)$applying$the$mask$(blue$fluorescent&channel,&Hoechst!based&staining&
of#live#cells)#+#target1#(red#fluorescence#channel,#mCherry#signal).#Master#mix#(200#μL),#containing#CD#CHO#+#
8"mM"L!glutamine*+*5*μg/mL*Hoechst!33342$(Life$Technologies),$and$cell$suspension$(3$μL)$were$mixed$in$a$
96!well$ optical!bottom% microplate% (Greiner% Bio!One),& and& cells& were& incubated& for& 40& min& at& room&
temperature.) Colonies,) homogeneous) in)mCherry) expression,)were) selected) as) having)90%$ of$mCherry$
positive(cells.!!
PCR$amplification$of$target$regions.$For$junction#and#insert#PCR#genomic#DNA#was#extracted#from#the#cell#
pellets&using&QuickExtractTM!DNA$extraction$solution$(Epicentre,$Illumina)$according$to$the$manufacturer’s$
instructions.*1!2"µL"of"genomic"DNA"mixture"was"used"as"PCR"template."5’/3’"junction"PCR"and"insert"PCR"
was$carried$out$using$2x$Phusion$Master$Mix$(Thermo$Fisher$Scientific)in$touchdown$PCR$(98°C$for$30$s;$98°C$
for$10$s;$66!56°C%(insert%PCR)%or%68!58°C%(junction%PCR)%[!1°C/cycle]*for*30*s;*72°C*2*min;*30*x:*98°C*for*10*s;*
56°C%(insert%PCR)%or%58°C$(junction$PCR)$for$30$s;$72°C$for$2$min;$72°C$for$10$min).$PCR$primers$for$insert$PCR$
are$listed$in$Supplementary$Table$S4,!primers'for'junction'PCR'are'not'disclosed'due'to'proprietary'reasons.'
PCR$products$were$visualized$on$a$1%$agarose$gel$and$verified%by%sequencing.!
Quantitative)real)time)PCR)(qRT!PCR)%for%copy%number%analysis.%qRT!PCR$was$carried$out$on$genomic$DNA$
samples'to'determine'relative'copy'number'of'transgene.'GeneJET'Genomic'DNA'Purification'Kit'(Thermo'
Fisher' Scientific)' was' used' for' genomic' DNA' preparation' for' copy' number' analysis' according' to' the'
manufacturer’s, instructions., The, qRT!PCR$ was$ run$ in$ the$ QuantStudio$ 5$ Real!Time% PCR% System% (Agilent%
Technologies).-Amplification-was-executed-with-the-following-conditions:-95°C-for-10-min;-40X:$95°C$for$20$
s,#60°C#30#s.#Copy#number#of#mCherry##gene#was#determined#using#Brilliant#III#Ultra!Fast%SYBR®%Green%QPCR%
Master'Mix'(Agilent'Technologies)'A'delta!delta&threshold&cycle&(∆∆CT)"method"was"applied"to"calculate"copy"
number'of'mCherry'transgene"compared""to"COSMC!mCherry'clone'(calibrator)'7,"using"GAPDH"as"internal"
control'gene'for'normalization.'Primers'are'listed'in'Supplementary'Table'S6,'and''were'validated'by'melting'
curve& analysis& and" primer" efficiency" test." Each" experiment" included" no" template" controls" in" every" PCR"
running,'and'had'3'replicates'with'2'times'repetition.!
Quantitative)real)time)PCR)(qRT!PCR)%for%relative%RNA%expression%levels%analysis.%qRT!PCR$was$carried$out$
on#RNA#samples%to%measure%relative%RNA%expression%level%of%transgenes.%RNA%was%extracted%from%a%minimum%
of#1.0#×#106!cells%using%TRIzolTM!Reagent'(Thermo'Fisher'Scientific),'followed'by'DNase'treatment'to'remove'
contaminating)DNA)(TURBO)DNA!free™%DNase%Treatment%and!Removal(Reagents,(Thermo(Fisher(Scientific).(
cDNAs&were&synthesized&from&1&µg&of&total&RNAs&using&Maxima&First&Strand&cDNA&Synthesis&Kit&for&RT!qPCR%
(Thermo( Fisher( Scientific).( The( qRT!PCR$ was$ run$ in$ the$ QuantStudio$ 5$ Real!Time% PCR% System% (Agilent%
Technologies).( To( determine( relative(mCherry( expression( level( Brilliant( III( Ultra!Fast% SYBR®% Green% QPCR%
Master'Mix'(Agilent'Technologies)'was'used,'as'described'earlier.''Relative'recombinant'protein'expression'
levels%were%determined%using%TaqManTM!Gene$Expression"Master"Mix"and"custom!made%TaqManTM#probes'
for$ transgenes$ and$ pre!made% TaqMan% assay% for% GAPDH% (Cg04424038_gh)% (Thermo% Fisher% Scientific).%
Amplification,was,executed,with,the,following,conditions:,50°C,for,2,min,,95°C,for,10,min;,40X:,95°C,for,15,
s,#60°C#for$1$min.$Using$∆∆CT!method,(relative(expression(level(was(calculated(by(normalization(to(expression(
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level$of$GAPDH.$Primers$and$probes$are$listed$in$Supplementary$Table$S5,$and$$were$validated$by$melting$
curve& analysis& and& primer& efficiency& test.& Each& experiment( included( no( template( controls( in( every( PCR(
running,'and'had'3'replicates'with'2'times'repetition.!
RMCE% subclone% generation.%MCLs% at% concentration%1% x% 106! cells/mL(were( transfected(with(promoterless(
expression) vector) and) Cre!recombinase+ vector+ in+ 3:1+ ratio+ (w:w)+ in+ 6!well$ plates$ using$ FreeStyleTM!MAX$
transfection+reagent.+For+generation+of+non!producer(clones(only(Cre!recombinase+vector+was+transfected.+
Cells#were#passaged#two#times#after#transfection.#After#7#days#cell#pool#was#single#cell#sorted#as#described#
above,'using'the'respective'MCLs'as'gating'control'for'mCherry'negative'cells.'Clones'were'expanded'and'
verified'by'insert'PCR'and'sequencing'of'the'inserted'GOI'or'empty'region'(for'non!producer(clones).(!
Batch&cultivation.&Cells%were%seeded%at%3%x%105!cells/mL(in(60(mL(CD(CHO(medium,(supplemented(with(8(mM(
L!Glutamine*and*1*μL/mL*anti!clumping)agent)(Life)Technologies),) in)Corning)vent)cap)250)mL)shake"flask"
(Sigma!Aldrich).*Cells*were*incubated*in*a*humidified*incubator*at*37°C,*5%*CO2!at#120#rpm.#VCD#and#viability#
were$ monitored$ daily$ using$ the$ NucleoCounter$ NC!200# Cell# Counter# (ChemoMetec).# Cultures# were#
discontinued*after*seven*days*in*culture.!
Long!term%cultivation.!1"x"107!cells%were%thawed%in%30%mL%CD%CHO%medium,%supplemented%with%8%mM%L!
Glutamine* and* 1* μL/mL* anti!clumping) agent) (Life) Technologies),) in) Corning) vent) cap) 125!mL# shake# flask#
(Sigma!Aldrich).*They*were*passaged*to*3*x*105! !cells/mL(three#times#a#week#for#three#months.#Cells#were#
cryopreserved*at*every*passage:*1*x*107"cells%were%harvested,%centrifuged%at%250%g%and%resuspended%in%spent%
media&with&5%&DMSO.&&Cells&from&passage&2&(viability&>&95%),&passage&17&and&passage&35,&was&selected&as"our"
0"month,"1.5"months"and"3"months"samples"respectively.""The"selected"samples"were"run"in"batch"cultivation"
as#described#above.#!
RNA$extraction$for$RNA!seq.%5"x"106!cells%were%harvested%on%day%four%in%late!exponential*phase*during*batch*
cultivation.+Cells$were$centrifuged$at$1000g$for$4$min$and$the$supernatant$was$discarded.$The$pellet$was$
completely) re!suspended' in' 1' mL' Invitrogen' Trizol™' Reagent' and' stored' at' !80°C.& RNA& was& extracted&
following(the(Trizol(manufacturer(instructions.((RNA(concentrations!were$measured$with$Qubit$fluorometric$
analysis' (Life' Technologies)' and' the' quality' was' assessed' with' Agilent' 2100' bioanalyzer' and' Fragment'
analyzer(automated(CE(system((Advanced(Analytical(Technologies,(Inc.).(Only(samples(of(good(quality(was(
used%for%RNA!sequencing!(RIN%or%RIQ%>%9).!
Library'preparation'and'RNA!seq.%The$total$RNA$samples$were$processed$by$the$NGS$lab$at$Novo$Nordisk$
Foundation)Center)for)Biosustainability)(Technical)University)of)Denmark),)and)prepared)and)depleted)for)
ribosomal)RNA)with)Illumina’s)TruSeq'Stranded'mRNA'sample'preparation'kit,"according"to"manufacturer’s"
instructions.*The*samples*were*pooled*and*sequenced*on*Illumina’s*NextSeq*500*using*reagents*from*the*
NextSeq'500/550'Mid'Output'v2'kit'and'2'x'150'bp'paired!end$reads$for$the#dataset#1#with#about#10#million#
reads& per& sample,& and&NextSeq& 500/550&High&Output& v2& kit& and& 300& bp& paired!end$ reads$ for$ remaining$
subclone)datasets)analyzed)(datasets)2,)3)and)4))with)about)20!million&reads&per&sample& (Supplementary&
Table&S6).&!
RNA!Seq$Analysis$and$Differential$Gene$Expression$Analysis.$!The$transcript$levels$in$all$the$experimental$
datasets,'were'quantified' following' the'pipeline'depicted' in'Supplementary'Fig'S11.'Raw'sequence'reads'
from%multiple% lanes%were% first%merged% into%one! for$each$biological$ replicate$of$each$sample.$The$merged$
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sequence'files'were'subjected'to'Trim'Galore'v0.4.4'(Babraham'Bioinformatics)'to'remove'illumina'adaptor'
sequences,( and( FastQC( (Babraham( Bioinformatics)( to( examine( data( quality.( Gene!level$ counts$ were#
produced(by(estimating(the(transcript(abundances(with(Salmon(v0.8.2(37!in#quasi!mapping!based&mode&(with&
default(parameters)(using(the(transcriptome(from(the(Cricetulus(griseus((Chinese(hamster)(representative)
genome&assembly&CriGri_1.0&(GCA_000223135.1)&as&reference.&The&transgenes&(ETC,&EPO,&GDF5,&C1INH,&and&
NeoR)&coding&sequences&used&in&this&study&were&all&added&to&the&transcriptome&reference,&and&included&in&
the$ DEG$ analysis.$ The$ salmon$ output$ was# imported# with# tximport# 38! into% R% 40! and$ analysed.$ $ Principal$
component(analysis(was(performed(by(applying(the(prcomp(R(function(to(the(complete(dataset((excluding(
transgenes))and)visualized)in)conjunction&with&ggplot241."Differential"gene"expression"was"determined"with"
limma!voom$ 39!using&ANOVA!style&F!test$on$ the$comparisons$of$ interest$ (Supplementary$Fig.$S11).$Genes$
were$ considered$differentially# expressed#when# the# adjusted#p!value&of& the& F!test!was$<$ 0.05.$ Functional$
enrichment)analysis)of)canonical)pathways)and)network)analysis)was)carried)out)using)QIAGEN’s)Ingenuity)
pathway'analysis'(IPA)'tool.'All'statistically'significant'DEGs'with'a'human"homolog"were"ranked"based"on"
their&log&fold&change,&the&1000&most&down!regulated)and)the)1000)most)up!regulated)genes)were)selected,)
which%provided%the%same%information%as%using%the%whole%list%of%DEGs%while%reducing%the%noise.%These%genes%
and$their$corresponding(log(fold(change((between(EPO(and(non!producer(subclones)(were(integrated(into(a(
core%analysis%using%the%IPA%tool.%!
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5.2 Applicability and future perspectives 
In the quest to better understand existing biological processes and engineer new biological 
pathways, it is crucial to have an optimal system where we can study the effect of expressing 
transgenes. The system can be used for studying the variation in amounts of product being 
produced and the reasons behind the phenomenon. This platform offers an unprecedented solution 
for testing and generating new strategies to specifically tailor the expression and secretory needs 
of recombinant therapeutic proteins. The technique can be further adapted and utilized to 
introduce several genes in different locations in a controllable and comparable manner, beginning 
the journey toward repairing or inserting entire pathways. The ability to study transgenes in 
combination with each other will allow us to better evaluate possible engineering strategies e.g. 
the optimal ratios for expression of different transgenes. Furthermore, the utilization of RMCE 
landing pads, allows these cell lines to be readily re-used in an endless amount of studies. The 
application of the platform can be extended beyond comparative analysis of transgenes; it would 
e.g. be optimal for the difficult but indispensable task of testing and developing existing and new 
genetic elements for optimal, coherent and regulated gene expression.  
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Chapter 6 
 
Concluding remarks 
 
 
The aim of this PhD thesis has been to develop new genome editing tools to advance the CHO 
cell engineering toolbox and to demonstrate their relevance to the field of recombinant production 
of therapeutic proteins by direct applications.  The primary contribution of the thesis is thus both 
the techniques presented and their demonstrated applicability.  
      To continue in the paths that started with this thesis, several projects in our laboratory have 
been initiated that build on using the tools and results presented here. CRISPR has enabled us to 
remove, insert and study a plethora of different genes. It has proved to be extremely efficient, and 
our biggest bottleneck is now the characterization of the clones we generate. A major obstacle 
currently facing the CHO cell engineering community, is how to ensure that changes observed in 
phenotypes are indeed due to our engineering efforts and not simply due to clonal variation. 
Chapter 5 clearly indicates that clonal variation needs to be taken into account when studying 
gene effects and phenotypic changes.  
    With the more precise and controllable tools presented in this thesis we have advanced the 
engineering toolbox for future CHO cell line development for the production of therapeutic 
proteins. The tools will help us gain an increasing understanding of biological processes to guide 
our engineering efforts towards our end goal of generating superior CHO cell lines for optimal 
production of a wide range of therapeutic proteins. 
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Supplementary	Figure	S3:	Verification	of	the	indels	generated	in	the	multiplexed	and	FACS	enriched	clones.	Alignment	of	
Sanger	sequences	of	amplicons	covering	the	FUT8	sgRNA	target	site	seperated	on	agarose	gels	using	the	CHO‐S,	CHO‐S	
conditioned	(5.2.20),	BAK(‐13)	BAX(‐2)	double	knockout	cell	line	(5.2.12),	FUT8(‐2,‐23)	BAK(‐19,‐14)	BAX(+88)	triple	
knockout	cell	line	(6.2.19)	and	FUT8(+59)	BAK(+1)	BAX(+1)	triple	knockout	cell	line	(6.1.17)	as	templates.	
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Supplementary	Figure	S4:	Verification	of	the	indels	generated	in	the	multiplexed	and	FACS	enriched	clones.	Alignment	of	
Sanger	sequences	of	amplicons	covering	the	BAK	sgRNA	target	site	seperated	on	agarose	gels	using	the	CHO‐S,	CHO‐S	
conditioned	(5.2.20),	BAK(‐13)	BAX(‐2)	double	knockout	cell	line	(5.2.12),	FUT8(‐2,‐23)	BAK(‐19,‐14)	BAX(+88)	triple	
knockout	cell	line	(6.2.19)	and	FUT8(+59)	BAK(+1)	BAX(+1)	triple	knockout	cell	line	(6.1.17)	as	templates.	
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Supplementary	Figure	S5:	Verification	of	the	indels	generated	in	the	multiplexed	and	FACS	enriched	clones.	Alignment	of	
Sanger	sequences	of	amplicons	covering	the	BAX	sgRNA	target	site	seperated	on	agarose	gels	using	the	CHO‐S,	CHO‐S	
conditioned	(5.2.20),	BAK(‐13)	BAX(‐2)	double	knockout	cell	line	(5.2.12),	FUT8(‐2,‐23)	BAK(‐19,‐14)	BAX(+88)	triple	
knockout	cell	line	(6.2.19)	and	FUT8(+59)	BAK(+1)	BAX(+1)	triple	knockout	cell	line	(6.1.17)	as	templates.	
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Supplementary	Figure	S6:	Growth	and	viability	of	the	multiplexed	and	FACS	enriched	clones.	The	graph	shows	the	viable	
cell	concentration	(left	Y‐axis)	and	viability	(right	Y‐axis)	of	CHO‐S,	CHO‐S	conditioned,	BAK(‐13)	BAX(‐2)	double	knockout	
cell	line,	FUT8(‐2,‐23)	BAK(‐19,‐14)	BAX(+88)	triple	knockout	cell	line	and	FUT8(+59)	BAK(+1)	BAX(+1)	triple	knockout	cell	
line	for	three	days	upon	transient	transfection	with	antibody	(Rituximab)	expression	vector.				
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Supplementary	Figure	S7:	Antibody	production	with	the	multiplexed	and	FACS	enriched	clones.	The	graph	shows	the	
amount	of	antibody	(Rituximab)	obtained	upon	transient	transfection	of	CHO‐S,	CHO‐S	conditioned,	BAK(‐13)	BAX(‐2)	double	
knockout	cell	line,	FUT8(‐2,‐23)	BAK(‐19,‐14)	BAX	(+88)	triple	knockout	cell	line	and	FUT8(+59)	BAK(+1)	BAX(+1)	triple	
knockout	cell	line	with	antibody	(Rituximab)	expression	vector	and	growth	for	three	days.	
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Supplementary	Table	S1:	Primer	list	for	GFP_2A_Cas9	cloning.	The	bases	in	red	mark	the	USER	overhangs	applied.	
Primer	number	 Primer	name Sequence	(5’	– 3’)
PR0239	 BB_Cas9_2A‐link_fw	 AGAAGCAUGGACAAGAAATACTCCATCG
PR0240	 BB_Cas9_2A‐link_rv			 ATGCATGGUGGCGGCGCTAGCCAGCTTC
PR0241	 eGFP_2A_2A‐link_fw	 ACCATGCAUGTGAGCAAGGGCGAGGAGCTG
PR0242	 eGFP_2A_2A‐link_rv	 ATGCTTCUCGATCGTGGGCCAGGATTCTCCTCGACG	
	
	
Supplementary	Table	S2:	FUT8,	BAK	and	BAX	sgRNA	target	sequences.	The	bases	in	red	mark	the	PAM	site.	
Target	gene	 Target	sequence	(5’	– 3’)
FUT8	 GTCAGACGCACTGACAAAGTGGG
BAK	 GGAAGCCGGTCAAACCACGTTGG
BAX	 GCTGATGGCAACTTCAACTGGGG
	
	
Supplementary	Table	S3:	Oligos	for	FUT8,	BAK	and	BAX	sgRNA	expression	vector	cloning	
Oligo	number	 Oligo	name Oligo	sequence	(5’	– 3’)
7823	 Oligo	sgRNA3_F_fw/	
sgRNA_FUT8_681494_fwd	
GGAAAGGACGAAACACCGTCAGACGCACTGACAAAGTGTTTTAGAGCTAGAAAT
7919	 Oligo	sgRNA3_F_rv/	
sgRNA_FUT8_681494_rev	
CTAAAACACTTTGTCAGTGCGTCTGACGGTGTTTCGTCCTTTCCACAAGATAT
7747	 sgRNA_BAK1_1544257_fwd	 GGAAAGGACGAAACACCGGAAGCCGGTCAAACCACGTGTTTTAGAGCTAGAAAT	
7843	 sgRNA_BAK1_1544257_rev	 CTAAAACACGTGGTTTGACCGGCTTCCGGTGTTTCGTCCTTTCCACAAGATAT	
7760	 sgRNA_BAX_1345650_fwd	 GGAAAGGACGAAACACCGCTGATGGCAACTTCAACTGGTTTTAGAGCTAGAAAT	
7856	 sgRNA_BAX_1345650_rev	 CTAAAACCAGTTGAAGTTGCCATCAGCGGTGTTTCGTCCTTTCCACAAGATAT	
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Supplementary	Table	S4:	Primer	list	for	deep	sequencing	(MiSeq).	The	primers	contain	overhang	sequences	compatible	
with	Illumina	Nextera	XT	indexing	(forward	primer	overhang:	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG,	reverse	primer	
overhang:	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG).	
Primer	number	 Primer	name	 Primer	sequence	(5’	–	3’)	
PR0222	 FUT8	gRNA3_F_Nex	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGCCCCCATGACTAGGGATA		
PR0223	 FUT8	gRNA3_R_Nex	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTGCGTTCGAGAAGCTGAAA	
PR0461	 Miseq_BAK1_1544257_fw	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAAGGTGGGCTCTCCGTGAT	
PR0462	 Miseq_BAK1_1544257_rv	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCGATGCAATGGTGCAGTATGAT	
PR0463	 Miseq_BAX_1345650_fw	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGTGGATACTAACTCCCCACG	
PR0464	 Miseq_BAX_1345650_rv	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCCCTGAACCTCACTACCCC	
A1	 MiSeq_Fut8_off1_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCTGTCTGCCATCTCAACTGT	
B1	 MiSeq_Fut8_off2_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTCTTGTCCCATGCTCCCTC	
C1	 MiSeq_Fut8_off3_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGTCTCTATGTGCACGGGAG	
D1	 MiSeq_Fut8_off4_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCTCTGTGCTCTCATGCTCC	
E1	 MiSeq_Fut8_off5_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCATTGGGTGCATAGCTGGA	
F1	 MiSeq_Fut8_off6_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGGGGTCTTGTGGCTCTTTA	
G1	 MiSeq_Fut8_off7_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATATCTGTGTGACCCCACGG	
H1	 MiSeq_Fut8_off8_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTACCACCCAAGGTCCCCAA	
A2	 MiSeq_Fut8_off9_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGCTGCGGAATCGATAGCAA	
B2	 MiSeq_Fut8_off10_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCACACTGCAGCTTACAACAG	
C2	 MiSeq_Fut8_off11_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTGGGAAGTGGACAGCAGAC	
D2	 MiSeq_Fut8_off12_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACTGACCAGCGAGACCCTAT	
E2	 MiSeq_Fut8_off13_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGAGCAGGGAGAGCTACCAA	
F2	 MiSeq_Fut8_off14_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCCTCCTTCCTTAGGCCTCT	
G2	 MiSeq_Fut8_off15_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCCATTCCTGCAGTGATGGT	
A1	 MiSeq_Fut8_off1_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGGCAAGATGAAGGTGGACG	
B1	 MiSeq_Fut8_off2_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAAGAGGCTGTCACTGCAGT	
C1	 MiSeq_Fut8_off3_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACCAGGCTCAGAGCTAGGAT	
D1	 MiSeq_Fut8_off4_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCTGTTCCAGGCTCTGCTTA	
E1	 MiSeq_Fut8_off5_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCATGCTAGCGGCTTGTTTT	
F1	 MiSeq_Fut8_off6_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTGGTCATCACCACTGCTCA	
G1	 MiSeq_Fut8_off7_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTGGCCAGACCCAAAGGATC	
H1	 MiSeq_Fut8_off8_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAACCTCTTCCTGGGGGCTAT	
A2	 MiSeq_Fut8_off9_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGATCTACCCAAGCACCACCT	
B2	 MiSeq_Fut8_off10_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCATCTCTCCAGCCCCTTCTT	
C2	 MiSeq_Fut8_off11_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACCCTCCTCTCTCCCAAAGA	
D2	 MiSeq_Fut8_off12_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGAGAGCAGGCTGAGTGAAG	
E2	 MiSeq_Fut8_off13_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCAGTGCCAGTTTCAATGGC	
F2	 MiSeq_Fut8_off14_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGGATTGAGGGGGTCACTGA	
G2	 MiSeq_Fut8_off15_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACACCCTGGGTCTGAGAAAC	
A4	 MiSeq_Bak1_off1_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGCAGGGTTCATCTGAGTGC	
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B4	 MiSeq_Bak1_off2_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTAGCTTGCTGCCTTTGAGCA	
C4	 MiSeq_Bak1_off3_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCAGGCCGAGAAGCACATAA	
D4	 MiSeq_Bak1_off4_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGGAGGGCTTCTGGATATGGT	
E4	 MiSeq_Bak1_off5_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGCCAAACTCCAGGAGTCC	
F4	 MiSeq_Bak1_off6_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCACAGTTAACAGGTTGGTTCC	
G4	 MiSeq_Bak1_off7_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCGTGGGGATATCTTGCCTC	
H4	 MiSeq_Bak1_off8_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCAAACCCAATAAGTGAGACCT	
A5	 MiSeq_Bak1_off9_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCCTGCTCACTAACACCCAT	
B5	 MiSeq_Bak1_off10_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAAGCCACATAATTGCCCCCT	
C5	 MiSeq_Bak1_off11_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCATTACCCAGTGCTCCCCG	
D5	 MiSeq_Bak1_off12_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCCTTTCTTGACATGGCCAA	
E5	 MiSeq_Bak1_off13_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCACAGTGAATTTGGCCACGG	
F5	 MiSeq_Bak1_off14_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCAGGTTCGGCACTTAGGTT	
G5	 MiSeq_Bak1_off15_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCCTTTTCTTCTGCTGTCACA	
A4	 MiSeq_Bak1_off1_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGCCTGCCTTACTGACTTTGA	
B4	 MiSeq_Bak1_off2_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTACCAACGCCCCACAGTTA	
C4	 MiSeq_Bak1_off3_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACTCCTGCTACTCCCTCACC	
D4	 MiSeq_Bak1_off4_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCACGACCTGGACCTCACTA	
E4	 MiSeq_Bak1_off5_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTAGACTTCCCAAGCCCTCGA	
F4	 MiSeq_Bak1_off6_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTGGGTTTGAGGCTACCCTG	
G4	 MiSeq_Bak1_off7_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCAGATATGTCACAACCCCGT	
H4	 MiSeq_Bak1_off8_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAGGCCCCATAGACTACCCA	
A5	 MiSeq_Bak1_off9_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCTGATGGAAGCAAAGCAGAC	
B5	 MiSeq_Bak1_off10_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACCCCACAGACTGACCAAG	
C5	 MiSeq_Bak1_off11_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTAGCGCCCTCTTGGACTTTG	
D5	 MiSeq_Bak1_off12_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGCTCCTCCTGCACGTTTTT	
E5	 MiSeq_Bak1_off13_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCCCCTTCATCCCAGCATAG	
F5	 MiSeq_Bak1_off14_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCATAGATGGCCGCTTGC	
G5	 MiSeq_Bak1_off15_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGGCCAAGCACTGTGAGAAT	
A7	 MiSeq_Bax_off1_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAGTGACACCATCCCTGTCA	
B7	 MiSeq_Bax_off2_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGCCACATTGACTCTCAGGC	
C7	 MiSeq_Bax_off3_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCAATGGGGTTGGTCTTCCG	
D7	 MiSeq_Bax_off4_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTCCTGGCTGCTCATTCCAT	
E7	 MiSeq_Bax_off5_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGAGCTTCAGAGGTTGGCTG	
F7	 MiSeq_Bax_off6_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCGTGACCCCCAAATGAGAA	
G7	 MiSeq_Bax_off7_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCCTTTAAATGGCTGGTTCCA	
H7	 MiSeq_Bax_off8_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTAACAGGCAGGTCCACCTTC	
A8	 MiSeq_Bax_off9_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCCTGAGATGCCCAGTATCC	
B8	 MiSeq_Bax_off10_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGTGTACAGTGGTGTTGCCA	
C8	 MiSeq_Bax_off11_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTGCTGCCACCTAAGAGGAC	
D8	 MiSeq_Bax_off12_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGGCAGAAGATCCCCTAGGT	
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E8	 MiSeq_Bax_off13_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGTGTCCATGGTAGTTTCTTTGTG	
F8	 MiSeq_Bax_off14_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGCAAACCAACACAGAATGAACA	
G8	 MiSeq_Bax_off15_fwd	 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACAAGAAAGAAGGAAAGGAAGAAAGG	
A7	 MiSeq_Bax_off1_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGTGTGGCCTGCTTTCTAGT	
B7	 MiSeq_Bax_off2_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCTGTCTAAGGGTGGCACTG	
C7	 MiSeq_Bax_off3_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAGGTGGGAGGGACACAAAC	
D7	 MiSeq_Bax_off4_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTCCCCAGTGCCCACATTAA	
E7	 MiSeq_Bax_off5_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGCTTGATTTCCACGGCTCA	
F7	 MiSeq_Bax_off6_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCACCCCAAACCCCACATTCA	
G7	 MiSeq_Bax_off7_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTCTGTGTCGTGGTAATCCA	
H7	 MiSeq_Bax_off8_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTTAGTGTGCCACCTACCCC	
A8	 MiSeq_Bax_off9_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCATCAACCACGAGCTGTTG	
B8	 MiSeq_Bax_off10_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCCCTCTTCACTCCAGCACA	
C8	 MiSeq_Bax_off11_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGAGTACACACGTGCACACT	
D8	 MiSeq_Bax_off12_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTGAGGGCCCAAGAATGCAT	
E8	 MiSeq_Bax_off13_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGATGACTGCTACCTGGCGTT	
F8	 MiSeq_Bax_off14_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCCCCACTTGGTTTTGGTCT	
G8	 MiSeq_Bax_off15_rev	 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGACCCAGAAGCCCAAACAG	
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Supplementary	Table	S5:	Off‐target	sites	identification.	The	top	15	sites	for	each	sgRNA	targeting	FUT8,	BAK	and	BAX	
respectively	are	shown	and	have	been	selected	based	on	the	Ham	score.	HAM	score	refers	to	Hamming	distance	indicating	the	
number	of	positions	in	a	sequence	that	differs	from	a	reference	sequence	[1].	In	this	case,	it	is	the	number	of	positions	in	
which	the	off‐target	sequence	differs	from	the	on‐target	sequence	in	either	the	13	bp	closest	to	the	PAM	or	in	total.	The	bases	
in	red	mark	the	sequence	difference	from	the	on‐target	site.	
	
	 Ham	score	in	first	13	bp	 Ham	score	in	total Contig Strand Position Sequence	
Fut8_on target	 0	 0	 NW_003613860 + 710987 GTCAGACGCACTGACAAAGT
Fut8_off1	 0	 4	 NW_003613648 ‐ 1396948 GTACTATGCACTGACAAAGT
Fut8_off2	 0	 4	 NW_003614846 ‐ 151698 GACGTAGGCACTGACAAAGT
Fut8_off3	 0	 6	 NW_003613896 + 39301 TAATGTGGCACTGACAAAGT
Fut8_off4	 1	 3	 NW_003613649 ‐ 2963243 GTCAAAAGCACTGACAAGGT
Fut8_off5	 1	 3	 NW_003613951 ‐ 740130 GCCCGACGCACTGAGAAAGT
Fut8_off6	 1	 4	 NW_003614027 + 545477 GACAGCATCACTGACAAAGT
Fut8_off7	 1	 5	 NW_003613583 ‐ 4130466 AGAAGAGGCACTGACAAACT
Fut8_off8	 1	 5	 NW_003613591 + 1717331 CCCGGAGGCACTTACAAAGT
Fut8_off9	 1	 5	 NW_003613596 + 4119735 AATAAACGCACTTACAAAGT
Fut8_off10	 1	 5	 NW_003613689 + 2115570 GGCACGGGCACTTACAAAGT
Fut8_off11	 1	 5	 NW_003613750 ‐ 1719535 TGAAGAAGCACTGAGAAAGT
Fut8_off12	 1	 5	 NW_003613777 + 239782 ACCGGAAGCACCGACAAAGT
Fut8_off13	 1	 5	 NW_003613780 + 483228 GGTAGGTGCACTGCCAAAGT
Fut8_off14	 1	 5	 NW_003613842 ‐ 344431 GCAACAGGCAATGACAAAGT
Fut8_off15	 1	 5	 NW_003613844 ‐ 1138412 TTCTATCTCACTGACAAAGT
	 	 	 	
Bak1_on target	 0	 0	 NW_003614972 ‐ 227662 GGAAGCCGGTCAAACCACGT
Bak1_off1	 1	 4	 NW_003613599 + 195202 GTAATCAGGTCAAACCATGT
Bak1_off2	 1	 4	 NW_003615993 ‐ 85713 GGAAAGGGGTCAAACCAGGT
Bak1_off3	 1	 5	 NW_003613681 ‐ 1683603 GTGACCAGGTCAAACCACTT
Bak1_off4	 1	 5	 NW_003614007 + 38086 GAAAAGAGGTCAAACCAGGT
Bak1_off5	 1	 5	 NW_003614165 + 227394 GCAAATAGGTCAAACCATGT
Bak1_off6	 1	 5	 NW_003614340 + 338518 AATAGCAGGTCAAACCAAGT
Bak1_off7	 1	 5	 NW_003615215 + 28553 TAAATCAGGTCAAACCACAT
Bak1_off8	 1	 5	 NW_003615261 + 144994 GCAAAGAGGTCAAACCATGT
Bak1_off9	 1	 5	 NW_003615939 ‐ 147940 GCAAAGTGGTCAAACCAGGT
BAK_off10	 1	 5	 NW_003616605 + 61822 AGAAAAGGGTCAAACCAAGT
Bak1_off11	 1	 6	 NW_003613725 + 1131426 CCAGCCAGGTCAAACCAGGT
Bak1_off12	 1	 6	 NW_003613753 ‐ 1078815 TGTGGTTGGTCAAACAACGT
Bak1_off13	 1	 6	 NW_003613831 + 460720 CAGGGCTGGTCAAGCCACGT
Bak1_off14	 1	 6	 NW_003613831 + 722520 GGCCAGAGGACAAACCACGT
Bak1_off15	 1	 6	 NW_003613839 + 1346280 CTGAGTTGGTCAAACCACTT
	 	 	 	 	
Bax_on target	 0	 0	 NW_003614570 + 281815	 GCTGATGGCAACTTCAACTG
Bax_off1	 0	 5	 NW_003613691 + 514917	 GGAAGAGGCAACTTCAACTG
Bax_off2	 0	 5	 NW_003617041 + 69462	 GAGAGTAGCAACTTCAACTG
Bax_off3	 1	 3	 NW_003613598 + 671039	 TCTGATTGCAACTTCAACTC
Bax_off4	 1	 3	 NW_003614075 + 114499	 GCTAAGGGCAACTTCAAGTG
Bax_off5	 1	 4	 NW_003613602 + 412112	 GCTAGAGGGAACTTCAACTG
Bax_off6	 1	 4	 NW_003613618 ‐ 1971061	 TTTTATGTCAACTTCAACTG
Bax_off7	 1	 4	 NW_003613646 + 321775	 TCTTAGGGCAACTTCCACTG
Bax_off8	 1	 4	 NW_003613686 ‐ 1252493	 GAAGAGGGGAACTTCAACTG
Bax_off9	 1	 4	 NW_003613866 ‐ 672417	 GATGTAGGCAACATCAACTG
Bax_off10	 1	 4	 NW_003614684 ‐ 92790	 AGTGATTGCAACTTGAACTG
Bax_off11	 1	 5	 NW_003613585 + 4201621	 GTGAGTGGCAAGTTCAACTG
Bax_off12	 1	 5	 NW_003613608 + 1389389	 TGTGAAAGCACCTTCAACTG
Bax_off13	 1	 5	 NW_003613649 ‐ 3145890	 GGGGAAAGCAACTTCATCTG
Bax_off14	 1	 5	 NW_003613754 + 1713055	 TGCCATGGCAACTCCAACTG
Bax_off15	 1	 5	 NW_003613775 ‐ 36278	 AAAGAAGGCAACCTCAACTG
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Supplementary	Table	S6:	Primers	for	Sanger	sequencing	of	genomic	regions	flanking	the	sgRNA	target	sites.	
Primer	number	 Primer	name	 Sequence	(5’	– 3’)
PR0750	 BAK1_topo_fwd	 ACTTTCTGACCTGGACTGGC
PR0751	 BAK1_topo_rev	 GCCCAACAGAACCACACCAA
PR0752	 BAX_topo_fwd	 CTGACTCCCCAGGACCTTGA
PR0753	 BAX_topo_rev	 CTTGTTTTGTTCGGGCAGAGG
PR0754	 FUT8_topo_fwd	 AATCTGTTGATTCCAGGTTCC
PR0755	 FUT8_topo_rev	 TGCGTTCGAGAAGCTGAAAA
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Supplementary	Table	S7:	Deep	sequencing	(MiSeq)	of	the	most	potential	off‐target	sites	predicted	for	each	of	the	sgRNAs	
targeting	FUT8,	BAK	and	BAX	respectively.	The	analysis	is	performed	on	the	GFP_2A_Cas9	only	and	the	two	multiplexed	
samples	with	high	sgRNA	to	GFP_2A_Cas9	ratio	before	and	after	FACS	enrichment,	which	contain	the	cell	population	with	
most	generated	indels	(biological	replicate	number	2).	Samples	marked	with	an	asterisk	are	high	in	all	samples.	N/A	indicates	
that	no	PCR	products	are	obtained	from	samples.	
	
	
GFP_2A_Cas9  GFP_2A_Cas9  GFP_2A_Cas9
no sgRNA FUT8 , BAK and BAX FUT8 , BAK and BAX
Before enrichment After enrichment
FUT8_on target 0.4% 11.5% 66.3%
FUT8_off1 0.2% 0.2% 0.2%
FUT8_off2 0.1% 0.1% 0.1%
FUT8_off3 0.2% 0.2% 0.2%
FUT8_off4 0.2% 0.2% 0.2%
FUT8_off5 0.2% 0.2% 0.2%
FUT8_off6 0.1% 0.1% 0.0%
FUT8_off7 0.1% 0.2% 0.1%
FUT8_off8 0.1% 0.1% 0.1%
FUT8_off9 0.2% 0.1% 0.1%
FUT8_off10 0.2% 0.3% N/A
FUT8_off11 0.1% 0.1% 0.1%
FUT8_off12 0.2% 0.2% 0.2%
FUT8_off13 3.7% 1.6% 0.7%
FUT8_off14 0.2% 0.2% 0.2%
FUT8_off15 0.1% 0.1% 0.1%
BAK_on target 0.1% 11.0% 66.3%
BAK_off1 0.2% 0.2% 0.1%
BAK_off2 0.1% 0.2% 0.2%
BAK_off3 0.1% 0.1% 0.1%
BAK_off4 0.3% 0.3% 0.2%
BAK_off5 0.1% 0.2% 0.2%
BAK_off6 0.4% 0.4% N/A
BAK_off7 0.1% 0.2% 0.2%
BAK_off8 0.5% 0.5% 0.4%
BAK_off9 1.8% 0.6% 0.4%
BAK_off10 N/A N/A N/A
BAK_off11 0.1% 0.1% 0.1%
BAK_off12 0.2% 0.2% 0.2%
BAK_off13 0.2% 0.2% 0.2%
BAK_off14 0.1% 0.1% 0.1%
BAK_off15 0.2% 0.2% 0.2%
BAX_on target 0.2% 17.9% 75.8%
BAX_off1 0.1% 0.1% 0.1%
BAX_off2 0.2% 0.2% 0.2%
BAX_off3 N/A N/A N/A
BAX_off4 0.1% 0.1% 0.6%
BAX_off5 48.4%* 48.4%* 46.3%*
BAX_off6 0.2% 0.2% 0.2%
BAX_off7 0.8% 0.8% 0.7%
BAX_off8 0.2% 0.2% 0.2%
BAX_off9 0.2% 0.2% 0.1%
BAX_off10 0.1% 0.1% 0.1%
BAX_off11 0.1% 0.1% 0.1%
BAX_off12 0.1% 0.1% 0.1%
BAX_off13 0.1% 0.1% 0.1%
BAX_off14 0.1% 0.1% 0.1%
BAX_off15 0.7% 0.6% 0.7%
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Supplementary	Table	S8:	Deep	sequencing	results	of	clones	(run	#1).	Each	clone	has	its	own	index	(column	1).	Column	3,	4	
and	5	show	the	number	of	reads	obtained	in	total,	of	wild‐type	sequences	and	sequences	with	indels	respectively.	Clones	with	
unclear	data	are	indicated	as	fail	in	column	7	and	are	also	marked	as	dark	gray	in	column	12.	Column	9,	10	and	11	show	the	
type	of	indels	identified	in	the	clones	(i.e.	basepair	difference	from	wild‐type),	where	peak	n	=	0	means	wild‐type	alleles.	The	
clones	marked	with	light	gray	indicate	absences	of	genes	with	indels	(wild‐type).	The	clones	marked	with	yellow	indicate	
presence	of	one	gene	with	indels	(potential	single	knockout	cell	line).	The	clones	marked	with	orange	indicate	presence	of	
two	genes	with	indels	(potential	double	knockout	cell	line).	The	clones	marked	with	red	indicate	presence	of	three	genes	with	
indels	(potential	triple	knockout	cell	line).	Clones	with	mixed	alleles	(presence	of	both	WT	allele	and	allele	with	indel)	are	
also	marked	as	dark	gray	and	are	also	not	included	in	Figure	2A.		The	clones	marked	with	an	asterisk	are	selected	for	further	
characterization	that	is	referred	to	in	the	manuscript.	
 
Index Product Counts WT Count WT Indels Knockout Peaks Peak 1 Peak 2 Peak 3 CLONE
1 FUT8_681494 18682 18660 99,88% 0,12% interesting 1 0
1 BAK1_1544257 79188 79009 99,77% 0,23% 1 0
1 BAX_1345650 80493 80224 99,67% 0,33% 0 1 0
2 FUT8_681494 9979 9965 99,86% 0,14% interesting 1 0
2 BAK1_1544257 45222 45121 99,78% 0,22% 1 0
2 BAX_1345650 45355 45231 99,73% 0,27% 0 1 0
3 FUT8_681494 18085 18065 99,89% 0,11% interesting 1 0
3 BAK1_1544257 77702 77540 99,79% 0,21% 1 0
3 BAX_1345650 79928 79679 99,69% 0,31% 0 1 0
4 FUT8_681494 7764 7755 99,88% 0,12% Fail 1 0
4 BAK1_1544257 77527 77404 99,84% 0,16% 1 0
4 BAX_1345650 89856 80294 89,36% 10,64% 0 2 0 -9
5 FUT8_681494 14595 14585 99,93% 0,07% interesting 1 0
5 BAK1_1544257 70637 70484 99,78% 0,22% 1 0
5 BAX_1345650 69541 69361 99,74% 0,26% 0 1 0
6 FUT8_681494 38477 38443 99,91% 0,09% Fail 1 0
6 BAK1_1544257 366 305 83,33% 16,67% 1 0
6 BAX_1345650 159566 4039 2,53% 97,47% 1 1 -16
7 FUT8_681494 15332 15314 99,88% 0,12% interesting 1 0
7 BAK1_1544257 75063 74923 99,81% 0,19% 1 0
7 BAX_1345650 92755 92506 99,73% 0,27% 0 1 0
8 FUT8_681494 60 57 95,00% 5,00% Fail 1 0
8 BAK1_1544257 54654 30001 54,89% 45,11% 1/2 allelle hit/2 clones 2 0 -13
8 BAX_1345650 89131 88859 99,69% 0,31% 0 1 0
9 FUT8_681494 6381 6375 99,91% 0,09% interesting 1 0
9 BAK1_1544257 32314 32266 99,85% 0,15% 1 0
9 BAX_1345650 26243 26152 99,65% 0,35% 0 1 0
10 FUT8_681494 11938 51 0,43% 99,57% interesting 1 116
10 BAK1_1544257 23030 411 1,78% 98,22% 1 -3
10 BAX_1345650 49234 3678 7,47% 92,53% 3 1 77
11 FUT8_681494 17004 16986 99,89% 0,11% interesting 1 0
11 BAK1_1544257 84651 84467 99,78% 0,22% 1 0
11 BAX_1345650 84467 84206 99,69% 0,31% 0 1 0
12 FUT8_681494 11851 11832 99,84% 0,16% interesting 1 0
12 BAK1_1544257 94059 93850 99,78% 0,22% 1 0
12 BAX_1345650 98495 98205 99,71% 0,29% 0 1 0
13 FUT8_681494 22836 22812 99,89% 0,11% interesting 1 0
13 BAK1_1544257 103364 102816 99,47% 0,53% 1 0
13 BAX_1345650 61267 60901 99,40% 0,60% 0 1 0
14 FUT8_681494 11380 14 0,12% 99,88% interesting 2 35 -4
14 BAK1_1544257 47424 159 0,34% 99,66% 2 62 2
14 BAX_1345650 11550 11409 98,78% 1,22% 2 1 0
15 FUT8_681494 5938 2639 44,44% 55,56% 1/2 allelle hit/2 clones 2 -2 0
15 BAK1_1544257 47295 267 0,56% 99,44% Fail 1 -2
15 BAX_1345650 116374 108415 93,16% 6,84% 1 1 0
16 FUT8_681494 10160 5273 51,90% 48,10% 1/2 allelle hit/2 clones 2 0 -11
16 BAK1_1544257 52469 637 1,21% 98,79% Fail 2 -3 -81
16 BAX_1345650 69377 69049 99,53% 0,47% 1 1 0
17 FUT8_681494 20225 20190 99,83% 0,17% interesting 1 0
17 BAK1_1544257 77800 220 0,28% 99,72% 1 -14
17 BAX_1345650 51430 51142 99,44% 0,56% 1 1 0
18 FUT8_681494 8515 34 0,40% 99,60% interesting 1 -54
18 BAK1_1544257 93177 166 0,18% 99,82% 2 -7 -4
18 BAX_1345650 88923 2903 3,26% 96,74% 3 1 -3
19 FUT8_681494 1883 50 2,66% 97,34% interesting 1 -2
19 BAK1_1544257 45823 2997 6,54% 93,46% 1 1
19 BAX_1345650 72622 67760 93,31% 6,69% 2 1 0
20 FUT8_681494 60 42 70,00% 30,00% Fail 1 0
20 BAK1_1544257 550 308 56,00% 44,00% 1 0
20 BAX_1345650 107083 100796 94,13% 5,87% 0 1 0
21 FUT8_681494 6458 6448 99,85% 0,15% interesting 1 0
21 BAK1_1544257 29700 29522 99,40% 0,60% 1 0
21 BAX_1345650 19043 813 4,27% 95,73% 1 1 1
22 FUT8_681494 10600 26 0,25% 99,75% interesting 1 -15
22 BAK1_1544257 59178 254 0,43% 99,57% 2 -14 -8
22 BAX_1345650 67517 2186 3,24% 96,76% 3 1 -2
23 FUT8_681494 12816 78 0,61% 99,39% interesting 1 1
23 BAK1_1544257 49419 428 0,87% 99,13% 1 -4
23 BAX_1345650 42223 41855 99,13% 0,87% 2 1 0
24 FUT8_681494 24594 24565 99,88% 0,12% interesting 1 0
24 BAK1_1544257 91694 276 0,30% 99,70% 1 -13
24 BAX_1345650 92741 3012 3,25% 96,75% 2 1 -2 *5.2.12
5.2.1
5.2.2
5.2.3
5.2.4
5.2.5
5.2.6
5.2.7
5.2.8
5.2.9
5.2.10
5.2.11
5.1.12
5.1.1
5.1.2
5.1.3
5.1.4
5.1.5
5.1.6
5.1.7
5.1.8
5.1.9
5.1.10
5.1.11
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25 FUT8_681494 67 31 46,27% 53,73% Fail (1/2 hit) 2 0 1
25 BAK1_1544257 653 316 48,39% 51,61% 1 0
25 BAX_1345650 732 540 73,77% 26,23% 0 2 0 -13
26 FUT8_681494 17467 27 0,15% 99,85% interesting 1 102
26 BAK1_1544257 53617 259 0,48% 99,52% 1 72
26 BAX_1345650 6227 6095 97,88% 2,12% 2 1 0
27 FUT8_681494 68 26 38,24% 61,76% Fail 3 0 -8
27 BAK1_1544257 148261 339 0,23% 99,77% 2 -10 -31
27 BAX_1345650 84223 3482 4,13% 95,87% 2 1 -46
28 FUT8_681494 21173 31 0,15% 99,85% Fail 1 1
28 BAK1_1544257 43415 217 0,50% 99,50% 1 -57
28 BAX_1345650 96570 27825 28,81% 71,19% 2 2 -15 0
29 FUT8_681494 18518 9691 52,33% 47,67% Fail 2 0 -8
29 BAK1_1544257 77868 34076 43,76% 56,24% 2 -10 0
29 BAX_1345650 80508 80214 99,63% 0,37% 0 1 0
30 FUT8_681494 26551 23 0,09% 99,91% interesting 2 -1 -3
30 BAK1_1544257 104468 275 0,26% 99,74% 1 -11
30 BAX_1345650 91614 91125 99,47% 0,53% 2 1 0
31 FUT8_681494 23495 23415 99,66% 0,34% interesting 1 0
31 BAK1_1544257 109343 108881 99,58% 0,42% 1 0
31 BAX_1345650 80827 3408 4,22% 95,78% 1 1 -37
32 FUT8_681494 14481 14417 99,56% 0,44% interesting 1 0
32 BAK1_1544257 72212 71829 99,47% 0,53% 1 0
32 BAX_1345650 62236 62007 99,63% 0,37% 0 1 0
33 FUT8_681494 5109 5085 99,53% 0,47% interesting 1 0
33 BAK1_1544257 27653 27509 99,48% 0,52% 1 0
33 BAX_1345650 23638 23507 99,45% 0,55% 0 1 0
34 FUT8_681494 13617 13563 99,60% 0,40% interesting 1 0
34 BAK1_1544257 63610 63240 99,42% 0,58% 1 0
34 BAX_1345650 62646 62355 99,54% 0,46% 0 1 0
35 FUT8_681494 6675 41 0,61% 99,39% interesting 1 -1
35 BAK1_1544257 149591 5355 3,58% 96,42% 2 -3 71
35 BAX_1345650 108304 107053 98,84% 1,16% 2 1 0
36 FUT8_681494 30028 52 0,17% 99,83% interesting 2 1 -8
36 BAK1_1544257 97591 487 0,50% 99,50% 2 1 -10
36 BAX_1345650 95504 5425 5,68% 94,32% 3 1 -13
37 FUT8_681494 18747 12961 69,14% 30,86% Fail 2 0 -8
37 BAK1_1544257 90913 32164 35,38% 64,62% 3 0 -2
37 BAX_1345650 59705 59257 99,25% 0,75% 0 1 0
38 FUT8_681494 7656 7619 99,52% 0,48% interesting 1 0
38 BAK1_1544257 38359 38209 99,61% 0,39% 1 0
38 BAX_1345650 32167 31569 98,14% 1,86% 0 1 0
39 FUT8_681494 13547 30 0,22% 99,78% interesting 2 -2 -15
39 BAK1_1544257 65952 510 0,77% 99,23% 2 1 -11
39 BAX_1345650 63463 2399 3,78% 96,22% 3 1 -3
40 FUT8_681494 10737 19 0,18% 99,82% Fail 2 1 -6
40 BAK1_1544257 57817 28243 48,85% 51,15% 1/2 allelle hit/2 clones 2 1 0
40 BAX_1345650 51229 2469 4,82% 95,18% 2 1 -2
41 FUT8_681494 8933 8906 99,70% 0,30% interesting 1 0
41 BAK1_1544257 48698 48160 98,90% 1,10% 1 0
41 BAX_1345650 52138 51928 99,60% 0,40% 0 1 0
42 FUT8_681494 11287 5348 47,38% 52,62% 1/2 allelle hit/2 clones 2 1 0
42 BAK1_1544257 41232 332 0,81% 99,19% Fail 1 2
42 BAX_1345650 44456 3135 7,05% 92,95% 2 1 1
43 FUT8_681494 7216 31 0,43% 99,57% interesting 1 -2
43 BAK1_1544257 32049 469 1,46% 98,54% 1 -14
43 BAX_1345650 10100 9894 97,96% 2,04% 2 1 0
44 FUT8_681494 14408 29 0,20% 99,80% interesting 2 -1 -4
44 BAK1_1544257 60962 417 0,68% 99,32% 1 -15
44 BAX_1345650 25494 25319 99,31% 0,69% 2 1 0
45 FUT8_681494 4855 17 0,35% 99,65% Fail 1 -12
45 BAK1_1544257 168 117 69,64% 30,36% 1 0
45 BAX_1345650 24415 697 2,85% 97,15% 2 1 1
46 FUT8_681494 5300 13 0,25% 99,75% interesting 1 -11
46 BAK1_1544257 26902 298 1,11% 98,89% 1 1
46 BAX_1345650 12573 11581 92,11% 7,89% 2 1 0
47 FUT8_681494 40394 40326 99,83% 0,17% interesting 1 0
47 BAK1_1544257 192086 191536 99,71% 0,29% 1 0
47 BAX_1345650 174340 173707 99,64% 0,36% 0 1 0
48 FUT8_681494 12745 12684 99,52% 0,48% interesting 1 0
48 BAK1_1544257 99759 439 0,44% 99,56% 2 -14 -8
48 BAX_1345650 49987 1362 2,72% 97,28% 2 1 1
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49 FUT8_681494 24035 24 0,10% 99,90% Fail 1 -3
49 BAK1_1544257 132821 470 0,35% 99,65% 2 18 -13
49 BAX_1345650 101749 53945 53,02% 46,98% 1/2 allelle hit/2 clones 2 0 4
50 FUT8_681494 15660 12 0,08% 99,92% interesting 1 -11
50 BAK1_1544257 67602 202 0,30% 99,70% 1 -15
50 BAX_1345650 57438 57208 99,60% 0,40% 2 1 0
51 FUT8_681494 37107 48 0,13% 99,87% interesting 1 1
51 BAK1_1544257 117005 263 0,22% 99,78% 1 -28
51 BAX_1345650 94985 94485 99,47% 0,53% 2 1 0
52 FUT8_681494 14023 13966 99,59% 0,41% interesting 1 0
52 BAK1_1544257 61089 60707 99,37% 0,63% 1 0
52 BAX_1345650 74698 74330 99,51% 0,49% 0 1 0
53 FUT8_681494 67 26 38,81% 61,19% Fail 4 0
53 BAK1_1544257 106415 298 0,28% 99,72% 1 -13
53 BAX_1345650 101088 86391 85,46% 14,54% 1 1 0
54 FUT8_681494 12876 15 0,12% 99,88% Interesting 2 -1 -5
54 BAK1_1544257 80300 174 0,22% 99,78% 2 87 -14
54 BAX_1345650 108677 4760 4,38% 95,62% 3 1 71
55 FUT8_681494 64 21 32,81% 67,19% Fail 3 0 1
55 BAK1_1544257 79546 477 0,60% 99,40% 2 1 6
55 BAX_1345650 141046 131312 93,10% 6,90% 1 1 0
56 FUT8_681494 33112 23 0,07% 99,93% Fail 2 117 -1
56 BAK1_1544257 73097 394 0,54% 99,46% 1 -5
56 BAX_1345650 64062 6273 9,79% 90,21% 3 1 -2
57 FUT8_681494 10655 6 0,06% 99,94% interesting 1 -1
57 BAK1_1544257 40452 109 0,27% 99,73% 1 -13
57 BAX_1345650 40207 611 1,52% 98,48% 3 1 -1
58 FUT8_681494 36698 22 0,06% 99,94% Fail 2 1 -4
58 BAK1_1544257 30698 30307 98,73% 1,27% 1 0
58 BAX_1345650 66373 51144 77,06% 22,94% 1 2 0 -2
59 FUT8_681494 182 103 56,59% 43,41% Fail 3 0 1
59 BAK1_1544257 832 335 40,26% 59,74% 2 0 -13
59 BAX_1345650 169551 3866 2,28% 97,72% 1 1 -9
60 FUT8_681494 39426 19930 50,55% 49,45% 1/2 allelle hit/2 clones 2 0 3
60 BAK1_1544257 103954 103300 99,37% 0,63% 1 0
60 BAX_1345650 103467 102960 99,51% 0,49% 0 1 0
61 FUT8_681494 13118 13082 99,73% 0,27% Fail 1 0
61 BAK1_1544257 96546 77843 80,63% 19,37% 2 0 1
61 BAX_1345650 110058 109658 99,64% 0,36% 0 1 0
62 FUT8_681494 9206 9186 99,78% 0,22% Fail 1 0
62 BAK1_1544257 52844 52621 99,58% 0,42% 1 0
62 BAX_1345650 54665 50570 92,51% 7,49% 0 1 0
63 FUT8_681494 10241 10207 99,67% 0,33% Fail 1 0
63 BAK1_1544257 87369 86914 99,48% 0,52% 1 0
63 BAX_1345650 118299 101373 85,69% 14,31% 0 2 0 -9
64 FUT8_681494 15600 28 0,18% 99,82% interesting 2 -20 -1
64 BAK1_1544257 51660 51399 99,49% 0,51% 1 0
64 BAX_1345650 95285 94929 99,63% 0,37% 1 1 0
65 FUT8_681494 40218 32 0,08% 99,92% Interesting 1 59
65 BAK1_1544257 85525 677 0,79% 99,21% 1 1
65 BAX_1345650 77133 5397 7,00% 93,00% 3 1 1
66 FUT8_681494 68 31 45,59% 54,41% Fail 4 0
66 BAK1_1544257 108290 492 0,45% 99,55% 2 -3 -25
66 BAX_1345650 112739 3767 3,34% 96,66% 2 1 1
67 FUT8_681494 19155 19100 99,71% 0,29% interesting 1 0
67 BAK1_1544257 99142 98736 99,59% 0,41% 1 0
67 BAX_1345650 110305 109900 99,63% 0,37% 0 1 0
68 FUT8_681494 15867 15802 99,59% 0,41% interesting 1 0
68 BAK1_1544257 78876 78342 99,32% 0,68% 1 0
68 BAX_1345650 63627 63274 99,45% 0,55% 0 1 0
69 FUT8_681494 7408 7385 99,69% 0,31% Interesting 1 0
69 BAK1_1544257 46556 46427 99,72% 0,28% 1 0
69 BAX_1345650 19289 19175 99,41% 0,59% 0 1 0
70 FUT8_681494 16190 19 0,12% 99,88% Interesting 1 -1
70 BAK1_1544257 84119 497 0,59% 99,41% 2 1 -2
70 BAX_1345650 61238 1673 2,73% 97,27% 3 1 -8
71 FUT8_681494 18796 18364 97,70% 2,30% Interesting 1 0
71 BAK1_1544257 116174 115719 99,61% 0,39% 1 0
71 BAX_1345650 103058 102592 99,55% 0,45% 0 1 0
72 FUT8_681494 116 75 64,66% 35,34% Fail 3 0 59
72 BAK1_1544257 68344 930 1,36% 98,64% 1 1
72 BAX_1345650 52091 51789 99,42% 0,58% 1 1 0
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73 FUT8_681494 18158 18112 99,75% 0,25% interesting 1 0
73 BAK1_1544257 89109 88831 99,69% 0,31% 1 0
73 BAX_1345650 82668 82392 99,67% 0,33% 0 1 0
74 FUT8_681494 12311 12278 99,73% 0,27% interesting 1 0
74 BAK1_1544257 58106 57958 99,75% 0,25% 1 0
74 BAX_1345650 51038 50875 99,68% 0,32% 0 1 0
75 FUT8_681494 24751 24723 99,89% 0,11% interesting 1 0
75 BAK1_1544257 111244 110932 99,72% 0,28% 1 0
75 BAX_1345650 103628 102727 99,13% 0,87% 0 1 0
76 FUT8_681494 448 34 7,59% 92,41% Fail 1 -1
76 BAK1_1544257 16595 470 2,83% 97,17% 2 -10 -14
76 BAX_1345650 72563 67314 92,77% 7,23% 2 1 0
77 FUT8_681494 17911 17883 99,84% 0,16% interesting 1 0
77 BAK1_1544257 87181 86904 99,68% 0,32% 1 0
77 BAX_1345650 84167 83925 99,71% 0,29% 0 1 0
78 FUT8_681494 33488 66 0,20% 99,80% Fail 1 1
78 BAK1_1544257 626 403 64,38% 35,62% 1 0
78 BAX_1345650 117101 6665 5,69% 94,31% 2 1 -16
79 FUT8_681494 17456 17423 99,81% 0,19% interesting 1 0
79 BAK1_1544257 81727 81470 99,69% 0,31% 1 0
79 BAX_1345650 102928 102634 99,71% 0,29% 0 1 0
80 FUT8_681494 21365 21325 99,81% 0,19% interesting 1 0
80 BAK1_1544257 99746 99450 99,70% 0,30% 1 0
80 BAX_1345650 89009 88730 99,69% 0,31% 0 1 0
81 FUT8_681494 10777 10753 99,78% 0,22% interesting 1 0
81 BAK1_1544257 39288 39146 99,64% 0,36% 1 0
81 BAX_1345650 26199 26090 99,58% 0,42% 0 1 0
82 FUT8_681494 13943 46 0,33% 99,67% interesting 2 -1 -2
82 BAK1_1544257 107010 512 0,48% 99,52% 2 40 3
82 BAX_1345650 51396 1266 2,46% 97,54% 3 1 -6
83 FUT8_681494 6501 3885 59,76% 40,24% Fail 2 0 -10
83 BAK1_1544257 1918 1773 92,44% 7,56% 1 0
83 BAX_1345650 203190 202660 99,74% 0,26% 0 1 0
84 FUT8_681494 15196 15166 99,80% 0,20% Fail 1 0
84 BAK1_1544257 118970 118657 99,74% 0,26% 1 0
84 BAX_1345650 117472 108005 91,94% 8,06% 0 1 0
85 FUT8_681494 12093 20 0,17% 99,83% Interesting 1 -5
85 BAK1_1544257 81864 465 0,57% 99,43% 2 -2 98
85 BAX_1345650 85296 4578 5,37% 94,63% 3 1 -1
86 FUT8_681494 57 11 19,30% 80,70% Fail 4 0
86 BAK1_1544257 568 228 40,14% 59,86% 1 0
86 BAX_1345650 112079 111508 99,49% 0,51% 0 1 0
87 FUT8_681494 24663 21 0,09% 99,91% Interesting 2 -4 -10
87 BAK1_1544257 109915 352 0,32% 99,68% 2 -10 -13
87 BAX_1345650 111986 6664 5,95% 94,05% 3 1 -4
88 FUT8_681494 11829 6 0,05% 99,95% interesting 1 -10
88 BAK1_1544257 114771 274 0,24% 99,76% 2 47 -1
88 BAX_1345650 60776 60418 99,41% 0,59% 2 1 0
89 FUT8_681494 21087 19 0,09% 99,91% interesting 1 -8
89 BAK1_1544257 123857 623 0,50% 99,50% 1 1
89 BAX_1345650 88189 87830 99,59% 0,41% 2 1 0
90 FUT8_681494 11016 47 0,43% 99,57% Interesting 1 -15
90 BAK1_1544257 55887 363 0,65% 99,35% 1 3
90 BAX_1345650 72389 5509 7,61% 92,39% 3 1 1
91 FUT8_681494 12221 20 0,16% 99,84% Interesting 2 -2 -23
91 BAK1_1544257 56027 370 0,66% 99,34% 2 -19 -14
91 BAX_1345650 137793 7295 5,29% 94,71% 3 1 88
92 FUT8_681494 18613 18544 99,63% 0,37% interesting 1 0
92 BAK1_1544257 95209 94622 99,38% 0,62% 1 0
92 BAX_1345650 78199 77813 99,51% 0,49% 0 1 0
93 FUT8_681494 25742 20 0,08% 99,92% Fail 2 39 1
93 BAK1_1544257 26419 201 0,76% 99,24% 1 -14
93 BAX_1345650 31876 6375 20,00% 80,00% 2 2 -13 0
94 FUT8_681494 7770 1338 17,22% 82,78% Fail 3 -8 0
94 BAK1_1544257 81415 36319 44,61% 55,39% 1/2 allelle hit/2 clones 2 -11 0
94 BAX_1345650 102215 100212 98,04% 1,96% 0 1 0
95 FUT8_681494 3693 36 0,97% 99,03% Fail 2 -3 -23
95 BAK1_1544257 109274 64280 58,82% 41,18% 1/2 allelle hit/2 clones 2 0 -5
95 BAX_1345650 164246 159004 96,81% 3,19% 1 1 0
96 FUT8_681494 4276 1485 34,73% 65,27% Fail 3 -22 -3
96 BAK1_1544257 141070 563 0,40% 99,60% 2 2 106
96 BAX_1345650 100062 99498 99,44% 0,56% 1 1 0
*
6.2.24
6.2.13
6.2.14
6.2.15
6.2.16
6.2.17
6.2.18
6.2.19
6.2.20
6.2.21
6.2.22
6.2.23
6.2.12
6.2.1
6.2.2
6.2.3
6.2.4
6.2.5
6.2.6
6.2.7
6.2.8
6.2.9
6.2.10
6.2.11
- Supplementary Materials for Chapter 3 -
102
19 
 
Supplementary	Table	S9:	Deep	sequencing	results	of	clones	(run	#2).	Each	clone	has	its	own	index	(column	1).	Column	3,	4	
and	5	show	the	number	of	reads	obtained	in	total,	of	wild‐type	sequences	and	sequences	with	indels	respectively.	Clones	with	
unclear	data	are	indicated	as	fail	in	column	7	and	are	also	marked	as	dark	gray	in	column	12.	Column	9,	10	and	11	show	the	
type	of	indels	identified	in	the	clones	(i.e.	basepair	difference	from	wild‐type),	where	peak	n	=	0	means	wild‐type	alleles.	The	
clones	marked	with	light	gray	indicate	absences	of	genes	with	indels	(wild‐type).	The	clones	marked	with	yellow	indicate	
presence	of	one	gene	with	indels	(potential	single	knockout	cell	line).	The	clones	marked	with	orange	indicate	presence	of	
two	genes	with	indels	(potential	double	knockout	cell	line).	The	clones	marked	with	red	indicate	presence	of	three	genes	with	
indels	(potential	triple	knockout	cell	line).	Clones	with	mixed	alleles	(presence	of	both	WT	allele	and	allele	with	indel)	are	
also	marked	as	dark	gray	and	are	also	not	included	in	Figure	2A.		
	
 
Index Product Counts WT Count WT Indels Knockout Peaks Peak 1 Peak 2 Peak 3 CLONE
1 FUT8_681494 3828 16 0,42% 99,58% Fail 1 1 5.2.37
1 BAK1_1544257 258 48 18,60% 81,40% 2 -2 0
1 BAX_1345650 62804 681 1,08% 98,92% 2 1 -15
2 FUT8_681494 4597 9 0,20% 99,80% Interesting 1 -30 5.2.38
2 BAK1_1544257 40536 91 0,22% 99,78% 1 1
2 BAX_1345650 35743 620 1,73% 98,27% 3 1 -2
3 FUT8_681494 16038 15843 98,78% 1,22% Fail 1 0 5.2.39
3 BAK1_1544257 51636 51370 99,48% 0,52% 1 0
3 BAX_1345650 51356 37784 73,57% 26,43% 0 2 0 1
4 FUT8_681494 8189 9 0,11% 99,89% Interesting 1 -4 5.2.40
4 BAK1_1544257 45281 40 0,09% 99,91% 1 -2
4 BAX_1345650 47724 529 1,11% 98,89% 3 1 -7
5 FUT8_681494 10374 10241 98,72% 1,28% Interesting 1 0 5.2.41
5 BAK1_1544257 48475 32 0,07% 99,93% 2 8 -3
5 BAX_1345650 42953 1359 3,16% 96,84% 2 1 -19
6 FUT8_681494 9198 6 0,07% 99,93% Interesting 2 -5 -23 5.2.42
6 BAK1_1544257 64131 60 0,09% 99,91% 2 -8 39
6 BAX_1345650 38936 776 1,99% 98,01% 3 1 -13
7 FUT8_681494 8933 8476 94,88% 5,12% Fail 1 0 5.2.43
7 BAK1_1544257 40555 16061 39,60% 60,40% 2 -2 0
7 BAX_1345650 55214 54609 98,90% 1,10% 0 1 0
8 FUT8_681494 6203 8 0,13% 99,87% Interesting 2 1 -46 5.2.44
8 BAK1_1544257 28591 40 0,14% 99,86% 1 -12
8 BAX_1345650 19532 256 1,31% 98,69% 3 1 -48
9 FUT8_681494 1506 10 0,66% 99,34% Fail 2 -2 1 5.2.45
9 BAK1_1544257 122 30 24,59% 75,41% 4 0 -2
9 BAX_1345650 20345 20151 99,05% 0,95% 1 1 0
10 FUT8_681494 4928 8 0,16% 99,84% Fail 1 34 5.2.46
10 BAK1_1544257 15237 29 0,19% 99,81% 1 -4
10 BAX_1345650 1883 1663 88,32% 11,68% 2 1 0
11 FUT8_681494 5602 20 0,36% 99,64% Fail 2 1 -10 5.2.47
11 BAK1_1544257 47194 107 0,23% 99,77% 1 -11
11 BAX_1345650 64554 51628 79,98% 20,02% 2 2 0 -15
12 FUT8_681494 12826 9 0,07% 99,93% Fail (3 peak 3 86 -1 -3 5.2.48
12 BAK1_1544257 39337 41 0,10% 99,90% 2 -15 -14
12 BAX_1345650 40123 557 1,39% 98,61% 3 1 1
13 FUT8_681494 13636 13587 99,64% 0,36% Interesting 1 0 5.2.49
13 BAK1_1544257 65211 65011 99,69% 0,31% 1 0
13 BAX_1345650 58396 57830 99,03% 0,97% 0 1 0
14 FUT8_681494 12467 31 0,25% 99,75% Fail 2 -15 1 5.2.50
14 BAK1_1544257 14119 214 1,52% 98,48% 1 -36
14 BAX_1345650 45232 15460 34,18% 65,82% 2 2 1 0
15 FUT8_681494 12307 34 0,28% 99,72% Fail 2 -2 -8 5.2.51
15 BAK1_1544257 48416 25463 52,59% 47,41% 1/2 hit 2 0 -21
15 BAX_1345650 17770 17522 98,60% 1,40% 1 1 0
16 FUT8_681494 15267 15235 99,79% 0,21% Fail 1 0 5.2.52
16 BAK1_1544257 49726 26291 52,87% 47,13% 3 0 -21 -8
16 BAX_1345650 46494 5561 11,96% 88,04% 0 2 1 0
17 FUT8_681494 12184 12070 99,06% 0,94% Interesting 1 0 5.2.53
17 BAK1_1544257 60166 59977 99,69% 0,31% 1 0
17 BAX_1345650 42141 41780 99,14% 0,86% 0 1 0
18 FUT8_681494 10270 7003 68,19% 31,81% Fail 2 0 1 5.2.54
18 BAK1_1544257 49981 49812 99,66% 0,34% 1 0
18 BAX_1345650 62268 59351 95,32% 4,68% 0 1 0
19 FUT8_681494 11723 88 0,75% 99,25% Interesting 1 -8 5.2.55
19 BAK1_1544257 72951 241 0,33% 99,67% 2 -25 -28
19 BAX_1345650 66204 2056 3,11% 96,89% 3 1 -3
20 FUT8_681494 9662 24 0,25% 99,75% Interesting 1 -1 5.2.56
20 BAK1_1544257 25984 134 0,52% 99,48% 1 -61
20 BAX_1345650 13888 13701 98,65% 1,35% 2 1 0
21 FUT8_681494 6289 5219 82,99% 17,01% Fail 2 0 -3 5.2.57
21 BAK1_1544257 188 123 65,43% 34,57% 1 0
21 BAX_1345650 17636 184 1,04% 98,96% 1 1 -15
22 FUT8_681494 6556 27 0,41% 99,59% Fail 1 -18 5.2.58
22 BAK1_1544257 3245 223 6,87% 93,13% 1 -4
22 BAX_1345650 14151 11769 83,17% 16,83% 2 2 0 1
23 FUT8_681494 16061 33 0,21% 99,79% Fail 2 66 -27 5.2.59
23 BAK1_1544257 385 233 60,52% 39,48% 1 0
23 BAX_1345650 14943 14688 98,29% 1,71% 1 1 0
24 FUT8_681494 7783 25 0,32% 99,68% Interesting 1 -7 5.2.60
24 BAK1_1544257 45224 185 0,41% 99,59% 2 -3 -21
24 BAX_1345650 42639 792 1,86% 98,14% 3 1 1
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25 FUT8_681494 2862 26 0,91% 99,09% Fail 1 1
25 BAK1_1544257 442 305 69,00% 31,00% 1 0
25 BAX_1345650 89164 1635 1,83% 98,17% 2 1 1
26 FUT8_681494 9588 9553 99,63% 0,37% Fail 1 0
26 BAK1_1544257 45119 44949 99,62% 0,38% 1 0
26 BAX_1345650 42495 28779 67,72% 32,28% 0 2 0 1
27 FUT8_681494 19687 62 0,31% 99,69% Fail 1 -9
27 BAK1_1544257 54874 300 0,55% 99,45% 1 -11
27 BAX_1345650 41759 5449 13,05% 86,95% 2 2 1 0
28 FUT8_681494 9225 32 0,35% 99,65% Fail 1 1
28 BAK1_1544257 20942 204 0,97% 99,03% 2 -8 75
28 BAX_1345650 74459 44186 59,34% 40,66% 2 2 0 -24
29 FUT8_681494 11498 27 0,23% 99,77% Interesting 2 -1 1
29 BAK1_1544257 68730 216 0,31% 99,69% 2 1 24
29 BAX_1345650 49924 786 1,57% 98,43% 3 1 2
30 FUT8_681494 13786 25 0,18% 99,82% Fail 1 -18
30 BAK1_1544257 448 271 60,49% 39,51% 1 0
30 BAX_1345650 65411 888 1,36% 98,64% 2 1 3
31 FUT8_681494 12792 12717 99,41% 0,59% Interesting 1 0
31 BAK1_1544257 58274 57945 99,44% 0,56% 1 0
31 BAX_1345650 66794 65994 98,80% 1,20% 0 1 0
32 FUT8_681494 8760 8486 96,87% 3,13% Fail 1 0
32 BAK1_1544257 40106 39804 99,25% 0,75% 1 0
32 BAX_1345650 36684 36148 98,54% 1,46% 0 1 0
33 FUT8_681494 7368 7342 99,65% 0,35% Interesting 1 0
33 BAK1_1544257 34697 34596 99,71% 0,29% 1 0
33 BAX_1345650 26603 26351 99,05% 0,95% 0 1 0
34 FUT8_681494 8093 8069 99,70% 0,30% Interesting 1 0
34 BAK1_1544257 45630 45452 99,61% 0,39% 1 0
34 BAX_1345650 44096 43687 99,07% 0,93% 0 1 0
35 FUT8_681494 17157 17095 99,64% 0,36% Interesting 1 0
35 BAK1_1544257 89545 89200 99,61% 0,39% 1 0
35 BAX_1345650 45132 44650 98,93% 1,07% 0 1 0
36 FUT8_681494 8765 20 0,23% 99,77% Interesting 1 -54
36 BAK1_1544257 72744 231 0,32% 99,68% 2 -7 -4
36 BAX_1345650 72633 2253 3,10% 96,90% 3 1 -3
37 FUT8_681494 9179 9127 99,43% 0,57% Interesting 1 0
37 BAK1_1544257 46161 45967 99,58% 0,42% 1 0
37 BAX_1345650 41231 40651 98,59% 1,41% 0 1 0
38 FUT8_681494 4160 10 0,24% 99,76% Interesting 1 -16
38 BAK1_1544257 23810 95 0,40% 99,60% 1 -12
38 BAX_1345650 18404 456 2,48% 97,52% 3 1 1
39 FUT8_681494 1308 20 1,53% 98,47% Fail 1 1
39 BAK1_1544257 220 98 44,55% 55,45% 1/2 hit 2 0 1
39 BAX_1345650 24096 23907 99,22% 0,78% 1 1 0
40 FUT8_681494 8417 8263 98,17% 1,83% Fail 1 0
40 BAK1_1544257 27287 27145 99,48% 0,52% 1 0
40 BAX_1345650 40857 38941 95,31% 4,69% 0 1 0
41 FUT8_681494 5920 16 0,27% 99,73% Interesting 1 -15
41 BAK1_1544257 26295 58 0,22% 99,78% 1 99
41 BAX_1345650 7870 7401 94,04% 5,96% 2 1 0
42 FUT8_681494 9140 14 0,15% 99,85% Interesting 2 -23 -15
42 BAK1_1544257 46960 177 0,38% 99,62% 1 1
42 BAX_1345650 40025 693 1,73% 98,27% 3 1 -3
43 FUT8_681494 88 31 35,23% 64,77% Fail 2 0 1
43 BAK1_1544257 37276 105 0,28% 99,72% 1 -13
43 BAX_1345650 40129 435 1,08% 98,92% 2 1 -21
44 FUT8_681494 5484 12 0,22% 99,78% Interesting 1 -33
44 BAK1_1544257 33504 72 0,21% 99,79% 1 -15
44 BAX_1345650 11987 11884 99,14% 0,86% 2 1 0
45 FUT8_681494 4063 4037 99,36% 0,64% Fail 1 0
45 BAK1_1544257 12987 61 0,47% 99,53% 1 97
45 BAX_1345650 4381 3309 75,53% 24,47% 1 2 0 -2
46 FUT8_681494 7450 636 8,54% 91,46% Fail 3 -1 21 1
46 BAK1_1544257 27805 112 0,40% 99,60% 2 1 -3
46 BAX_1345650 33559 33350 99,38% 0,62% 2 1 0
47 FUT8_681494 9516 9050 95,10% 4,90% Fail 1 0
47 BAK1_1544257 45614 45391 99,51% 0,49% 1 0
47 BAX_1345650 35123 32737 93,21% 6,79% 0 1 0
48 FUT8_681494 4431 1925 43,44% 56,56% Fail 3 0 6 1
48 BAK1_1544257 39068 90 0,23% 99,77% 2 51 66
48 BAX_1345650 34029 570 1,68% 98,32% 2 1 71
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49 FUT8_681494 26445 37 0,14% 99,86% Fail 2 -3 103
49 BAK1_1544257 395 285 72,15% 27,85% 1 0
49 BAX_1345650 70638 3949 5,59% 94,41% 2 1 -1
50 FUT8_681494 7797 7279 93,36% 6,64% Fail 1 0
50 BAK1_1544257 41698 41546 99,64% 0,36% 1 0
50 BAX_1345650 36594 36330 99,28% 0,72% 0 1 0
51 FUT8_681494 16646 16099 96,71% 3,29% Fail 1 0
51 BAK1_1544257 61997 61783 99,65% 0,35% 1 0
51 BAX_1345650 55053 54625 99,22% 0,78% 0 1 0
52 FUT8_681494 9088 18 0,20% 99,80% Fail 1 1
52 BAK1_1544257 314 197 62,74% 37,26% 3 0 -10 -14
52 BAX_1345650 19179 18823 98,14% 1,86% 1 1 0
53 FUT8_681494 14273 20 0,14% 99,86% Interesting 1 -5
53 BAK1_1544257 56069 211 0,38% 99,62% 2 -13 -27
53 BAX_1345650 71073 1017 1,43% 98,57% 3 1 3
54 FUT8_681494 16023 15052 93,94% 6,06% Fail 1 0
54 BAK1_1544257 69838 69620 99,69% 0,31% 1 0
54 BAX_1345650 71091 70618 99,33% 0,67% 0 1 0
55 FUT8_681494 12619 3753 29,74% 70,26% Fail 5 0 -42
55 BAK1_1544257 58285 262 0,45% 99,55% 1 -14
55 BAX_1345650 74722 904 1,21% 98,79% 2 1 -6
56 FUT8_681494 8656 11 0,13% 99,87% Interesting 2 -1 -11
56 BAK1_1544257 44119 189 0,43% 99,57% 1 -10
56 BAX_1345650 13302 13089 98,40% 1,60% 2 1 0
57 FUT8_681494 8200 4028 49,12% 50,88% Fail (1/2 hit) 2 -5 0
57 BAK1_1544257 38095 38009 99,77% 0,23% 1 0
57 BAX_1345650 23101 500 2,16% 97,84% 1 1 -3
58 FUT8_681494 10448 10406 99,60% 0,40% Fail 1 0
58 BAK1_1544257 53576 53391 99,65% 0,35% 1 0
58 BAX_1345650 49326 43613 88,42% 11,58% 0 2 0 1
59 FUT8_681494 10664 49 0,46% 99,54% Interesting 2 -6 -22
59 BAK1_1544257 73435 316 0,43% 99,57% 2 -14 -6
59 BAX_1345650 65495 808 1,23% 98,77% 3 1 -7
60 FUT8_681494 11733 4649 39,62% 60,38% Fail 3 0 -25 -13
60 BAK1_1544257 62139 61935 99,67% 0,33% 1 0
60 BAX_1345650 52152 20941 40,15% 59,85% 0 2 1 0
61 FUT8_681494 14188 19 0,13% 99,87% Interesting 1 -2
61 BAK1_1544257 49583 113 0,23% 99,77% 2 -32 -35
61 BAX_1345650 88854 1067 1,20% 98,80% 3 1 37
62 FUT8_681494 5828 4807 82,48% 17,52% Fail 2 0 1
62 BAK1_1544257 32710 32270 98,65% 1,35% 1 0
62 BAX_1345650 49791 45844 92,07% 7,93% 0 1 0
63 FUT8_681494 4717 14 0,30% 99,70% Fail 2 -11 1
63 BAK1_1544257 39084 121 0,31% 99,69% 1 -2
63 BAX_1345650 39174 33548 85,64% 14,36% 2 2 0 1
64 FUT8_681494 10503 7368 70,15% 29,85% Fail 2 0 -47
64 BAK1_1544257 55445 46 0,08% 99,92% 1 -14
64 BAX_1345650 70472 484 0,69% 99,31% 2 1 -11
65 FUT8_681494 11263 10 0,09% 99,91% Interesting 1 -27
65 BAK1_1544257 75408 40 0,05% 99,95% 1 52
65 BAX_1345650 71984 517 0,72% 99,28% 3 1 -3
66 FUT8_681494 8524 13 0,15% 99,85% Fail 1 -1
66 BAK1_1544257 58122 97 0,17% 99,83% 2 -4 -9
66 BAX_1345650 18486 16433 88,89% 11,11% 2 1 0
67 FUT8_681494 16234 18 0,11% 99,89% Fail 2 -12 -5
67 BAK1_1544257 35979 129 0,36% 99,64% 1 -13
67 BAX_1345650 119378 36488 30,57% 69,43% 2 2 -12 0
68 FUT8_681494 5798 7 0,12% 99,88% Interesting 2 -23 36
68 BAK1_1544257 34124 56 0,16% 99,84% 1 -14
68 BAX_1345650 5300 4884 92,15% 7,85% 2 1 0
69 FUT8_681494 9570 9 0,09% 99,91% Interesting 1 -15
69 BAK1_1544257 49234 104 0,21% 99,79% 2 -14 -8
69 BAX_1345650 40540 1136 2,80% 97,20% 3 1 -2
70 FUT8_681494 24300 13 0,05% 99,95% Fail 1 102
70 BAK1_1544257 67635 95 0,14% 99,86% 1 72
70 BAX_1345650 7979 7534 94,42% 5,58% 2 1 0
71 FUT8_681494 25185 16 0,06% 99,94% Interesting 2 -1 -3
71 BAK1_1544257 91586 146 0,16% 99,84% 1 -11
71 BAX_1345650 63549 62977 99,10% 0,90% 2 1 0
72 FUT8_681494 22714 9 0,04% 99,96% Interesting 2 -2 -15
72 BAK1_1544257 98478 115 0,12% 99,88% 2 1 -11
72 BAX_1345650 76270 2288 3,00% 97,00% 3 1 -3
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73 FUT8_681494 10275 8612 83,82% 16,18% Fail 2 0 1
73 BAK1_1544257 70380 70044 99,52% 0,48% 1 0
73 BAX_1345650 64374 63588 98,78% 1,22% 0 1 0
74 FUT8_681494 5984 12 0,20% 99,80% Fail 1 -11
74 BAK1_1544257 45893 157 0,34% 99,66% 2 -4 68
74 BAX_1345650 13514 11563 85,56% 14,44% 2 1 0
75 FUT8_681494 17581 16 0,09% 99,91% Interesting 2 31 -6
75 BAK1_1544257 71989 207 0,29% 99,71% 1 24
75 BAX_1345650 58099 1017 1,75% 98,25% 3 1 -9
76 FUT8_681494 3335 17 0,51% 99,49% Interesting 1 1
76 BAK1_1544257 17773 135 0,76% 99,24% 2 1 -1
76 BAX_1345650 45917 1219 2,65% 97,35% 3 1 1
77 FUT8_681494 19441 14 0,07% 99,93% Fail 2 39 -5
77 BAK1_1544257 389 108 27,76% 72,24% 3 0 -10 1
77 BAX_1345650 5152 4863 94,39% 5,61% 1 1 0
78 FUT8_681494 11175 11 0,10% 99,90% Interesting 1 -21
78 BAK1_1544257 68580 208 0,30% 99,70% 2 -3 -10
78 BAX_1345650 73933 1426 1,93% 98,07% 3 1 1
79 FUT8_681494 8317 32 0,38% 99,62% Interesting 1 1
79 BAK1_1544257 57133 137 0,24% 99,76% 2 -10 2
79 BAX_1345650 62269 3469 5,57% 94,43% 3 1 -8
80 FUT8_681494 5735 17 0,30% 99,70% Fail 3 1 -23 -12
80 BAK1_1544257 349 140 40,11% 59,89% 2 0 -10
80 BAX_1345650 72617 67078 92,37% 7,63% 1 1 0
81 FUT8_681494 3832 2572 67,12% 32,88% Fail 2 0 1
81 BAK1_1544257 14363 14241 99,15% 0,85% 1 0
81 BAX_1345650 12594 12400 98,46% 1,54% 0 1 0
82 FUT8_681494 7123 10 0,14% 99,86% Fail 3 -11 -18 1
82 BAK1_1544257 27803 152 0,55% 99,45% 1 -10
82 BAX_1345650 61826 33080 53,50% 46,50% 2 clones 2 0 1
83 FUT8_681494 11510 11440 99,39% 0,61% Interesting 1 0
83 BAK1_1544257 60886 60503 99,37% 0,63% 1 0
83 BAX_1345650 56542 56054 99,14% 0,86% 0 1 0
84 FUT8_681494 8550 15 0,18% 99,82% Interesting 1 -5
84 BAK1_1544257 49563 157 0,32% 99,68% 2 1 -10
84 BAX_1345650 46514 514 1,11% 98,89% 3 1 -3
85 FUT8_681494 10351 381 3,68% 96,32% Interesting 2 1 -19
85 BAK1_1544257 36367 297 0,82% 99,18% 1 1
85 BAX_1345650 60044 1743 2,90% 97,10% 3 1 -1
86 FUT8_681494 14014 13951 99,55% 0,45% Interesting 1 0
86 BAK1_1544257 64992 64744 99,62% 0,38% 1 0
86 BAX_1345650 64879 64404 99,27% 0,73% 0 1 0
87 FUT8_681494 13090 31 0,24% 99,76% Interesting 1 -1
87 BAK1_1544257 57280 277 0,48% 99,52% 1 3
87 BAX_1345650 32009 31650 98,88% 1,12% 2 1 0
88 FUT8_681494 17790 25 0,14% 99,86% Fail 3 -12 -3 1
88 BAK1_1544257 33376 174 0,52% 99,48% 1 -10
88 BAX_1345650 112350 64969 57,83% 42,17% 2 clones 2 0 -2
89 FUT8_681494 9810 26 0,27% 99,73% Fail 2 -11 1
89 BAK1_1544257 431 203 47,10% 52,90% 2 0 1
89 BAX_1345650 134946 134106 99,38% 0,62% 1 1 0
90 FUT8_681494 9610 1837 19,12% 80,88% Fail 2 1 0
90 BAK1_1544257 65674 65345 99,50% 0,50% 1 0
90 BAX_1345650 114638 113798 99,27% 0,73% 0 1 0
91 FUT8_681494 11646 33 0,28% 99,72% Fail 3 -8 -19 1
91 BAK1_1544257 50784 400 0,79% 99,21% 1 -1
91 BAX_1345650 123193 77252 62,71% 37,29% 2 2 0 1
92 FUT8_681494 11730 19 0,16% 99,84% Interesting 2 -8 -23
92 BAK1_1544257 78820 220 0,28% 99,72% 2 -32 -13
92 BAX_1345650 20577 20351 98,90% 1,10% 2 1 0
93 FUT8_681494 9723 8342 85,80% 14,20% Fail 1 0
93 BAK1_1544257 55002 45923 83,49% 16,51% 1 0
93 BAX_1345650 48889 42436 86,80% 13,20% 0 2 0 2
94 FUT8_681494 14722 13726 93,23% 6,77% Fail 1 0
94 BAK1_1544257 71740 31254 43,57% 56,43% 2 -3 0
94 BAX_1345650 76820 43595 56,75% 43,25% 2 clones 2 0 -15
95 FUT8_681494 15043 36 0,24% 99,76% Interesting 2 1 -2
95 BAK1_1544257 66898 401 0,60% 99,40% 1 1
95 BAX_1345650 71771 2304 3,21% 96,79% 3 2 1 -15
96 FUT8_681494 20148 424 2,10% 97,90% Fail 1 1
96 BAK1_1544257 501 260 51,90% 48,10% 2 0 1
96 BAX_1345650 162801 151035 92,77% 7,23% 1 1 0
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Accelerated,Homology5Directed,Targeted,Integration,of,Transgenes,in,Chinese,Hamster,Ovary,
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"
FIGURES,
,
,
Supplementary,Figure,S1.,Profiles$of$(A)$cell$growth$(viable$cell$density,$VCD)$and$(B)$viability$in$the$presence$of$various$concentrations$of$Scr7.$CHO$cells$were$inoculated$at$6 × 105 cells/mL into 12-well 
plates containing 1 mL culture medium with or without Scr7.$Adjacent$light$and$dark$grey$bars$represent$the$results$on$day$1$and$day$2$respectively$with$mean$±$standard$deviations$of$at$least$three$independent$experiments.$$$ ,
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"
,
,
,
Supplementary,Figure,S2.,Changes$in$cell$cycle$distribution$in$the$presence$of$various$concentrations$of$LiCl.$CHO$cells$were$treated$with$LiCl$for$24$h,$followed$by$cell$cycle$analysis$to$reveal$arrest$at$G2/M$phase.$The$error$bars$represent$the$standard$deviations$calculated$from$two$independent$experiments.$$$ ,
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"
,
,
Supplementary,Figure,S3.,The$effect$of$chemical$treatment$on$transfection$efficiency.$CHO$cells$were$treated$with$Scr7$or$LiCl$under$three$different$conditions$Q$1)$immediately$after$transfection$2)$both$before$and$after$transfection$(3)$before$transfection$only$(See$Methods)$Q$upon$transfection$with$donor$plasmid,$expression$vectors$encoding$GFP_Cas9$and$sgRNA.$Transfection$efficiency$was$analyzed$on$a$basis$of$mCherry$fluorescent$populations$48$hr$postQtransfection.$The$data$are$expressed$as$%$transfection$efficiency$of$nonQchemical$treated$samples$(set$at$100%).$Adjacent$dark$and$light$grey$bars$represent$the$results$of$two$target$sites,$COSMC$and$FUT8$respectively$with$mean$±$standard$deviations$of$two$independent$experiments.$$$ ,
- Supplementary Materials for Chapter 4 -
116
5"
"
TABLES,
Supplementary,Table,S1.,Plasmids$used$in$this$study$$
Plasmid,name, Description, Reference,GFP_Cas9$ GFP$2A$peptideQlinked$Cas9$expression$vector$ Grav$et$al.,$2015$COSMC$sgRNA2$ sgRNA$expression$vector$targeting$COSMC$locus$[Target$genomic$sequence:GAATATGTGAGTGTGGATGGAGG]$ Lee$et$al.,$2015b$FUT8$sgRNA3$ sgRNA$expression$vector$targeting$FUT8$locus$[Target$genomic$sequence:$GTCAGACGCACTGACAAAGTGGG]$ Grav$et$al.,$2015$COSMCQBamHIQHDRQTI$donor$ Donor$plasmid$targeting$COSMC$[Target$GOI:$BamHI]$ This$study$FUT8QBamHIQHDRQTI$vector$ Donor$plasmid$targeting$FUT8$[Target$GOI:$BamHI]$ This$study$COSMCQcoEPOQHDRQTI$donor$ Donor$plasmid$targeting$COSMC$[Target$GOI:$EPO]$ This$study$COSMCQRituximabQHDRQTI$donor$ Donor$plasmid$targeting$COSMC$[Target$GOI:$Rituximab]$ This$study$$$
Supplementary,Table,S2.,Primer$sequences$$
Primer,name, Purpose, Sequence,(5'53'),
Donor,plasmid,COSMC$5'$arm_fwd$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$COSMC$donor$plasmid$(Homology$arm)$ AGTCGGTGUGTAATCCATGGAGGAGTTTCT$COSMC$5'$arm_rev$$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$COSMCQmodel$proteins$donor$plasmid$(Homology$arm)$ ACGCTGCTUAAGGTCTCCAGATTTTACAGT$
COSMC$5'$arm_BamHI_rev$ USER$PCR$primer$for$COSMCQBamHI$donor$plasmid$(Homology$arm$with$BamHI)$ ACGCTGCTUGGATCCAAGGTCTCCAGATTTTACAGT$COSMC$3'$arm_fwd$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$COSMCQmodel$proteins$donor$plasmid$ AGGTCTGAGUGATTGTCTTAAGCATAGAGTC$
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(Homology$arm)$
COSMC$3'$arm_fwd2$ USER$PCR$primer$for$COSMCQBamHI$donor$plasmid$(Homology$arm)$ AAGCAGCGUGATTGTCTTAAGCATAGAGTC$COSMC$3'$arm_rev$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$COSMC$donor$plasmid$(Homology$arm)$ AGCGACGUCCTCATTTGCATATATTTGAA$
FUT8$5'$arm_fwd$ USER$PCR$primer$for$FUT8QBamHI$donor$plasmid$(Homology$arm)$ AGTCGGTGUACCCCAGTGTGCTACAGCCCT$
FUT8$5'$arm_BamHI_rev$ USER$PCR$primer$for$FUT8QBamHI$donor$plasmid$(Homology$arm$with$BamHI)$ ACGCTGCTUGGATCCATGGACTCTGGGGAGAAGTGG$
FUT8$3'$arm_fwd$ USER$PCR$primer$for$FUT8QBamHI$donor$plasmid$(Homology$arm)$ AAGCAGCGUAACAGAAGCAGCCTTCCATCCC$
FUT8$3'$arm_rev$ USER$PCR$primer$for$FUT8QBamHI$donor$plasmid$(Homology$arm)$ AGCGACGUCTCCCATCTCACTCCCCCATC$EFQ1α_fwd$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$model$proteins$donor$plasmid$(EFQ1α)$ AAGCAGCGUGTGAGGCTCCGGTGCCC$EFQ1α$_fwd2$ USER$PCR$primer$for$Rituximab$donor$plasmid$(Rituximab$LC)$ AGTGCGAUGTGAGGCTCCGGTGCCC$EFQ1α$_rev$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$model$proteins$donor$plasmid$(EFQ1α)$ ATGACGTCUTCACGACACCTGAAATGGAA$kozak_coQEPO_fwd$ USER$PCR$primer$for$EPO$donor$plasmid$(EPOQBGH$pA)$ AGACGTCAUCGCCACCATGGGAGTGCACG$kozak_Rituximab$HC_fwd$ USER$PCR$primer$for$donor$plasmid$(Rituximab$HCQBGH$pA)$AGACGTCAUGACACCATGGGCTGGTCCTG$BGH$pA_rev$ USER$PCR$primer$for$donor$plasmid$(model$proteinQBGH$pA)$ACTCAGACCUCCATAGAGCCCACCGCATCC$BGH$pA_rev3$ USER$PCR$primer$for$donor$plasmid$(RituximabQBGH$pA)$ ATCGCACUCCATAGAGCCCACCGCATCC$CMV_fwd$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$donor$plasmid$(mCherry)$ ACGTCGCUGTTGACATTGATTATTGACT$
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BGH$pA_rev2$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$donor$plasmid$(mCherry)$ ACGCAAGUCCATAGAGCCCACCGCATCC$pJ204$backbone_fwd$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$donor$plasmid$(Backbone)$ ACTTGCGUAGTGAGTCGAATAAGGGCGACACAAA$pJ204$backbone_rev$(Lee$et$al.,$2015b)$ USER$PCR$primer$for$donor$plasmid$(Backbone)$ ACACCGACUGAGTCGAATAAGGGCGACACCCCA$
5’/3’,Junction,PCR,and,Out5Out,PCR,COSMC$genomic$fwd$[junction]$$(Lee$et$al.,$2015b)$ COSMC$amplicon$for$5’$junction$and$outQout$PCR$ TGGTTTCTAGGCTAATGCTTTGA$COSMC$genomic$rev$[junction]$(Lee$et$al.,$2015b)$ COSMC$amplicon$for$3’$junction$and$outQout$PCR$ CCTGCCCCCACAGAAAAGTA$FUT8$genomic$fwd$[junction]$$ FUT8$amplicon$for$5’$junction$and$outQout$PCR$ ACACACGGAACAAGTCCAAT$FUT8$genomic$rev$[junction]$ FUT8$amplicon$for$3’$junction$PCR$ AAGGAGACAGAAGTGCACAAGT$EFQ1α$rev$[junction]$(Lee$et$al.,$2015b)$ Amplicon$for$5’$junction$PCR$ ATCCTGGCCCGCATTTACAA$BGH$fwd$[junction]$ Amplicon$for$3’$junction$PCR$ CGACTGTGCCTTCTAGTT$
Deep,sequencing,
COSMC$sgRNA2_F_Nex$(Lee$et$al.,$2015b)$$ COSMC$amplicon$for$MiSeq$analysis$(sgRNA2$site)$ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCCCACCTTGTTCAGGACACT$COSMC$sgRNA2_R_Nex$(Lee$et$al.,$2015b)$ COSMC$amplicon$for$MiSeq$analysis$(sgRNA2$site)$ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGATCCATCGCAGCCTTTCTAT$FUT8$sgRNA3_F_Nex$(Grav$et$al.,$2015)$ FUT8$amplicon$for$MiSeq$analysis$(sgRNA3$site)$ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGCCCCCATGACTAGGGATA$FUT8$sgRNA3_R_Nex$(Grav$et$al.,$2015)$ FUT8$amplicon$for$MiSeq$analysis$(sgRNA3$site)$ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTGCGTTCGAGAAGCTGAAA$
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qRT5PCR,
EFQ1α$_1F$ EFQ1α$amplicon$for$qRTQPCR$[Amplicon$size:$127$bp]$ GGAGAACCGTATATAAGTGCAGTAG$EFQ1α$_1R$ EFQ1α$amplicon$for$qRTQPCR$[Amplicon$size:$127$bp]$ AAGGGCCATAACCCGTAAAG$BGHpA_2F$ BGHpA$amplicon$for$qRTQPCR$[Amplicon$size:$103$bp]$ TGCCAGCCATCTGTTGTT$BGHpA_2R$ COSMC$amplicon$for$qRTQPCR$[Amplicon$size:$103$bp]$ AATGCGATGCAATTTCCTCATT$Vinculin_1F$(Lee$et$al.,$2015b)$ Vinculin$amplicon$for$qRTQPCR$[Amplicon$size:$73$bp]$ GCTGGTTGCTAAGAGGGAGG$Vinculin_1R$(Lee$et$al.,$2015b)$ Vinculin$amplicon$for$qRTQPCR$[Amplicon$size:$73$bp]$ ATCAGAGGCAGCTTTCACGG$$$
Supplementary,Table,S3.,Targeted$integration$efficiency$$
Target,
GOI,
Size,
(kb),
Total,
clonesa,
5’/3’,Junction,PCR,
positive,
Out/Out,PCR,
positiveb,
Targeting,
efficiencyc,(%),EPO$ 2.1$ 81$ 1$ 1$ 1.2$Rituximab$ 5.1$ 76$ 1$ 1$ 1.3$a$The$number$of$total$single$cell$sorted$clones$without$mCherry$and$GFP$fluorescence.$$b$Positive$indicates$the$number$of$clones$with$expected$size$of$PCR$products$generated$by$targeted$integration.$$c$Targeting$efficiency$indicates$the$percentage$of$out/out$PCR$positive$clones$among$total$clones$investigated.$$
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!Figures,
!
Supplementary,Fig.,S1,Relative!mCherry!expression!levels!of!the!panel!of!mCherryYEP!clones,!compared!to!
COSMCYmCherry! clone,! generated! in! previous! study! 7., Error! bars! represent! the! standard! deviations! of!
technical!replicates!(n≥3)!
!
,
Supplementary,Fig.,S2!Relative!levels!of!transgene!expression!in! isoCHOYEPYderived!subclones,!measured!by!qRTY
PCR,! normalized! to! average! value! of! corresponding! isoCHOYEP! subclones.! The! error! bars! represent! the! standard!
deviations!of!technical!replicates!(n=3).!
!
!
! !
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!,
Supplementary, Fig., S3! Comparison! of! expression! values! for! a! pair! of! replicates! in! dataset! 1!
!
,
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!!
,
Supplementary,Fig.,S4,Overview,of,differential,expression,analysis,datasets,
!
,
,
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!!
Supplementary, Fig., S5! Comparison! of! expression! values! for! a! pair! of! replicates! in! dataset! 2!
!
!
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!!
Supplementary,Fig.,S6.,Relative!mCherry!expression!levels!of!the!panel!of!mCherryYCP!clones,!normalized!
to!isoCHOYEP.,Error!bars!represent!the!standard!deviations!of!technical!replicates!(n≥3)!
!
!
Supplementary,Fig.,S7.,Phenotypes,of, isoCHOICP,subclones., (a)!Viable!cell!densities!of! isoCHOYCP!subclones!
expressing!ETC,!EPO,!GDF5!or!C1INH.!The!error!bars!of!each!line!represent!the!standard!deviations!of!three!isogenic!
subclones!expressing!the!same!GOI!(n=3).!(b)!Relative!levels!of!transgene!expression,!as!measured!in!transcripts!per!
kilobase!million!(TPM)!of!ETC,!EPO,!GDF5!or!C1INH.!The!error!bars!represent!the!standard!deviations!of!three!isogenic!
clones!expressing!the!same!GOI!(n=3).!
!
Supplementary,Fig.,S8!Relative!levels!of!transgene!expression!in!isoCHOYCPYderived!subclones,!measured!by!qRTY
PCR,! normalized! to! average! value! of! corresponding! isoCHOYCP! subclones.! The! error! bars! represent! the! standard!
deviations!of!technical!replicates!(n=3).!
!
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,
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!Supplementary,Fig.,S9!Comparison!of!expression!values!for!a!pair!of!replicates!in!dataset!3!and!4!!
!
!
Supplementary,Fig.,S10!Canonical!pathways!enrichment!analysis!
!
!
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!!
Supplementary,Fig.S11,Overview!of!transcriptomics!pipeline!
,
,
,
! ,
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!Tables,
Supplementary,Table,S1.,,Fluorescence!level!analysis!of!mCherryYEP!clones.!Data!shows!mean!value!of!two!
replicates.!
Clone, CHOIS,WT, A4, A6, A9, C12, D1, isoCHOIEP,
mCherry,positive,population, 0,0%! 99,7%! 100,0%! 99,8%! 99,8%! 99,8%! 100,0%!
mCherry,intensity, 4! 138! 133! 136! 128! 128! 158!
,
!
Supplementary,Table,S2.,,Fluorescence!level!analysis!of!mCherryYCP!clones.!Data!shows!mean!value!of!two!
replicates.!
Clone, CHOIS,WT, A2, A5, A6, A7, isoCHO
ICP,
B12, C3, C4, C6, D9, D12, C5,
mCherry,positive,
population,
0,2%! 97,6%! 92,0%! 97,2%! 87,4%! 93,2%! 77,1%! 84,3%! 80,9%! 83,6%! 85,6%! 94,4%! 93,4%!
mCherry,intensity, 6! 139! 165! 160! 148! 205! 127! 180! 171! 176! 169! 136! 188!
!
!
Supplementary,Table,S3.!Nucleotide!sequence!of!CHO!codonYoptimized!human!GDF5!gene!
ATGAGACTGCCCAAGCTGCTGACCTTCCTGCTGTGGTATCTGGCCTGGCTGGACCTGGAATTCATCTGCACCGTGCTGGGCGCTCCCGATCTGGGACAGAGGCCT
CAGGGAACCAGACCCGGACTGGCTAAGGCCGAGGCCAAAGAGAGGCCTCCCCTGGCCAGAAACGTGTTCAGACCTGGCGGCCACTCTTACGGCGGAGGCGCCA
CCAATGCCAACGCCAGAGCTAAGGGCGGCACCGGACAGACAGGTGGCCTGACCCAGCCTAAGAAGGACGAGCCCAAGAAGCTGCCTCCTAGACCAGGCGGCCC
TGAGCCTAAGCCTGGACATCCTCCACAGACCAGACAGGCCACCGCCAGAACCGTGACCCCTAAGGGACAGCTGCCTGGCGGAAAGGCCCCTCCTAAGGCTGGCT
CTGTGCCCTCCAGCTTTCTGCTGAAGAAGGCCAGAGAGCCTGGCCCCCCTAGAGAGCCCAAAGAGCCCTTCAGACCCCCCCCTATCACCCCCCACGAGTACATGCT
GTCCCTGTACCGGACCCTGTCTGACGCCGATCGGAAGGGCGGAAACTCCTCCGTGAAGCTGGAAGCCGGCCTGGCCAACACCATCACCAGCTTCATCGACAAGG
GCCAGGACGACAGGGGTCCCGTCGTGCGGAAGCAGAGATACGTGTTCGACATCTCCGCCCTGGAAAAGGACGGCCTGCTGGGAGCCGAGCTGCGGATCCTGAG
AAAGAAGCCTTCCGACACCGCCAAGCCTGCTGCTCCTGGCGGAGGTAGAGCTGCCCAGCTGAAGCTGTCCAGCTGCCCTTCTGGCAGACAGCCTGCCGCTCTGCT
GGATGTGCGATCTGTGCCAGGACTGGACGGCTCCGGATGGGAGGTGTTCGATATCTGGAAGCTGTTCCGCAACTTCAAGAACTCCGCCCAGCTGTGCCTGGAAC
TGGAAGCTTGGGAGAGGGGCAGAGCCGTGGATCTGAGAGGCCTGGGCTTCGACAGAGCCGCTAGACAGGTGCACGAGAAGGCCCTGTTTCTGGTGTTCGGCC
GGACCAAGAAGCGGGACCTGTTCTTCAACGAGATCAAGGCCAGATCCGGCCAGGATGACAAGACCGTGTACGAGTACCTGTTCTCCCAGCGGCGGAAGCGGAG
AGCCCCTCTGGCTACAAGACAGGGCAAGCGGCCCTCCAAGAACCTGAAGGCCCGGTGCTCTAGAAAGGCCCTGCACGTGAACTTCAAGGACATGGGCTGGGAC
GACTGGATCATTGCCCCCCTGGAATACGAGGCCTTCCACTGCGAGGGCCTGTGCGAGTTCCCTCTGAGATCCCACCTGGAACCCACCAACCACGCCGTGATCCAG
ACCCTGATGAACTCCATGGACCCCGAGTCCACCCCCCCTACCTGTTGTGTGCCTACCCGGCTGTCCCCCATCTCCATCCTGTTCATCGACTCCGCCAACAACGTGGT
GTACAAGCAGTACGAGGACATGGTGGTGGAATCCTGCGGCTGCCGGTGA!
!
!
,
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!Supplementary,Table,S4.!Primers!for!plasmids!construction!and!insert!PCR!
loxImCherryOri,vector,construction,(USER,primers),
Primer,name, Sequence,
LoxPYkozak_mcherry_LA_fwd! agtcggtgUATAACTTCGTATAGCATACATTATACGAAGTTATCGCCACCATGGTGAGCA!
Lox2272Ymcherry_O4_rev! AGACTGTGUataacttcgtataaagtatcctatacgaagttatCTACTTGTACAGCTCGT!
BGH!pA_O4_fwd! ACACAGTCUCTGTGCCTTCTAGTTGCC!
BGH!pA_O5_rev! ACGCAAGUCCATAGAGCCCACCGCAT!
!
Landing,pad,vectors,construction,(USER,primers),
Primer,name, Sequence,
EFY1a_LB_fwd! aagcagcgUGTGAGGCTCCGGTGCCC!
EFY1a_LC_rev! atgacgtcUTCACGACACCTGAAATGGAA!
LinkBYmCMVenhancerYfwd! AAGCAGCGUGAGTCAATGGGAAAAACC!
HTLV5'UTRYlinkCYRev! ATGACGTCUGTAGGCGCCGGTCACA!
LoxP_LC_fwd! agacgtcaUATAACTTCGTATAGCATACAT!
BGH!pA_O2_rev! ATCGCACUccatagagcccaccgcatcc!
Marker!NeoR_O2_fwd! ! AGTGCGAUCTGTGGAATGTGTGTCAGTT!
Marker!NeoR_LD_rev! ! actcagaccUcagacatgataagatacattg!
CMV_O1_fwd! ! ACGTCGCUGTTGACATTGATTATTGACT!
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!BGH!pA_O5_rev! ! ACGCAAGUccatagagcccaccgcatcc!
pJ204!backbone_O5_fwd! ! ACTTGCGUAGTGAGTCGAATAAGGGCGACACAAA!
pJ204!backbone_LA_rev! ! acaccgacUGAGTCGAATAAGGGCGACACCCCA!
!
RMCE,donor,vectors,construction,(USER,primers),
Primer,name, Sequence,
LoxPYkozak_EPO_LA_fwd! agtcggtgUATAACTTCGTATAGCATACATTATACGAAGTTATCGCCACCATGGGAGTGC!
Lox2272YEPO_O5_rev! ACGCAAGUataacttcgtataaagtatcctatacgaagttatTCATCTATCGCCGGTCC!
LoxPYkozak_ETC_LA_fwd! agtcggtgUATAACTTCGTATAGCATACATTATACGAAGTTATAGCACCATGGCGCCCGT!
Lox2272YETC_O5_rev! ACGCAAGUataacttcgtataaagtatcctatacgaagttatTTATCATTTACCCGGAG!
LoxPYkozak_C1INH_LA_fwd! agtcggtgUATAACTTCGTATAGCATACATTATACGAAGTTATAGCACCATGGCCAGCAG!
Lox2272YC1INH_O5_rev! ACGCAAGUataacttcgtataaagtatcctatacgaagttatTCAGGCTCTGGGGTCGTA!
LoxPYkozak_GDF5_LA_fwd! AGTCGGTGUATAACTTCGTATAGCATACATTATACGAAGTTATGCCACCATGAGACTGCC!
Lox2272YGDF5_O5_rev! ACGCAAGUataacttcgtataaagtatcctatacgaagttatTCACCGGCAGCCGCAG!
!
Insert,PCR,
Primer,name, Sequence,
EF1aYmcherry!junction!fwd! CCTCAGACAGTGGTTCAAAGT!
BGH!pA!rev!! AGATGGCTGGCAACTAGAAG!
! ,
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!Supplementary,Table,S5.!qRTYPCR!primers!and!probes!
qRTIPCR,(SYBR,Green,assay),
Gene, Fwd,primer,, Rev,primer,
mCherry, AGGACGGCGAGTTCATCTA! CCCATGGTCTTCTTCTGCATTA!
GAPDH, TTGTCATCAACGGGAAGG! GTGAAGACGCCAGTAGATT!
!
TaqMan,assays,,
Gene, Fwd,primer, Rev,primer, Probe, Dye,
ETC, CAGCCGGAGAACAACTACAA! CATCACGGAGCATGAGAAGA! TACAGCAAGCTCACCGTGGACAAG! FAMYMGB!
EPO, CTGGAAAGATACCTGCTGGAAG! AGGCGTAGAAGTTCACTTTGG! CCAAAGAGGCCGAGAACATCACCA! FAMYMGB!
GDF5, GTGATCCAGACCCTGATGAAC!! !GTCGATGAACAGGATGGAGATG! !TACCTGTTGTGTGCCTACCCGG! FAMYMGB!
C1INH, GGATGGAGCCCTTTCACTTTA! GGATGACCAGGCTCAGATTATG! TCATCGACCAGACCCTGAAGGCTA! FAMYMGB!
!
Supplementary,Table,S6.!RNAYseq!datasets!
Dataset, Samples, Sequencing,kit,
1! isoCHOIEP:!ETC!(n=3),!EPO!(n=3),!GDF5!(n=3),!C1INH!(n=3)! midYoutput!
2! isoCHOIEP:!ETCY0!months!(n=3),!ETCY1.5!months!(n=3),!
ETCY3!months!(n=2),!C1INHY0!months!(n=3),!C1INHY1.5!
months!(n=3),!C1INHY3!months!(n=2)!
highYoutput!
3! isoCHOICP:!ETC!(n=3),!EPO!(n=3),!GDF5!(n=3),!C1INH!
(n=3),!nonYproducer!(n=3)!
highYoutput!
4! isoCHOIEP:!ETC!(n=3),!C1INH!(n=3),!nonYproducer!(n=3)!
isoCHOICP:!ETC!(n=3),!C1INH!(n=3),!nonYproducer!(n=3)!
highYoutput!
!
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